LIVER DISEASE A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Liver Disease: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84011-3 1. Liver Disease-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on liver disease. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON LIVER DISEASE .......................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Liver Disease ............................................................................... 13 E-Journals: PubMed Central ....................................................................................................... 75 The National Library of Medicine: PubMed ................................................................................ 76 CHAPTER 2. NUTRITION AND LIVER DISEASE .............................................................................. 123 Overview.................................................................................................................................... 123 Finding Nutrition Studies on Liver Disease.............................................................................. 123 Federal Resources on Nutrition ................................................................................................. 125 Additional Web Resources ......................................................................................................... 126 CHAPTER 3. ALTERNATIVE MEDICINE AND LIVER DISEASE ........................................................ 129 Overview.................................................................................................................................... 129 The Combined Health Information Database............................................................................. 129 National Center for Complementary and Alternative Medicine................................................ 130 Additional Web Resources ......................................................................................................... 132 General References ..................................................................................................................... 141 CHAPTER 4. DISSERTATIONS ON LIVER DISEASE .......................................................................... 143 Overview.................................................................................................................................... 143 Dissertations on Liver Disease................................................................................................... 143 Keeping Current ........................................................................................................................ 144 CHAPTER 5. CLINICAL TRIALS AND LIVER DISEASE..................................................................... 145 Overview.................................................................................................................................... 145 Recent Trials on Liver Disease................................................................................................... 145 Keeping Current on Clinical Trials ........................................................................................... 153 CHAPTER 6. PATENTS ON LIVER DISEASE ..................................................................................... 155 Overview.................................................................................................................................... 155 Patents on Liver Disease ............................................................................................................ 155 Patent Applications on Liver Disease ........................................................................................ 182 Keeping Current ........................................................................................................................ 202 CHAPTER 7. BOOKS ON LIVER DISEASE ........................................................................................ 203 Overview.................................................................................................................................... 203 Book Summaries: Federal Agencies............................................................................................ 203 Book Summaries: Online Booksellers......................................................................................... 206 The National Library of Medicine Book Index ........................................................................... 212 Chapters on Liver Disease.......................................................................................................... 214 Directories.................................................................................................................................. 218 CHAPTER 8. MULTIMEDIA ON LIVER DISEASE.............................................................................. 221 Overview.................................................................................................................................... 221 Video Recordings ....................................................................................................................... 221 Bibliography: Multimedia on Liver Disease............................................................................... 222 CHAPTER 9. PERIODICALS AND NEWS ON LIVER DISEASE........................................................... 225 Overview.................................................................................................................................... 225 News Services and Press Releases.............................................................................................. 225 Newsletter Articles .................................................................................................................... 227 Academic Periodicals covering Liver Disease ............................................................................ 230 CHAPTER 10. RESEARCHING MEDICATIONS ................................................................................. 231 Overview.................................................................................................................................... 231 U.S. Pharmacopeia..................................................................................................................... 231 Commercial Databases ............................................................................................................... 234
viii Contents
APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 237 Overview.................................................................................................................................... 237 NIH Guidelines.......................................................................................................................... 237 NIH Databases........................................................................................................................... 239 Other Commercial Databases..................................................................................................... 244 The Genome Project and Liver Disease...................................................................................... 244 APPENDIX B. PATIENT RESOURCES ............................................................................................... 249 Overview.................................................................................................................................... 249 Patient Guideline Sources.......................................................................................................... 249 Associations and Liver Disease .................................................................................................. 260 Finding Associations.................................................................................................................. 260 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 263 Overview.................................................................................................................................... 263 Preparation................................................................................................................................. 263 Finding a Local Medical Library................................................................................................ 263 Medical Libraries in the U.S. and Canada ................................................................................. 263 ONLINE GLOSSARIES................................................................................................................ 269 Online Dictionary Directories ................................................................................................... 270 LIVER DISEASE DICTIONARY ................................................................................................ 271 INDEX .............................................................................................................................................. 363
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with liver disease is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about liver disease, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to liver disease, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on liver disease. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to liver disease, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on liver disease. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON LIVER DISEASE Overview In this chapter, we will show you how to locate peer-reviewed references and studies on liver disease.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and liver disease, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “liver disease” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Model for End-Stage Liver Disease (MELD) and Allocation of Donor Livers Source: Gastroenterology. 124(1): 91-96. January 2003. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. (800) 654-2452. Website: www.gastrojournal.org. Summary: A consensus has been reached that liver donor allocation should be based primarily on liver disease severity and that waiting time should not be a major determining factor. This article reports on a study that assessed the capability of the Model for End Stage Liver Disease (MELD) score to correctly rank potential liver recipients according to their severity of liver disease and mortality risk on the OPTN liver waiting list. The MELD model predicts liver disease severity based on serum creatinine, serum total bilirubin, and INR (international normalized ratio) and has been
4
Liver Disease
shown to be useful in predicting mortality in patients with compensated and decompensated cirrhosis (liver scarring). In this study cohort with chronic liver disease (n = 3,437), 412 patients (12 percent) died during the 3 month follow up period. Waiting list mortality increased directly in proportion to the listing MELD score. Patients having a MELD score less than 9 experienced a 1.9 percent mortality, whereas patients having a MELD score greater than 40 had a mortality rate of 71.3 percent. The authors conclude that the MELD score is able to accurately predict 3 month mortality among patients with chronic liver disease on the liver waiting list and can be applied for allocation of donor livers. 3 figures. 4 tables. 14 references. •
Autoimmune Liver Disease in Children Source: Journal of Gastroenterology and Hepatology. 16(6): 674-677. 2001. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E- mail:
[email protected]. Website: www.blackwell-science.com. Summary: Autoimmune liver disease (AILD) in children progresses to cirrhosis (liver scarring) and liver failure if not diagnosed and managed in time. In this article, the authors report on their prospective analysis of their patients with liver disease for autoimmune etiology and their outcome with treatment. All patients with liver disease were evaluated with liver function tests, abdominal ultrasonography, endoscopy, liver biopsy, viral markers, and investigations for Wilson's disease. Immunoglobulin (Ig) M hepatitis A virus, hepatitis E virus (HEV) and IgM hepatitis B core antibody were tested if acute viral hepatitis was suspected. Antinuclear antibody (ANA), antismooth muscle antibody (SMA), and liver kidney microsomal antibody (anti LKM1) were done in all cases. Autoimmune liver disease was diagnosed when one or more autoantibodies tested positive and no other etiology of liver disease was identified. Cases diagnosed to have AILD were treated with immunosuppressive drugs. AILD constituted 3.9 percent of chronic liver disease cases (6 of 153 patients; median age and duration of illness 8.5 years and 3 months, respectively). Four patients had acute hepatitis-like presentation. Three of the patients achieved remission with combination therapy of oral prednisolone (OP) and azathioprine (AZT), and one with only OP. The other two patients were not treated. Two of the patients in remission have been weaned off from immunosuppressive therapy, and one is in a withdrawal phase. Another patient, while in biochemical remission developed superimposed anicteric (without jaundice) acute HEV infection. The authors conclude that although AILD is uncommon in children, its search is rewarding, as remission is achieved with immunosuppressive therapy. Superimposed acute viral hepatitis can occur in endemic areas (the authors report from Lucknow, India). 1 figure. 2 tables. 14 references.
•
Cholestatic Liver Disease Source: Practical Gastroenterology. 25(1): 28, 30, 32-35. January 2001. Contact: Available from Shugar Publishing. 12 Moniebogue Lane, Westhampton Beach, NY 11978. (516) 288-4404. Fax (516) 288-4435. Summary: Cholestatic liver disease remains a rare but increasingly recognized cause of illness affecting adults worldwide. Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the two major cholestatic liver diseases. This article provides an overview of adult cholestatic liver disease and the options available to clinicians in the management of these patients. The author discusses epidemiology, pathologic features, clinical features, diagnosis, medical therapy, management of
Studies
5
complications, and prognosis of each disease. While there is much current evidence supporting an underlying immunologic process for both PBC and PSC, no unifying hypothesis exists to allow for the development of target specific therapies. Because of advances in technology and the refinement of diagnostic modalities, an increasing number of individuals are being identified at earlier stages of disease who may benefit from existing treatment options. In the majority of patients with PBC, a progressive clinical course resulting in fibrosis and eventual cirrhosis (scarring) is observed. Pruritis (itching) as a frequently complication creates difficult management options as significant impairments in quality of life are observed. Individuals undergoing orthotopic liver transplantation (OLT) for PBC have the highest rates of graft and patient survival over 5 years. Disease progression in PSC as a result of chronic bile duct obliteration eventually leads to biliary cirrhosis, hepatic (liver) failure, and complications from portal hypertension. Despite improvements in the management of complications from end stage liver disease and excellent long term results from liver transplantation, a continued understanding of the clinicopathologic processes responsible for cholestatic liver disease remains important. 23 references. •
Complementary and Alternative Medicine in Chronic Liver Disease Source: Hepatology. 34(3): 595-603. September 2001. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000. Summary: Chronic liver disease is a major cause of mortality and morbidity in the United States. Medical therapies for these diseases are often difficult to handle and limited in effectiveness and, therefore, affected patients often seek other treatments, either to complement or to replace standard care. This article reviews the types of complementary and alternative medical (CAM) therapies used, which encompass a wide range of approaches, including prayer, meditation, hypnosis, biofeedback, herbal medicals, chiropractic, diet, and lifestyle modifications. The authors note that at least 42 percent of the general population and a similar proportion of liver disease patients use some form of CAM on a regular basis. Herbal preparations are used by 20 percent of liver disease patients, typically without the advice or even knowledge of their physician. Current impediments to progress in developing reliable information on the safety and efficacy of botanicals are the incomplete understanding of their modes of action, the lack of standardization in their manufacture, and the complexity of the chemical ingredients in the average herbal extract. The authors conclude with four recommendations, including the advice that physicians should routinely and nonconfrontationally ask patients about use of CAM, and should become knowledgeable about CAM products, their traditional indications, and potential toxicities. 2 tables. 81 references.
•
Liver Disease in the Elderly Source: Gastroenterology Clinics of North America. 30(2): 547-563. June 2001. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 32821-9816. (800) 654-2452. Summary: Despite several morphologic and functional changes that have been described in the aging liver, most relevant studies fail to identify a significant age related deficit in liver function in humans. This article, from a special issue on gastrointestinal (GI) disorders in the elderly, addresses liver disease in this population. One of the important age related changes is a decrease in regenerative capacity, which may partly explain the impaired recovery after severe viral and toxic injury in the
6
Liver Disease
elderly. Nevertheless, livers from older subjects are used successfully for transplantation. Substantial morbidity (illness or disease) and mortality (death) in the elderly is attributable to liver diseases, and the number of patients older than 65 years of age with chronic liver disease is increasing rapidly. Although there are no liver diseases specific to advanced age, the presentation (symptoms), clinical course, and management of liver diseases in the elderly may differ in important respects from those of younger individuals. The authors specifically consider hepatitis in older patients, notably hepatitis A, hepatitis B, and hepatitis C; drug induced liver disease; cirrhosis (liver scarring) and portal hypertension; primary biliary cirrhosis; autoimmune hepatitis; and hepatocellular carcinoma (liver cancer). 4 figures. 1 table. 115 references. •
Burden of Liver Disease in the United States: Summary of a Workshop Source: Hepatology. 36(1): 227-242. July 2002. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000. Summary: Disease burden is a term that encompasses a number of aspects of the impact of a disease on the health of a population, ranging from the frequency of the disease, as measured by incidence and prevalence, to its effect on longevity, such as case-fatality rate and years of life lost due to premature death, morbidity including decrease in health status and quality of life, and finance, including direct health care expenditures and indirect costs related to lost income from premature death or disability. This article summarizes a workshop conducted by the American Association for the Study of Liver Disease in May 2001. The goal of the workshop was to assemble available data on epidemiology and burden of liver disease in the United States and identify areas in which further research is needed. The authors conclude that liver disease is an important cause of morbidity (illness) and mortality (death) in the United States: currently, up to 2 percent of all deaths are attributable to liver disease. To improve the understanding of the epidemiology and impact of liver disease and to enhance effective means of diagnosis, therapy and prevention of liver disease at the population level, there are key factors required: objective and generalizable research data, appropriate personnel with necessary qualifications and expertise, and research infrastructure and funding. 5 figures. 5 tables. 72 references.
•
Is Severe Liver Disease a Common Outcome for People with Chronic Hepatitis C? Source: Journal of Gastroenterology and Hepatology. 17(4): 423-430. April 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: For people with chronic hepatitis C, an assessment of their risk of progression to advanced liver disease is a major priority. Early studies of the natural history of chronic hepatitis C suggested that development of cirrhosis (liver scarring) was a relatively common outcome, even in the first 20 years of infection. More recent studies indicate that liver disease progression is generally slow, and that a minority of people with chronic hepatitis C will develop advanced liver disease. This article reports on a Markov model of liver disease progression that the authors developed based on an extensive review of studies reporting on chronic hepatitis C natural history. This model estimates that the risk of progression to cirrhosis in 7 percent and 20 percent after 20 and 40 years of infection, respectively. Corresponding estimates for hepatitis C related mortality (death) are 1 percent and 4 percent. However, liver disease progression is
Studies
7
highly variable, and certain subgroups of people with chronic hepatitis C are at increased risk of advanced liver disease. Those groups include people with a heavy alcohol intake, those who have coinfection with HIV or HBV, and those who have already progressed to moderate to severe hepatic fibrosis. 6 figures. 2 tables. 61 references. •
Liver Disease in Cystic Fibrosis: A Prospective Study on Incidence, Risk Factors, and Outcome Source: Hepatology. 36(6): 1374-1382. December 2002. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000. Summary: Incidence of liver disease (LD) associated with cystic fibrosis (CF) and its clinical characterization still is unsettled. The authors of this article assessed prospectively the incidence and risk factors of this complication, and its impact of the clinical course of CF. Between 1980 and 1990, the authors enrolled 177 CF patients without LD in a systematic clinical, laboratory, ultrasonography screening program of at least a 10 year duration. During a 14 year median follow (2,432 patient-years), 48 patients developed LD, with cirrhosis already present in 5 patients. Incidence rate (number of cases per 100 patient-years) was 1.8 percent, with sharp decline after the age of 10 years and higher risk in patients with a history of meconium ileus, male sex, or severe mutations. Incidence of cirrhosis (liver scarring) was 4.5 percent during a median period of 5 years from diagnosis of liver disease. Among the 17 cirrhotic patients, 13 developed portal hypertension, 4 developed esophageal varices, and 1 developed liver decompensation requiring liver transplantation. Development of LD did not condition different mortality or higher incidence of other clinically relevant outcomes. The authors conclude that LD is a relatively frequent and early complication of CF, whose detection should be focused at the first life decade in patients with history of meconium ileus, male sex, or severe genotype. Although LD does not condition a different clinical course of CF, in some patients it may progress rapidly and require liver transplantation. 2 figures. 4 tables. 46 references.
•
Liver Disease in Pediatric Patients with Cystic Fibrosis is Associated with Glutathione S-Transferase P1 Polymorphism Source: Hepatology. 36(4 Part 1): 913-917. October 2002. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000. Summary: Liver disease in patients with cystic fibrosis (CF) is inconstant and has not yet been clearly related to any specific risk factor. Among liver detoxifying enzymes, the glutathione S-transferases (GSTs) play a key role in the protection against oxidative stress. This article reports on a study that provides the first demonstration of a significant association between GST gene polymorphism and the development of liver disease in patients with CF. The authors hypothesize that the major role of GSTs as detoxifying enzymes is probably emphasized in CF disease by the frequent use of antibiotics and other drugs in these patients. Identification of GSTP1 polymorphism may have prognostic significant in pediatric patients with CF and may direct more targeted therapy toward children with an increased risk of liver disease. 3 tables. 25 references.
8
Liver Disease
•
Pediatric Liver Disease in the United States: Epidemiology and Impact Source: Journal of Gastroenterology and Hepatology. 17 (5): 521-525. May 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Liver diseases which affect children are different than those that affect adults. Diseases such as inborn errors of metabolism are fertile grounds for investigation (research). Study of these 'experiments of nature' will provide insight into hepatobiliary (liver and bile system) function and lead to new treatment options. Successful treatment or prevention of liver diseases in children will have long term implications. This article describes the current burden of pediatric liver disease and offers approaches to intervention. Topics include epidemiology, burden of disease, biliary atresia, intrahepatic cholestasis, metabolic liver disease, nonalcoholic steatohepatitis, viral hepatitis, acute liver failure in children, and immune diseases of the liver and biliary tract. 1 table. 16 references.
•
Nonalcoholic Fatty Liver Disease Source: New England Journal of Medicine. 346(16): 1221-1231. April 18, 2002. Summary: Nonalcoholic fatty liver disease (NAFL) is an increasingly recognized condition that may progress to end stage liver disease. This review article considers the epidemiology, clinical manifestations (symptoms), pathogenesis (development), diagnosis, natural history, and management of NAFL. Insulin resistance and oxidative stress have critical roles in the pathogenesis of NAFL. Liver biopsy remains the most sensitive and specific means of providing important prognostic information. Simple steatosis may have the best prognosis within the spectrum of NALF, but it has the potential to progress to Steatohepatitis, fibrosis, and even cirrhosis (scarring of the liver). No effective medical therapy is currently available for all patients with nonalcoholic fatty liver disease. Weight reduction, when achieved and sustained, may improve the liver disease. Drug therapy aimed at the underlying liver disease holds promise, however, questions remain regarding the use of drug therapy and the effect of recommended dietary measures. Liver transplantation is a therapeutic alternative for some patients with decompensated, end stage NALF disease, but NALF may recur or develop after liver transplantation. 5 figures. 3 tables. 95 references.
•
Nonalcoholic Fatty Liver Disease: An Agenda for Clinical Research Source: Hepatology. 35(4): 746-752. April 2002. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000. Summary: Nonalcoholic steatohepatitis (NASH) is a pathological condition often seen in obese women with diabetes in the absence of significant alcohol use and hepatic histology consistent with alcoholic hepatitis. NASH is part of a larger spectrum of conditions comprising nonalcoholic fatty liver (NAFL) that also includes hepatic steatosis alone and hepatic steatosis with nonspecific inflammation. This review article summarizes the epidemiologic impact of NAFL, risk factors and determinants of severity of NAFL, the theories of pathogenesis (development) of NASH, and treatment options. There is no universally effective treatment for NASH, and therapeutic strategies have been largely empirical because the pathogenesis remains unknown. Treatments discussed include modification of the clinical conditions associated with NASH (treating
Studies
9
the underlying diabetes, hyperlipidemia, and obesity), weight reduction, the use of ursodeoxycholic acid (UDCA), clofibrate, betaine, N-acetylcysteine, gemfibrozil, atorvastatin, troglitazone, and vitamin E. The authors note that current evidence supports the notion that NASH has the potential to progress to cirrhosis (scarring of the liver) and liver-related mortality (death) and morbidity (complications). 2 figures. 56 references. •
Efficacy of Granulocyte-Macrophage Colon-Stimulating Factor or Lamivudine Combination with Recombinant Interferon in Non-Responders to Interferon in Hepatitis B Virus-Related Chronic Liver Disease Patients Source: Journal of Gastroenterology and Hepatology. 17(7): 765-771. July 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Non-response to interferon (IFN) monotherapy is a major therapeutic problem in the management of chronic hepatitis B virus (HBV) infection. This article reports on a study in which the effectiveness of combination therapy to enhance the immunomodulatory effect of IFN by combining GMCSF (granulocyte-macrophage colony stimulating factor) or decreasing viral load by adding an antiviral agent such as lamivudine was evaluated prospectively. The study included 24 patients with chronic hepatitis B who were non-responders to previous IFN therapy were randomized to receive an IFN and GMCSF (group A, n = 10) or IFN and lamivudine (group B, n = 14) combination for 6 months. All patients successfully completed both the treatment schedules. At the end of treatment, there was a significant decrease in mean ALT levels. The HBV-DNA and HBeAg loss was seen in six of 10 (60 percent) patients in group ! and seven of 15 (50 percent) patients in group B. During follow up, two of six patients (33 percent) in group A and three of seven (43 percent) patients in group B relapsed with HBV-DNA and HBeAg positivity, which meant an overall sustained response of 40 percent and 28 percent respectively. None of the factors such as HBV viral load, ALT levels or liver histology could predict the non-response to combination therapy or occurrence of relapse. The authors conclude that larger studies using such combination therapies would be helpful in improving treatment strategies for chronic hepatitis B. 4 tables. 34 references.
•
Alterations of Chemosensory Function in End-Stage Liver Disease Source: Physiology and Behavior. 66(2): 203-207. April 1999. Contact: Available from Elsevier Science. P.O. Box 945, New York, NY 10159-0945. (888) 437-4636 or (212) 633-3730. Fax (212) 633-3680. E-mail:
[email protected]. Summary: Taste and smell dysfunction have been documented in patients with both acute and chronic liver disease. This article reports on a study undertaken to determine if chemosensory function is improved after restoration of hepatic function with liver transplantation. Nine subjects (seven women and two men) with end stage liver disease participated in the study. Taste and smell detection and recognition thresholds were determined before and after transplantation. A significant improvement in detection of the taste of sodium chloride (table salt) and the odor of phenethyl alcohol was found after transplantation. These findings may have clinical significance in food choices and nutritional status of these patients. Smell and taste play an important role in appetite and food intake. Specifically, the inability to taste salt is of potential importance in controlling the disordered salt and fluid balance often present in patients with end stage
10
Liver Disease
liver disease. Also, the chemosensory alterations demonstrated in this study may play a role in the anorexia and weight loss often seen in end stage liver disease and the improvement of nutritional status after transplantation. 2 figures. 2 tables. 15 references. (AA-M). •
Drug-Induced Liver Disease in Older Adults Source: Practical Gastroenterology. 25(3): 43, 47, 50, 52, 54, 56, 58, 60. March 2001. Contact: Available from Shugar Publishing. 12 Moniebogue Lane, Westhampton Beach, NY 11978. (516) 288-4404. Fax (516) 288-4435. Summary: The elderly population consumers more prescription and over the counter (OTC) medications than any other segment of the population. As a result, they are more prone to adverse drug events and are more susceptible to drug induced liver injury. Further, age related changes in the liver also influence drug metabolism, contributing to an increased risk of adverse effects. This article explores drug induced liver disease in older adults, which can vary from frequently noted mild abnormality of liver function tests to occasional severe injury, resulting in death. In the elderly, drugs must be considered as the most likely basis for abnormal liver function. Age related hepatic changes that may increase risk of liver injury include decrease in hepatic blood flow, decrease in hepatic microsomal enzyme activity, and decrease in serum albumin. Management is usually supportive. Early recognition of a toxic drug reaction with prompt discontinuation of the offending agent is paramount to limiting the amount of hepatic damage. This is usually followed by clinical and biochemical improvement. Rechallenge with the drug should be considered only if the need for the drug clearly outweighs the risks or if the initial reaction was observed was highly questionable. The authors conclude that to minimize the risk of adverse hepatic (liver) drug reactions in the elderly, physicians must be aware of age related pharmacokinetic and pharmacodynamic alterations, presence of comorbidity (other illnesses), and the many medications that the patient may be consuming. Close monitoring and review of the drug regimen and liver function tests will reduce the magnitude of this problem. A brief posttest is appended to the article. 4 tables. 24 references.
•
Oxidative Damage in Alcoholic Liver Disease Source: European Journal of Gastroenterology and Hepatology. 13(1): 49-53. January 2001. Contact: Available from Lippincott Williams and Wilkins. 241 Borough High Street, London SE1 1GB, UK 44(0)20-7940-7502. Fax: 44(0)20-7940-7574. Website: http://www.eurojgh.com/. Summary: The metabolic effects of alcohol are due both to its direct action and to that of its first metabolite, and can also be connected with the changes in redox state. Differences in ethanol distribution, bioavailability, and hepatic (liver) metabolism can provide insight into the protective and predisposing factors in alcoholism, as well as gender differences of alcohol toxicity. Oxidative stress occurs following various conditions of ethanol consumption. This article reports on a study of oxidative damage in patients with alcoholic liver disease. The study included 26 Caucasian patients with alcoholism and 32 health, abstinent controls of both sexes who were investigated with special regard to reduction-oxidation status and ad hoc free radical antioxidant balance. Patients with alcoholism showed a decrease of free SH-group concentration, hydrogendonating ability, and an increase of reducing power property in plasma. A decreased total scavenger capacity of erythrocytes and plasma of alcoholic patients, combined with
Studies
11
gender differences, could be detected. The authors conclude that alcoholic dependence causes gradual exhaustion of the antioxidant capacity of erythrocytes, therefore this non invasive measurement may be useful as a follow up of the evolution of alcoholic liver disease. The results also suggest a gender susceptibility of alcohol toxicity. 2 tables. 27 references. •
Genetic Liver Disease in Adults: Early Recognition of the Three Most Common Causes Source: Postgraduate Medicine. 107(2): 147-152, 155, 158-159. February 2000. Contact: Available from McGraw-Hill, Inc. 1221 Avenue of the Americas, New York, NY 10020. (612) 832-7869. Summary: This article is the final entry in a four article symposium that provides a practical approach to the diagnosis and management of common hepatic disorders encountered by primary care physicians. In this article, the authors review the early recognition and diagnosis of the three most common causes of genetic liver disease in adults: Wilson's disease, hereditary hemochromatosis (HHC), and alpha1 antitrypsin deficiency. Although advances in molecular biology have led to the identification and characterization of the genetic defects in these disorders, gene testing has its strengths and limitations. The longstanding techniques of serum (blood) testing and histologic assessment can be combined with genetic evaluation to clarify the diagnosis. Genetic testing is probably most helpful in HHC because of the high frequency of the homozygous C282Y mutation among patients of northern European descent and the relatively high penetrance of the mutation with regard to clinical expression. Genetic testing is much less helpful in the other genetic liver diseases because of the high number of possible mutations and variable clinical expression. However, noninvasive phenotype based screening tests and specific treatments are available for most genetic liver diseases. A patient care algorithm is included. 1 figures. 4 tables. 19 references.
•
Utility of Radiological Imaging in Nonalcoholic Fatty Liver Disease Source: Gastroenterology. 123(3): 745-750. September 2002. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. (800) 654-2452. Website: www.gastrojournal.org. Summary: This article reports on a prospective study that evaluated the role of radiological modalities in establishing the diagnosis of nonalcoholic steatohepatitis (NASH). Consecutive patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were enrolled in the study. Each patient underwent liver biopsy, limited abdominal ultrasonography (US), computerized tomography (CT), and magnetic resonance imaging (MRI). Patients with NASH had greater aspartate aminotransferase levels, greater ferritin levels, more hepatocyte ballooning, and more fibrosis. None of the radiological features distinguished between NASH and other types of NAFLD. No radiological modality detected the presence of hepatocyte ballooning, Mallory's hyaline, or fibrosis, which are important features in the diagnosis of NASH. The presence of more than 33 percent fat on liver biopsy was optimal for detecting steatosis on radiological imaging. 3 tables. 35 references.
•
Non-Alcoholic Fatty Liver Disease: An Overview Source: Journal of Gastroenterology and Hepatology. 17(11): 1136-1143. November 2002.
12
Liver Disease
Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: This article reviews non-alcoholic fatty liver disease (NAFL), a condition that includes a spectrum of clinicopathological conditions and that is seen with increasing prevalence in the developed world. Although steatosis alone seems to have a benign course, those patients with the diagnosis of non-alcoholic steatohepatitis (NASH) can have a progressive course. Additionally, there is now evolving indirect evidence that some of the patients with cryptogenic cirrhosis (liver scarring) may be the result of 'burned-out' NASH. Although NAFL and NASH are associated with insulin-resistance syndrome, some patients with NAFL may have no obvious risk factors. Despite preliminary data from a number of pilot studies, no established therapies can be offered to patients with NASH. Over the next few years, a number of research projects dealing with the epidemiology as well as the pathogenesis of NAFL are expected to be completed. The authors anticipate that through a better understanding of NAFL, more effective treatment protocols can be developed targeting only those patients with NASH who are at the highest risk for progression to cirrhosis and liver failure. 2 table. 94 references. •
Liver Disease: Fat Inflames the Liver Source: Harvard Health Letter. 26(4): 4. February 2001. Contact: Harvard Health Letter. P.O. Box 420300, Palm Coast, FL 32142-0300. (800) 8299045. Website: www.health.harvard.edu/newsletters/subinfo.html. Summary: This health education newsletter article describes nonalcoholic steatohepatitis (NASH), a common form of chronic liver disease in which the liver has excess fat cells and those cells cause inflammation. The author contends that NASH is another result of the epidemics of obesity and diabetes sweeping the United States. NASH is found most often in people who are 10 to 40 percent of their ideal body weight, or have diabetes, or both. At the cellular level, the changes produced by NASH resemble the liver tissue inflammation caused by alcohol. For up to 20 percent of people with NASH, the condition is the beginning of a dangerous cycle that leads to fibrosis (a buildup of fibrous tissue in the liver) and that can lead to life threatening cirrhosis (scarring of the liver). Most people with NASH have no symptoms, or vague symptoms, such as fatigue, an achy feeling on the right side of the abdomen, and malaise (generally feeling bad). Liver function tests (blood tests) can show the first signs of trouble, but a liver biopsy must be used to confirm the diagnosis of NASH. Treatment involves weight loss, close monitoring of blood glucose levels in patients with diabetes, and cessation of alcohol consumption. Present research studies are investigating the role of vitamin E and ursodeoxycholic acid as possible drug therapies for NASH.
•
Non-alcoholic Fatty Liver Disease Source: Journal of Gastroenterology and Hepatology. 17 (Supplement): S186-S190. February 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: This review article considers nonalcoholic fatty liver disease (NAFLD), a chronic liver disease that affects a high proportion of the world's population. Insulin
Studies
13
resistance and oxidative stress play a critical role in the pathogenesis (development) of NAFLD. Clinical, biochemical and imaging studies are of value in the diagnostic evaluation of patients with NAFLD, but liver biopsy remains the most sensitive and specific means of providing important diagnostic and prognostic information. Simple steatosis (fatty liver) has the best prognosis within the spectrum of NAFLD, but NAFLD has the potential to progress to steatohepatitis, fibrosis, and even cirrhosis (liver scarring). No effective medical therapy is currently available for all patients with NAFLD. In patients with diabetes mellitus and hyperlipidemia (high levels of blood fats), appropriate metabolic control is always recommended, but rarely effective in resolving the liver disease. Weight reduction, when achieved and sustained, may improve the liver disease, although the results with weight loss have been inconsistent. Drug therapy aimed at the underlying liver disease holds promise. Several medications with different mechanisms of action and potential benefit are currently being evaluated in clinical trials. Liver transplantation is a life-extending treatment choice for patients with end stage NAFLD, but NAFLD may recur after liver transplantation. 43 references. •
Outcome of Hospital Care of Liver Disease Associated with Hepatitis C in the United States Source: Hepatology. 33(1): 201-206. January 2001. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000. Summary: This study describes mortality and resource utilization for inpatient (hospital) care of hepatitis C (HCV) in comparison to alcohol induced liver disease (ALD) in the United States. The study also identifies factors that affect outcomes. The Healthcare Cost and Utilization Project database, a national inpatient sample was used to identify hospitalization records with diagnoses related to liver disease from HCV and ALD. Outcomes of hospitalizations was analyzed in terms of inhospital deaths and health care resource utilization. For 1995, the authors estimate that there were 26,700 hospitalizations and 2,600 deaths in acute, nonfederal hospitals in the United States for liver diseases caused by HCV. Total charges for these hospitalizations were $514 million. In comparison, ALD was associated with 101,200 hospitalizations; 13,400 deaths, and $1.8 billion in charges. Simultaneous HCV and alcohol abuse was associated with younger ages at the time of hospitalization and death compared with HCV or ALD alone. In analyses, alcohol abuse and HIV infection were associated with an increased risk of death among those with HCV. Liver transplantation and patient death were associated with the largest increase in hospitalization charges. Major complications of cirrhosis (such as variceal bleeding, encephalopathy, and hepatorenal syndromes) and sociodemographic factors (such as race and health insurance) were also significantly associated with the risk of death and hospitalization charges, which were similar in HCV and ALD. The authors provide new estimates regarding the public health impact of HCV, for use in health policy decision and cost effectiveness analyses of preventive and therapeutic interventions. 6 tables. 21 references.
Federally Funded Research on Liver Disease The U.S. Government supports a variety of research studies relating to liver disease. These studies are tracked by the Office of Extramural Research at the National Institutes of
14
Liver Disease
Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to liver disease. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore liver disease. The following is typical of the type of information found when searching the CRISP database for liver disease: •
Project Title: ADENOSINERGIC THERAPY FOR TREATMENT OF HEPATIC FIBROSIS Principal Investigator & Institution: Ito, Bruce R.; Metabasis Therapeutics, Inc. 9390 Towne Centre Dr, Ste 200 San Diego, Ca 921213026 Timing: Fiscal Year 2001; Project Start 28-SEP-2001; Project End 31-MAR-2002 Summary: Hepatic fibrosis, and its irreversible form, cirrhosis, afflicts millions of individuals in the US and is a major cause of death for those with chronic liver disease. The long-term objective for the proposed research is the discovery of effective and safe anti-fibrotic agents for treating liver fibrosis and thereby decreasing the risk of cirrhosis in individuals with liver disease. Activation and trans-differentiation of the hepatic stellate cell (HSC) into the collagen-forming myofibroblast are key events involved in liver fibrosis. We, and others, have shown that stimulation of adenosine receptors on other matrix forming cells leads to inhibition of activation, proliferation, and synthesis of connective tissue proteins. We propose that inhibition/ reversal of HSC activation in fibrosis can be achieved through stimulation of adenosine receptors on HSCs. The research plan includes the use of various subtype specific adenosine receptor agonists, antagonists, and agents that modulate adenosine metabolism and biosynthesis. Using these biological tools and other molecular probes, all available at Metabasis Therapeutics, rat HSCs will be studied in order to confirm the presence of adenosine receptors and probe their function. After identification of the subtype, the concept will be tested using an in-vivo model of fibrosis. PROPOSED COMMERCIAL APPLICATIONS: Given the worldwide increase in liver disease resulting in hepatic fibrosis/ cirrhosis, and the current lack of proven therapies, the medical need and potential market for a therapeutic to treat hepatic fibrosis are large. The research in this proposal will provide the scientific and commercial foundation to support the development of a novel small- molecule therapeutic for the treatment of hepatic fibrosis/cirrhosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ADULT TO ADULT LIVING DONOR LIVER TRANSPLANTATION COHORT Principal Investigator & Institution: Freise, Chris; Surgery; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
15
Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2009 Summary: (provided by applicant): Cadaveric liver transplantation is recognized as the optimal therapy for end stage liver disease, with marked improvement in results over the last two decades. With the increasing success of this treatment, the demand for suitable donor organs has also risen, resulting in a large discrepancy between the number of transplantable organs and the number of patients waiting. This imbalance has led to the development of living donor liver transplantation (LDLT) as an additional method to increase organ supply. The exact indications for this procedure as well as long-term results and potential impact on the healthy donor are questions that remain unanswered. These issues form the basis for this research protocol, which proposes a longitudinal cohort study of live donor liver transplant recipients and their donors across eight transplant centers with an extended period of follow-up. The aims of this cohort study will be the formation of a core database containing information collected pre-transplant, intraoperatively and post-transplant. At least 250 living liver donor/recipient pairs and an equal or greater number of cadaveric recipients will be followed for a minimum of two years to provide critically needed information on the safety and efficacy of living donor liver transplantation, the potential impact on disease progression and recurrence, and ultimately to better define the specific role of living donor liver transplantation in the management of end stage liver disease.In addition to core data collection, this cohort study will offer an opportunity to address specific research questions unique to the setting of LDLT. The first project focuses on patients with hepatitis C, the most common indication for transplantation in the U.S. The kinetics of recurrent hepatitis C viral load post-transplantation will be compared in living donor and matched cadaveric recipients, and the effect of pre-transplant interferon treatment on the tempo and severity of recurrence evaluated. The second project focuses on optimization of pain control in living donors, comparing the use of preemptive thoracic epidural catheter analgesia delivery with patient controlled intravenous analgesia, and using pain scores and quality of life instruments to evaluate the impact of these treatments on long and short-term outcomes.We anticipate that the study will provide the necessary information to aid physicians in the counseling of patients regarding transplant options, and help prospective donors and recipients to better understand the risks and benefits of the procedure. Additionally, the information gained through this cohort study can be expected to impact the entire living donor transplantation procedure itself, by identifying factors that can be modified pre-transplantation, intraoperativiely, and post-transplantation to improve donor and recipient outcomes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALCOHOL AS A MODULATOR OF PREFIBROTIC LIVER INJURY Principal Investigator & Institution: Clemens, Mark G.; Professor and Chair; Biology; University of North Carolina Charlotte Office of Research Services Charlotte, Nc 282230001 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-JUL-2003 Summary: Alcohol is implicated as the etiologic agent in greater than 50% of deaths due to liver cirrhosis, a growing national health concern. It is widely accepted that ethanolinduced oxidative injury can result in inflammation, steatohepatitis, hepatocellular carcinoma and fibrosis. However, it is unknown why only a subpopulation of alcoholic liver disease patients present with end stage liver cirrhosis. Likewise, factors contributing to increased obesity-related susceptibility to the deleterious effects of ethanol are poorly understood. This NIAAA R03 has as its primary focus to achieve a basic understanding of whether differences in the severity of alcoholic liver disease can
16
Liver Disease
be explained, in part, by alcoholinduced acceleration of preexisting liver injury. This proposal builds on our recent observation that combined hyperlipidemic mice that overexpress apolipoprotein C-I maintained on a chow diet develop prefibrotic liver injury. The hypothesis that will be tested is that alcohol can exacerbate preexisting liver injury initiated by chronic hyperlipidemia. In this study, normolipidemic and hyperlipidemic mice fed alcohol or a control diet will be evaluated for changes in plasma lipids and lipoproteins. Intravital microscopy will be used to monitor liver microcirculation, tissue damage and collagen deposition. Tissue evaluation will indicate the metabolic health and extent of liver injury. This study is of immediate interest because while hyperlipidemia is pandemic in the US, the observation that chronic hyperlipidemia can result in liver injury was previously unappreciated. With our recent observation that chronic hyperlipidemia can result in liver injury we will determine whether alcohol can accelerate the development of liver disease in a spontaneous liver injury model where the damage is initiated by preexisting hyperlipidemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALCOHOL EFFECTS ON LIVER DISEASE IN HCV AND HIV COINFECT Principal Investigator & Institution: Schmidt, Warren N.; Assistant Professor; Internal Medicine; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2001; Project Start 25-SEP-2000; Project End 31-JUL-2003 Summary: (Applicant's Abstract) Hepatitis C (HCV) and Human Immunodeficiency virus (HIV) cause chronic infections of worldwide importance. Because they share parenteral factors for transmission, over one third of patients with HIV are usually coinfected with HCV and nearly 400,000 individuals in the United States are positive for both viruses. Patients with co-infection have more aggressive liver disease and increased incidence of cirrhosis than patients with HCV only. While the reasons for this are unclear, it is possible that co-existent alcoholism in this population is at least partially responsible. Alcohol may further modulate host immune suppression and have specific effects on host immune defenses resulting in increased viral replication and mutational pressure on HCV. The overall goal of this proposal is to study and clarify the effects of alcohol on HCV and progressive liver disease in patients who are co-infected with HIV. The specific aims are: 1) We will evaluate a cohort of HCV/HIV positive patients and identify the sociodemographic, histological, and clinical variables of these individuals that are affected by excess alcohol consumption and most likely to be important for progressive liver disease. 2) We will then sequence and compare important genomic regions of HCV isolated from these patients and determine the significance of quasispecies diversity for HCV pathology. 3) We will study the effects of antiviral therapy on the composition and diversity of HCV genomic regions and determine their importance for patient prognosis and response to therapy. Our work will clarify the epidemiology, natural history, and pathology of alcohol in these patients. It will also provide an increased understanding of progressive liver disease in this population that will aid in future management and antiviral therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BILIARY SECRETORY PATHWAYS IN CYSTIC FIBROSIS Principal Investigator & Institution: Cho, Won K.; Medicine; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2001; Project Start 01-MAY-1999; Project End 31-DEC-2003
Studies
17
Summary: Cystic fibrosis (CF) is the most common lethal inherited diseases in white population. As CF patients live longer, liver disease has become the second leading cause of death. The development of CF disease is believed to result from the secretory defects in the bile ducts leading to the obstructions of bile ductules by tenacious bile secretions, thereby secreting in focal periportal biliary fibrosis/cirrhosis. This explanation in addition to the recent finding that CFTR is only expressed on bile duct cells, but not on hepatocytes, suggest that studying biliary secretion is crucial to understanding the pathophysiology and developing therapeutic strategies for CF liver. A novel polarized isolated bile duct unit (IBDU) prepared from rat liver has demonstrated to be an ideal tool to study bile ductular secretion but the lack of CF rat model limited its use in CF studies. By applying these isolation methods, recently, IBDUs have been isolated from normal and CF mice. Therefore, the aims of this research are to further characterize bile duct cells (BDC) and IBDU from normal and CF knockout mice, to characterize ion transporters in BDC, and to study the actions and mechanisms of various secretagogues including neuroendocrine peptides in biliary secretion in order to find ways to activate alternative, cAMP-independent biliary secretory pathways in CF mice. Preliminary experiments to isolate IBDU from normal mouse yielded intact polarized functional IBDU that responds to secretin, vasoactive intestinal peptide, and DBcAMP-IBMX. Similar IBDUs were also isolated from CF mice but need further characterization. Quantitative videomicroscopy will be used to screen potential secretagogues to stimulate biliary secretion in normal and CF mice and to characterize their underlying ion transporters by using ion substitutions and inhibitor studies. These ion transporters will be further studied by BCECF dual ratio methods for measuring pH, micropuncture, and patch clamping techniques. Signal transduction systems involved in their action will be studied by monitoring changes in the concentrations of secondary messengers. Understanding transport systems and their underlying mechanisms of biliary secretion in normal and CF mice will help to formulate therapeutic approaches to overcome the CFTR defect. This project, in turn, will provide the candidate with an excellent opportunity to broaden and develop research and cognitive skills to become independent researcher, as well as help to successfully compete for future research grants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CD36 AND HEPATIC STELLATE CELL ACTIVATION Principal Investigator & Institution: Devilliers, Willem Js.; Medicine; University of Kentucky 109 Kinkead Hall Lexington, Ky 40506 Timing: Fiscal Year 2001; Project Start 01-AUG-2000; Project End 31-JUL-2003 Summary: The central hypothesis to be examined in this R21 proposal is that the class B scavenger receptor, CD36, plays an important role in hepatic stellate cell activation and hepatic fibrogenesis through the alcohol-induced generation of lipid peroxidation products and activation of the nuclear transcription factor, peroxisome proliferatoractivated receptor gamma (PPAR-G). The major difficulty in devising specific therapies for alcoholic liver disease has been our limited understanding concerning the mechanisms underlying the progressive nature of the liver injury and fibrosis in this disease process. The class B scavenger receptor CD36 binds oxidized LDL (OxLDL) and is critical in macrophage foam cell formation and lipid flux. Oxidized cholesterol esters and lipid peroxidation products have been shown to act as ligands for PPAR-G in cells. The expression of CD36, which takes up oxidized cholesterol esters from OxLDL, is positively regulated by PPAR-G, thereby establishing a positive feedback control loop through which oxidized LDL induces greater CD36 expression which in turn leads to
18
Liver Disease
increased OxLDL accumulation in cells. The CD36-thrombospondin complex is required on the cell surface for the formation of activated transforming growth factor-beta (TGFb). We present preliminary data that PPAR-G agonists similarly increases CD36 expression and function in hepatic stellate cells, linking alcohol-induced generation of lipid peroxidation products and hepatic fibrosis. It is well documented in experimental models of alcoholic liver disease that addition of polyunsaturated fatty acids to the diet enhances liver injury and fibrosis. It is our working hypothesis that the CD36 scavenger receptor is upregulated in alcoholic liver disease and is critical for stellate cell activation and fibrogenesis. We therefore propose basic studies in vitro and in animal models of liver fibrosis that address the specific role of CD36 class B scavenger receptors in hepatic stellate cell activation. We believe the proposed research is likely to generate data that will lead to a regular research project grant. The specific aims of this R21 Experimental/Developmental Proposal are: Aim 1: To determine the extent to which PPARG activation and CD36 expression regulate stellate cell activation. Stellate cell activation will be measured by Collagen expression and secretion of activated TGF-B. Aim 2: To document that stellate cells from spontaneously hypertensive rats deficient in CD36 are resistant to activation and fibrogenesis. Moreover, we will determine whether the over expression of CD36 in these CD36-deficient stellate using an adenoviral vector will reconstitute their ability to become activated in response to lipid peroxidation products. Aim 3: To determine the influence of hepatic stellate cell CD36 expression on the development of hepatic fibrosis in rodent models. We will determine whether spontaneously hypertensive rats and CD36-deficient mice are resistant to the development of hepatic fibrosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELLULAR IMMUNITY TO HEPATITIS C VIRUS IN HIV Principal Investigator & Institution: Graham, Camilla S.; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2006 Summary: (Provided by Applicant) The epidemics of HIV and hepatitis C virus (HCV) infections meet in individuals with parenteral exposure to blood, including injecting drug users (IDU) and persons with hemophilia, where rates of coinfection range from 60-90 percent. Coinfected individuals have a significantly increased risk of progression to end-stage liver disease, though mechanisms by which HIV modifies the course of HCV are poorly understood. It is paradoxical that HIV, an immunosuppressive state, leads to an accelerated progression of liver disease, and that HAART is associated with liver failure as well. Our central hypothesis is that both peripheral and intrahepatic HCV-specific cellular immune responses are qualitatively and quantitatively different in patients coinfected with HIV compared with those with HCV monoinfection, and that this is not solely a function of the degree of immunosuppression. Our goals are to determine whether coinfected individuals have an altered cellular immune response to HCV, to determine if immune reconstitution impacts HCV-specific cellular immunity, and if cellular immune responses to HCV are associated with improved outcome with anti-HCV therapy. To address these hypotheses we are examining HCV-specific cellular immune responses in three groups: 1) individuals with HCV/HIV versus HCV alone, 2) individuals with HIV/HCV prior to HAART and during immune reconstitution, and 3) individuals with HIV/HCV who are entering a protocol of interferon-ribavirin therapy. We are using ELISPOTS to characterize secretion of interferon-gamma, tumor necrosis factor alfa, and interleukin-10 at the single cell level in peripheral mononuclear cells and liver-infiltrating lymphocytes in these populations. We are complementing these
Studies
19
functional assays with flow cytometry to phenotypically characterize lymphocyte populations. Determining alterations in cellular immune responses to HCV in individuals with HIV may help us to understand the pathophysiology underlying the accelerated progression of severe liver disease as well as help define subgroups of persons with HIV who may benefit from treatment of hepatitis C. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHIMERIC VIRUS PRIMATE MODEL OF HEPATITIS C Principal Investigator & Institution: Lemon, Stanley M.; Professor & Dean, Sch. of Medicine; Clinical Research Center; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-JAN-2006 Summary: (Provided by the applicant): Chronic HCV infection is a major threat to the public health. Current therapies have limited efficacy, but the search for more effective treatments is hampered by the lack of available animal models of HCV infection. The chimpanzee (Pan troglodytes) is the only animal species permissive for infection with this virus. This deficiency will be addressed by developing a small nonhuman primate model of hepatitis C involving the closely related, unclassified flavivirus GBV-B. GBV-B replicates to high titers, is hepatotropic, and causes liver disease in susceptible tamarins (Saquinus sp.). Since tamarins are more readily available than chimpanzees for such studies, GBV-B infection of these animals represents a potentially useful surrogate for studies of hepatitis C. However, although GBV-B among all animal viruses has the closest phylogenetic relationship to HCV, its proteins still share only approximately 25% identity at the amino acid level. Moreover, unlike HCV, GBV-B does not appear capable of establishing persistent infection in these animals. These features of GBV- B limit its usefulness. To overcome these limitations, the applicants will construct chimeric genome-length GBV-B cDNA clones in which specific functional domains of HCV are inserted in lieu of homologous GBV-B sequence. The hypothesis is that the close phylogenetic relationship between GBV-B and HCV will allow the rescue of viable chimeric viruses from these clones, and that these viruses will represent uniquely valuable resources to the research community since they will allow the in vivo evaluation of candidate inhibitors of critical HCV replication functions in a readily available and relatively inexpensive small, nonhuman primate species. Under Aim 1, the investigators have constructed a fulllength, infectious cDNA copy of the GBV-B genome. The infectivity of RNA transcribed from this clone has been demonstrated following intrahepatic injection of the RNA in a susceptible tamarin. In Aim 2, the investigators are constructing infectious chimeric flavivirus cDNAs containing the following HCV domains within a GBV-B background: the internal ribosome entry site (IRES), the major proteinase (NS3) with its cofactor molecule (NS4A), the RNA helicase (NS3) and the RNA dependent, RNA polymerase (NSSB). In Aim 3, chimeras in which the structural proteins of GBV-B and HCV are placed within the genetic background of the alternate virus will be constructed. For both Aims 2 and 3, the applicants will assess the ability of RNAs transcribed from these chimeric cDNA clones to induce infection in tamarins following intrahepatic inoculation, and determine the extent to which the viruses rescued from these clones cause acute or chronic liver disease on subsequent passage in these nonhuman primates. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
20
Liver Disease
•
Project Title: CHRONIC HEPATITIS C: MOLECULAR & CELLULAR MARKERS Principal Investigator & Institution: Farrell, Geoffrey C.; University of Sydney Main Quadrangle, Bld A14 Sydney, 2006 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: Only a minority of HCV-infected individuals have progressive forms of chronic hepatitis that will result in cirrhosis in 20 to 30 years. This project is concerned with the biological basis of disease progression in chronic hepatitis C. We have noted that, to date, viral factors and the systemic immune response to HCV are poorly correlated with disease progression. The key pathobiological process that determines progression of liver disease in chronic hepatitis C is fibrogenesis, with hepatocyte cell death and proliferation playing lesser roles. In the present proposal, these processes are conceptualized as responses to hepatic inflammation and oxidative stress causing activation of hepatic stellate cells and liver cell injury. Thus our overall objective is to characterize how interactions between HCV, the hepatic inflammatory response and liver cells promote fibrogenesis and disease progression in chronic hepatitis C. In particular, we will test the hypothesis that, in the early stages of chronic HCV infection, an intrahepatic "molecular map" can be created to identify subsets of individuals who will develop progression of liver disease. We will then seek to identify patterns of hepatic gene expression that correlate with the pathogenesis of fibrosis, hepatocyte death and proliferation. A particular focus will be on the identification of genes not previously known to be associated with individual susceptibility to HCV. A unique feature of these studies is that they will be performed on serial liver biopsy samples obtained at 3 to 5 year intervals from 200 patients with mild to moderate chronic hepatitis C who will be followed prospectively and monitored by quantitative liver functional assessments. The Specific Aims are: 1) To establish the relationship between cytokine mediators of the hepatic inflammatory response, macrophage activation and the presence of oxidative stress in the liver, and to compare these with characteristics of the HCV infection in hepatocytes and other cell types; 2) To determine whether expression of these cytokines and/or oxidative stress correlate with the activity of hepatic fibrogenesis, using both cross-sectional and prospective longitudinal approaches. 3) To identify hepatic genes previously not known to be associated with a progressive course for hepatitis C. The findings may allow those individuals most at risk of progressive liver disease from HCV to be identified at a time when they are most likely to respond to antiviral therapy. It will also allow the design of adjunctive treatments more appropriately targeted towards the key pathogenic processes that determine disease progression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CINCINNATI DEVELOPMENT (CGD
DDRDC:
CENTER
FOR
GROWTH
AND
Principal Investigator & Institution: Cohen, Mitchell B.; Professor; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2003; Project Start 08-MAY-2003; Project End 31-MAR-2008 Summary: OVERALL (provided by applicant): The overall goal of the Cincinnati DDRDC: Center for Growth and Development (CGD) is to promote research that will yield insights into the fundamental processes of growth and development in the digestive tract and lead to novel or improved therapies. The specific goals of the CGD derive from the central theme that understanding the molecular mechanisms that control development of the gastrointestinal tract and liver will result in strategies to
Studies
21
correct intestinal, nutritional and liver disease. Furthermore, our working model of interdisciplinary collaboration and our strong research environment will continue to lead to productive investigation in digestive diseases. The 28 full members and 6 associate members come from 9 different divisions within the Department of Pediatrics and a total of 6 Departments within the University of Cincinnati College of Medicine. These investigators are grouped into four working areas that all impact growth and development: Differentiation, Absorption and Secretion, Inflammation, and Regeneration and Repair. The Aims of the Cincinnati DDRDC:CGD are: 1) To promote research in basic and translational science areas relevant to understanding of gastrointestinal and liver growth and development, as well as digestive disease, by studying differentiation, absorption and secretion, inflammation, and regeneration and repair; 2) To promote interactions among scientists with diverse backgrounds, 3) To attract basic investigators to the study of gastrointestinal and liver growth and development, and 4) To foster translational research in digestive disease. The specific aims of the Center will be achieved primarily through three inter-related Biomedical Research Cores. 1) The Microarray Core will perform high quality state of the art experiments to identify novel genes expressed in the digestive organs of humans and in animal models of disease. 2) The Bioinformatics Core will provide design assistance and statistical and computational analysis for the complex experiments performed in the Microarray Core. 3) The Integrative Morphology Core will provide consultation and technical support for morphology studies, including in situ hybridization to localize gene expression identified by microarray analysis. Thus, at many levels, there is strong synergy among the research base and among the Biomedical Research Cores. This synergy will increase efficiency, promote new research directions, and foster collaborations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLIN. & HISTOLOGIC SPECTRUM OF HCV LIVER DISEASE IN IDU Principal Investigator & Institution: Edlin, Brian R.; Associate Professor of Medicine and Publ; Family and Community Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2002 Summary: Injection drug users (IDUs) have the highest hepatitis C (HCV) infection rates of any risk group in the United States; fully 70-96 percent of IDUs have been infected. Natural history studies of transfusion recipients have suggested that HCV infection represents a slowly progressive disease culminating in cirrhosis and liver cancer after decades. But while active IDUs represent the largest single group of persons infected with HCV, there are no studies to date describing the prevalence and severity of HCVrelated liver disease among street-recruited, actively injecting IDUs. Because most IDUs acquired HCV when they began injecting decades ago, many are at imminent risk for life-threatening complications. We propose a cross-sectional study of 1000 active, streetrecruited IDUs who test positive for HCV antibody in the Urban Health Study's ongoing program of HIV and hepatitis testing in inner-city neighborhoods in San Francisco. Indepth epidemiological, clinical and laboratory evaluations of HCV-positive participants will be conducted to assess signs, symptoms, and correlates of liver disease. A subset of 200 HCV-positive participants will undergo liver biopsies. Specifically, this study aims to: 1) to describe the clinical and laboratory spectrum of HCV-related liver disease among 1000 active, street-recruited IDUs in San Francisco, 2) to determine the correlates of advanced liver disease among active IDUs, including demographic factors, injection and other behaviors, comorbidities, and viral markers. Advanced liver disease will be
22
Liver Disease
defined as Child-Pugh score B or greater, 3) to describe the histologic spectrum of HCVrelated liver disease in a subset of 200 active IDUs who will undergo liver biopsy, and 4) to determine the correlates of progressive liver disease among the 200 IDUs who undergo biopsy. Progressive liver disease will be defined as fibrosis stage 3 or 4 on liver biopsy. In addition, contact information will be collected so that this cross-sectional study can serve as a baseline for future cohorts to examine the incidence of clinical and histological disease in this cohort. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL IMPACT ON HCV & ALCOHOL IN HIV INFECTED PERSONS Principal Investigator & Institution: Samet, Jeffrey H.; Professor of Medicine; Boston Medical Center Gambro Bldg, 2Nd Fl, 660 Harrison Ave, Ste a Boston, Ma 02118 Timing: Fiscal Year 2001; Project Start 26-SEP-2000; Project End 31-JUL-2005 Summary: (Applicant's Abstract) The complex relationships between alcohol use, HCV disease, and HIV disease progression have not been well characterized. The cooccurrence of these conditions is common. Both alcohol and HIV infection accelerate the development of HCV complications. The impact of alcohol and HCV infection on the course of HIV infection is less clear. The objective of this project, the HIV Longitudinal Interrelationships of Viruses and Ethanol Study (the HIV-LIVE Study), is to test whether alcohol consumption and HCV, separately and together, are associated with worse HIVrelated disease outcomes, and to determine the magnitude and importance of the effects. We will draw upon an existing cohort to enroll 400 subjects with both alcohol diagnoses and HIV infection from a diverse population with a HCV combined prevalence of 50 percent at Boston Medical Center and the Beth Israel-Deaconess Medical Center. The cohort will be assessed at baseline regarding alcohol diagnosis and consequences, recent and lifetime consumption, drug use and addiction severity, CD4 cell counts, HIV viral load, HCV antibody, viral RNA and genotype, liver disease, HIV disease severity, health-related quality of life, and comorbidity using standard measures. Subjects will be followed twice a year for 3.5 years to determine the primary outcomes, disease progression as determined by CD4 count and incident opportunistic infections. Additional outcomes include clinical progression of liver disease, acute care hospitalization, mortality, health-related quality of life, HIV viral load, and HIV and HCV medication use. Using data from this cohort and the literature, we will develop a comprehensive computer simulation model that will delineate the magnitude of impact that alcohol, HCV and other important determinants such as drug use, other comorbidity, antiretroviral therapy and opportunistic infection prophylaxis have on HIV disease progression. This HIV/HCV policy model will provide a framework for the understanding of the policy implications of a wide range of interventions and will allow the extrapolation of the cohort study data beyond the end of the study. The main hypotheses to be tested are that HCV-infected persons have worse HIV-related outcomes than those without HCV, hazardous alcohol consumption leads to worse HIVrelated outcomes, and subjects with both HCV and alcohol diagnoses have the worst outcomes. The results of this study will provide crucial information needed for the development and prioritization of interventions for coinfected persons with addictions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
23
Project Title: CONTROL OF CAMP-MEDIATED GLUCAGON RESPONSE BY BILE ACIDS Principal Investigator & Institution: Bouscarel, Bernard E.; Associate Research Professor; Medicine; George Washington University 2121 I St Nw Washington, Dc 20052 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-JUL-2006 Summary: Cholestatic liver disease with cirrhosis in particular, is the 9th leading cause of death in the USA. Prognosis is poor, with a generally irreversible condition marked by progressive destruction of liver cells. Around 50 percent of patients with liver disease and 80 percent of cirrhotic patients display glucose intolerance associated with decreased gluconeogenic response to glucagon. Regulation of helpatocellular metabolism by glucagon is in part through increased cAMP synthesis. The central hypothesis is that certain bile acids alter the glucagon receptor-stimulatory G protein (Gs) coupling through a phosphorylation/dephosphorylation mechanism and that these alterations are responsible for attenuation and delayed recovery of glucagon responsiveness in cholestasis. We have shown that bile acids inhibit hepatic glucagoninduced cAMP synthesis at physiologic concentrations. The effect was at the level of receptor-Gs coupling, most likely through phosphorylation, and was mediated by a calcium-dependent PKC. We have reported that hepatic glucagon-mediated cAMP production was attenuated in cholestasis in hamster induced by ligation of the common bile duct (BDL). Bile acids were either without or with reduced effects after BDL suggesting that the site of cAMP synthesis cascade altered in cholestasis is the same as that altered by bile acids. Specific aims will test the hypotheses: 1)that short-term incubation of hepatocytes with bile acids leads to decreased glucagon receptor-Gs coupling through a phosphorylation/dephosphorylation mechanism involving PKC; 2)that alteration of both glucagon receptor-Gs coupling and receptor dephosphorylation are responsible for the respective attenuation and delayed recovery of glucagon responsiveness in cholestasis. In HEK293 clones expressing glucagon receptor, and in hepatocytes from BDL hamsters we will study the respective effect of physiologic/pathophysiologic bile acid concentrations and cholestasis on receptor/Gs coupling and phosphorylation using a multifaceted approach designed to determine the protein phosphorylation target. We will study the role of protein phosphatases on the time course of glucagon response recovery in cholestasis. Knowledge gained from these studies will have bearing on both diagnosis and treatment of cholestatic hepatobiliary disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--MICROARRAY & VIROLOGY Principal Investigator & Institution: Katze, Michael G.; Professor; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: In the Microarray & Virology Core, we have brought together a diverse group of NIH-funded investigators from basic science and clinical medicine. These investigators have a common interest in using state-of-the-art technologies to better understand the molecular mechanisms underlying the progression from HCV infection to end-stage liver disease. Our goal is to use DNA microarrays to provide a molecular blueprint of the changes in cellular gene expression that occur at multiple points along the continuum from virus infection to liver disease, including cirrhosis and hepatocellular carcinoma. Our Specific Aims are the following: Aim 1: Supply biological samples for microarray and proteomic analyses and provide molecular biology and
24
Liver Disease
virology support. Investigators associated with this core will provide the biological samples used for microarray and proteomic analyses. These samples will come from a variety of in vitro and in vivo systems, including HCV replicon cell lines, cultured primary human hepatocytes, liver biopsy material from patients with recurrent HCV after liver transplantation, and liver biopsy material from patients co-infected with HCV and human immunodeficiency virus (HIV). Aim 2: Use DNA microarrays to profile changes in cellular gene expression that occur during HCV infection and HCVassociated liver disease. This core will leverage the capabilities of a pre-existing microarray facility, the Center for Expression Arrays, to apply the technologies of global gene expression analysis to the study of HCV infection and liver disease. This technology infrastructure will be coupled with expertise in hepatitis C virology, virushost interactions (including extensive experience in the use of global gene expression profiling), and liver disease and transplantation. Data obtained from these analyses will be provided to the Bioinformatics & Biostatistics core for analysis and integration with data generated by the Proteomics & Modeling core. The information is likely to yield improved diagnostic methods, markers of disease progression, and novel approaches for therapeutic intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--MOLECULAR BIOLOGY FACILITY Principal Investigator & Institution: Wu, Gary D.; Associate Professor of Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 15-JUL-2002; Project End 30-JUN-2007 Summary: Description (provided by applicant) The purpose of the Molecular Biology Core as stated in the original Center Application in 1996 was to provide advice, equipment and technical applications for molecular cellular experimental approaches specific to digestive and liver disease. The major components of the Services of the Molecular Biology Core included: A) Digestive Disease regents, B) DNA Sequencing, C) Image analysis, D) Molecular and Cellular Biology Techniques, and E) Education. Many components of this Core have been highly successful under the directorship of Dr. Rebecca Taub. Enhancing the availability of reagents and protocols specifically targeted to digestive and liver research is of vital importance in attracting both current and potential Digestive Disease Center investigators. In this regard, components A-C have been instrument to the success of the Molecular Biology Core and the overall Center. They will be retained and expanded in the following fashion: A) Digestive Disease Reagents: We have expanded this repository of reagents to include significant additions to the stock of cDNA libraries, cDNA probes antibodies, Tab polymerase, expression vectors, and general purpose vectors already available through this core. A new component of the Molecular Biology Reagent Bank is a Human RNA Source Bank; B) DNA oligonucleotide synthesis and DNA sequencing. New components include: Direct PCR product sequencing, direct sequencing of cosmids/P1/BAC/ and PAC clones, walking strategy, and site directed mutagenesis; and c) Image Analysis: The Molecular Biology Core will continue to support the use of a Molecular Dynamics be a fully equipped workstation to analyze both custom gene arrays as well as commercially available arrays through Affymetrics (GeneChip Analysis Suite) and Genemax (Informax). The last two components of the Molecular Biology Core, D) Molecular and Cellular Biology Techniques and E) Education, have been redesigned and expanded to incorporate the analysis of gene expression at the level of mRNA through the use of array technology. At the time of the initial Center grant submission, many of the molecular techniques in item D were new to many investigators involved in digestive
Studies
25
disease research. These include cDNA library construction, bacterial expression of proteins, and yeast two-hybrid cloning. However, with time, these techniques have become more widely used by many investigators, in part through the success of the Molecular Biology Core under Dr. Taub's direction. As a result, the need for many of the services in components D and E has diminished. In contrast, there has been considerable interest by Center Members to have services that would permit utilization of emerging technologies in the analysis of gene expression. Therefore, components D and E of the Molecular Biology Core will be replaced by a new Gene Expression Facility. This was met with great enthusiasm by the Executive Committee and the External Advisory Committee. The ability to examine and quantify alterations in gene expression is fundamental to the understanding of molecular mechanisms that determine biological processes. High density gene arrays are now a technical reality. The cost of this technology, although previous prohibitive for most investigators, has very recently become affordable for most investigators, has very recently become affordable This facility will have 2 components: 1) Digestive organ custom arrays, Affymetrix commercial arrays, and the Genomax Bioinformatics Workstation, and 2) Real-Time Quantitative PCR. The Gene Expression Facility will be highly interactive, not only with the other Cores of the Center, but also with the Clinical Investigators from both the Division of Gastroenterology and the Department of Surgery. Examples of these interactions include: 1) Interact with the transgenic/chimeric core facility by assisting in the analysis of murine tissues from wild-type and genetically engineered mice; 2) Complement the analysis of gene expression performed by the Morphology Core through in situ hybridization; 3) Assist in the analysis of in vitro cell culture model systems developed by the Cell Culture Core; and 4) Interact in a translational fashion with patient oriented research through the analysis of gene expression in human tissues. The services provided by the Gene Expression Facility are designed to provide access to several important components in the analysis of gene expression at the level of mRNA. Patterns of mRNA expression, acquired from various sources by interacting with the other Core facilities in the Digestive Disease Center, can be determined by gene array analysis either using custom gene arrays (murine) or Affymetrix arrays (murine and human). Bioinformatics and computational biology are critical components to the analysis of the data obtained from these array experiments and will be supported by the Molecular Biology Core through various Data Analysis tools provided by the Core, principally Genomax. Ultimately, with the identification of specific target genes of interest, quantification of target gene expression in a large number of samples can be performed by Quantitative Real-Time PCR and cellular localization can be determined by in situ hybridization. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CYCLOOXYGENASE 2 AND ALCOHOLIC LIVER DISEASE Principal Investigator & Institution: Nanji, Amin A.; Director; University of Hong Kong Pokfulam Rd Hong Kong, Timing: Fiscal Year 2001; Project Start 17-SEP-2001; Project End 31-AUG-2002 Summary: Conventional treatment options for alcoholic liver disease have, in general, not been successful either in reversing liver injury or preventing progression in patients who continue to abuse alcohol. Current understanding of alcoholic liver injury revolves around the roles of endotoxin and oxidative stress. These stimuli acting in concert lead to upregulation of cyclooxygenase-2 (Cox-2). Based on studies in Cox-2 deficient mice and the intragastric feeding rat model for alcoholic liver disease, induction of Cox-2 appears to be a final common pathway for alcoholic liver injury. The studies proposed
26
Liver Disease
will evaluate the role of Cox-1 and Cox-2 in alcoholic liver injury and test the role of specific Cox inhibitors in preventing and reversing established alcohol-induced liver injury. A specific Cox-2 inhibitor and a non-specific Cox inhibitor (indomethacin) will be administered to rats fed ethanol intragastrically and their effects on the development of pathological changes, endotoxin levels, lipid peroxidation and cytokines will be evaluated. Based on our preliminary studies that show that Indomethacin aggravates liver injury, another drug with higher Cox-2 selectivity (Meloxicam) will be used in the prevention/treatment studies. Additionally, the effects of the drugs will be tested in a model (CCI4) in which extensive fibrosis is seen. The effect of the Cox inhibitors (Cox-2 and Meloxicam) in reversing established alcoholic liver injury will also be tested in rats by simulating an in-hospital alcoholic hepatitis setting and an outpatient alcoholic liver disease setting. In the first set of experiments (in-hospital model), rats will be fed a fish oil- ethanol diet for 6 weeks to induce liver injury. After discontinuing ethanol, the Cox2 inhibitor or Meloxicam will be administered for two weeks with fish oil and dextrose. In the outpatient model, rats will be fed the fish oil-ethanol diet for 6 weeks followed by two weeks of treatment with the Cox-2 inhibitor or Meloxicam with continued ethanol administration. In both models, reversal of inflammatory and fibrotic changes will be evaluated. The prevention and treatment of alcoholic liver injury by Cox-2 inhibitors in these experiments should provide data for the testing of these drugs in patients with alcoholic liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHENOTYPE
DETERMINANTS
OF
SINUSOIDAL
ENDOTHELIAL
CELL
Principal Investigator & Institution: Deleve, Laurie D.; Associate Professor; Medicine; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 30-JUN-2007 Summary: (provided by applicant): Capillarization precedes fibrosis in alcoholic liver disease. In capillarization, sinusoidal endothelial cells (SEC) lose fenestrae and form a basement membrane, a loss of phenotype that has not been examined previously. We propose to examine determinants of SEC phenotype in a series of in vitro and in vivo experiments. In vitro, isolated cells will be examined in homotypic culture and in coculture with other liver cells to determine whether SEC phenotype is regulated by paracrine regulation or by heterotypic contact. The in vitro studies will utilize cells isolated from normal rats and from liver disease models, notably models of steatosis, alcoholic liver disease and fibrosis using thioacetamide. Studies in SEC from liver disease models will examine changes in response to determinants of normal SEC phenotype by heterotypic cells. Studies in hepatocytes and stellate cells from liver disease models will look for changes in factors that determine SEC phenotype. A proteomic approach will be used to identify and examine proteins involved in paracrine regulation. In vivo studies will provide confirmation of the relevance of the soluble factors implicated as determinants of SEC phenotype using continuous intraportal infusions of the soluble factors or their inhibitors in normal rats or rats from the above mentioned liver disease models by monitoring changes in liver histology. Differences in gene expression between SEC from normal and liver disease model rats will be characterized to understand what regulates SEC phenotype. These studies will be used to identify markers of SEC that are altered in the models, to confirm the findings of the proteomic studies and to identify common pathways that regulate expression of genes that are expressed in normal SEC, but not in SEC isolated from liver disease models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
27
Project Title: DIGESTIVE DISEASES RESEARCH CORE CENTERS Principal Investigator & Institution: Boyer, James L.; Professor; Internal Medicine; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2001; Project Start 30-SEP-1984; Project End 31-AUG-2004 Summary: This is a renewal application for support of the Yale University Digestive Disease Research Core Center, a multi-disciplinary Center whose research focus is Liver Structure, Function and Disease. Thirty-five independently funded investigators comprise a research based of approximately $8.5 million. Current research programs in the Center are distributed in 10 departments of the University including Biology, Cell Biology, Cellular and Molecular Physiology, Epidemiology and Public Health, Human Genetics, Medicine, Pathology, Pediatrics, Pharmacology and Surgery. The research based focuses on six major areas: 1) Cellular and Molecular Biology of the Liver, 2) Hepatic Transport Mechanisms, 3) Basic Biology of Disease Processes, 4) Studies of the Hepatic and Splanchnic Circulation, 5) Clinical Hepatology, and 5) Liver Immunology. The research programs in the Center are quite broad and range from fundamental studies of the biology of liver research programs in the Center are quite broad and range from fundamental studies of the biology of liver cells to clinical therapeutic trials of immediate clinical relevance to the diagnosis and treatment of chronic liver cells to clinical therapeutic trials of immediate clinical relevance to the diagnostic and treatment of chronic liver cells to clinical therapeutic trials of immediate clinical relevance to the diagnosis and treatment of chronic liver cells to clinical therapeutic trials of immediately clinical relevance to the diagnosis and treatment of chronic liver disease in patients with these disorders. The major goals of the Center continue to be: 1) to stimulate multidisciplinary interactions between basic and clinical faculty and departments, 2) to provide in-depth training environment, 3) to efficiently organize time consuming, often costly techniques and procedures in core facilities for use by multiple investigators, 4) to stimulate basic scientists to direct their talents and technologies to specific areas of research interest in the Center, 5) to promote important new research and training opportunities through a pilot feasibility project program, and 6) to create an intellectual environment within opportunities through a pilot feasibility project program, and 6) to create an intellectual environment within the institution in the field of Hepatology and to foster collaborations both within and outside the institution. To achieve these goals the Center is organized into five Core Facilities including both within and outside the institution. To achieve these goals the Center is organized into five Core Facilities including: 1) Administrative Core, 2) Cell Isolation, Culture and Organ Perfusion Core, 3) Molecular Biology Core, and 4) Imaging Core. A Pilot Feasibility Program supports small 1-2 year grants for new scientific initiatives. An Enrichment program consists of a seminar program, journal clubs, symposia, retreats and Center newsletters. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DRUG METABOLISM AND CHRONIC LIVER DISEASE Principal Investigator & Institution: Branch, Robert A.; Professor/Director; Medicine; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 30-JUN-2006 Summary: (provided by applicant): This is a resubmission of a proposal whose goal is to use pharmacogenetic principles to better understand the influence of liver disease associated with hepatitis C on drug disposition and develop new tools to evaluate hepatic function. We propose to address the following specific hypotheses: In Specific Aim 1: Hepatitis C influences the clearance of drugs that undergo metabolism in
28
Liver Disease
comparison to matched controls. Furthermore, the extent of change in clearance is different for drugs that are metabolized by different drug metabolizing enzymes and is associated with the severity of the liver disease. Specific Aim 2: Selective decreases in drug metabolism in patients with hepatitis C without hepatic decompensation is associated with enzyme specific down-regulation of hepatic expression of mRNA for that enzyme and increased circulating levels of the cytokines, Interleukin-6 and Tumor Necrosis Factor- ?. Specific Aim 3: The measurement of activity of multiple drug metabolizing enzymes can be interpreted in the context of a sequential, progressive model of hepatic dysfunction to provide an integrated assessment of hepatic function and prognosis in patients with hepatitis C. We propose to study patients with hepatitis C (n= 112) associated with chronic persistent hepatitis, chronic active hepatitis and cirrhosis with or without hepatic decompensation and age, sex matched controls (n=48) on two occasions. Each study subject will participate in three pharmacokinetic (PK) studies that uses drugs selected as probes of substrates metabolized predominantly or exclusively by an individual drug metabolizing enzyme. Part 1: A cocktail to include: caffeine (CYP1A2), flurbiprofen (CYP2C9), mephenytoin (CYP2C19), debrisoquine (CYP2D6), chlorzoxazone (CYP2E1) and dapsone (acetylation). Part 2: Semisimultaneous oral:intravenous administration with midazolam to measure intestinal and hepatic contributions to CYP3A metabolism and Part 3: oral administration of acetaminophen (UGT1A6) simultaneously with intravenous morphine (UGT2B7). When feasible, liver tissue obtained at the time of diagnostic liver biopsy as part of routine patient care will have concentrations of mRNA for CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, UGT1A6 and UGT2B7 measured. Patients with hepatitis C-associated liver disease will be followed at 6 monthly intervals until liver transplantation, death or duration of funding. The study will be repeated either after a change in clinical status or at 2 years in patients with liver disease and after one or 12 months in control subjects. Collectively, these studies will provide a consolidated base of information within the same cohort of patients with hepatitis C and normal subjects to better understand the influence of hepatitis C-associated live disease on drug metabolizing enzymes. This information has potential to create new integrated indices to evaluate hepatic function and prognosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EARLY DETECTION OF LIVER CANCER AND HEPATITIS Principal Investigator & Institution: Block, Timothy M.; Professor and Director; Biochem & Molecular Pharmacol; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: The goal of this proposal is to develop methods for the early detection of hepatocellular carcinoma (HCC) and hepatitis. The hypothesis that changes in the amount or modification of serum polypeptides correlate with the onset of HCC or hepatitis will be determined. Individuals chronically infected with hepatitis B or C virus (HBV, HCV) are at high risk for the development of HCC and hepatitis, with disease progression occurring after many years. Serum polypeptides from individuals at different stages in the disease continuum will be resolved by "Proteomic" 2-dimensional gel analysis. Our preliminary evidence and the work of others demonstrate that 2D gel technology has advanced to the point where expressed protein profiles of biological samples can be reproducibly resolved. Polypeptides that correlate (by their appearance, disappearance or post translational modification) with disease status will be identified. Correlating polypeptides will be characterized by a variety of methods available to us:
Studies
29
data base reference, immunological methods or micro sequencing. Identification of biomarkers that help in the diagnosis and prediction of liver disease in this high-risk population will have enormous public health benefit, given the limitations on current methods. It will also provide insights about the mechanisms of progression of this disease family and offer a platform technology for the use of proteome diagnostics in other areas of cancer detection and liver decompensation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFECT OF HEPATOTOXINS & ADOMET ON LIVER GENE EXPRESSION Principal Investigator & Institution: Kruger, Warren D.; Member; Fox Chase Cancer Center Philadelphia, Pa 19111 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): Chronic liver disease such as cirrhosis, hepatitis, fibrosis, and fatty liver, is associated with reduced levels of S-Adenosylmethionine (AdoMet) in the liver. AdoMct affects a variety of metabolic pathways including methylation, anti-oxidant defense and polyamine production. Evidence from a variety of model systems suggest that dietary supplementation with AdoMet can attenuate liver damage and improve liver function. Despite these intriguing observations, little is known about the effect of AdoMet supplementation at the molecular level. In this R21 exploratory proposal we will examine the effects of AdoMet supplementation at the level of gene expression on a global scale using a rodent model. We will test the hypothesis that hepatotoxins, such as alcohol, have discreet effects on gene expression and that AdoMet supplementation can reverse at least some of these effects. Our experimental approach will use Wistar rats that are assigned to one of six groups: untreated AdoMet treated, alcohol treated, alcohol+AdoMet treated, CCI_ treated, and CC14+AdoMet treated. Using DNA microarrays we will compare global gene expression patterns in each of these groups and determine what! genes and biological pathways are affected by various hepatotoxins and AdoMet supplementation. In addition, we will measure various AdoMet metabolites in the liver to determine the effect of these treatments on AdoMet metabolism. From these studies we will determine how liver hepatotoxins and AdoMet affect gene expression profiles. This information should be informative as to what types of biological pathways are perturbed by these treatments. This knowledge will be useful in understanding the molecular changes that characterized liver disease and the molecular basis for clinical improvement with AdoMet in liver disease. This work may also be useful in the identification of biological pathways affected in chronic liver disease that are not affected by AdoMet supplementation, which may represent other correctable targets in chronic liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: END-STAGE LIVER DISEASE/PREVALENCE & TREATMENT VARIATION Principal Investigator & Institution: Bryce, Cindy L.; Medicine; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2001; Project Start 15-SEP-2000; Project End 31-AUG-2005 Summary: (adapted from the application) The primary purpose of this proposal is to provide the applicant with means and structure for achieving two goals. The immediate goal is to evaluate the effect of gender, race and income on access to liver transplant services. The long-term goal is to gain independence as a health services researcher by
30
Liver Disease
developing methodological expertise in decision sciences and multivariate statistical modeling and research expertise in organ transplantation and health policy evaluation. The applicant will obtain further instruction in computer simulation, geographic information systems, and advanced statistical analysis; in addition, she will receive clinical education to better understand the liver transplantation process and overall delivery of patient care. This training will be provided through formal coursework, directed readings, seminars and conferences, a clinical preceptorship, and research. Most activities will take place at the University of Pittsburgh's School of Medicine, Graduate School of Public Health, and Center for Research on Health Care. The applicant's research project evaluates the role of gender, race, and income in determining access to liver transplantation and explaining variation in liver transplant rates. To date, most studies on access to transplantation have focused on renal transplant services; few researchers have studied hepatic transplantation because of serious data limitations. Whereas the federal government maintains a comprehensive database of persons with renal disease from the time they receive dialysis, there is no centralized, population-based registry for persons with end-stage liver disease (ESLD). Most information on ESLD patients is collected on liver transplant candidates by the United Network for Organ Sharing. The hypothesis of this project is that demographic and economic factors significantly affect early access to transplant services, namely referral rates to transplant centers and listing rates by transplant centers. To address this issue, better information is needed. Therefore, the project will satisfy two aims: (1) develop and validate a population-based methodology for identifying and tracking a cohort of "transplant potential" patients with ESLD; and (2) estimate the effect of gender, race and income on movement through the transplantation process. This project will collect new information on patients with ESLD and combine it with existing data resources made available through The Optimal Timing of Liver Transplantation Project (AHCPR, R01 HS09694-02). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EPIDEMIOLOGY AND IMPACT OF HEPATITIS C IN THE COMMUNITY Principal Investigator & Institution: Kim, W R.; Assistant Professor; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2003; Project Start 15-MAR-2003; Project End 31-DEC-2007 Summary: (provided by applicant): Hepatitis C virus (HCV) is the most common chronic blood-borne infection in the US: an estimated 2.7 million Americans have been infected with the virus. Although the prevalence of HCV infection in the population is well established, the public health impact of liver disease caused by HCV remains uncertain. Based on established resources for population-based research in Olmsted County (the Rochester Epidemiology Project), we have already established a registry of all community residents presently diagnosed with HCV. In this study, we propose to screen community residents for HCV and then determine the impact of HCV infection in the community. In Aim 1, we will measure the prevalence of HCV which has not previously been diagnosed by screening the serum of Olmsted County residents of ages 30 to 49 years for HCV. For screening, we will utilize an established method to obtain serum samples from the majority of the target population in the community. In Aim 2, we will compare the prevalence and severity of liver disease, health status, quality of life and comorbidity profile among three groups of community residents, namely those with established HCV diagnosis, those with HCV infection discovered only by screening, and those without HCV infection. In Aim 3, based on these three groups, we
Studies
31
will measure community-wide healthcare resource utilization related to HCV, independent of effects of comorbid conditions, particularly substance abuse and mental health problems. The results of this work will address the substantial gap between patient outcome data derived from referral patient samples and prevalence data based on population surveys, by providing key information about the impact of HCV on morbidity and health of the majority of Americans whose HCV infection remains undetected. My long-term goal is to establish a comprehensive patient-oriented research program in viral hepatitis and liver disease, encompassing epidemiology, survival statistics, quality of life, and health services research. Resources created by the current project, namely detailed clinical information and biologic specimens from a large cohort of community residents with HCV, will provide future opportunities to study natural history, virologic and host prognostic determinants of progression, and effectiveness of community-based interventions on HCV outcomes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EPIDEMIOLOGY OF HEPATOCELLULAR CARCINOMA Principal Investigator & Institution: Ko, Cynthia W.; Medicine; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2002; Project Start 06-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): The goals of the proposed research project are: 1) to prepare and train the candidate for a career in academic gastroenterology by providing the necessary environment, education, and research support, and 2) to gain insight into the epidemiology of hepatocellular carcinoma in the United States. The candidate is a clinically trained gastroenterologist with additional training in basic epidemiology and biostatistics. As part of this proposal, she will be provided with more advanced training in both general and applied epidemiology and biostatistics. The candidate will be supported and mentored by Dr. John Potter. Her progress will be monitored by the sponsor and the Division of Gastroenterology. The Department of Medicine and Division of Gastroenterology will provide full commitment and support toward the development of the candidate's independent research career. The focus of the scientific portion of this proposal is on hepatocellular carcinoma, a common tumor worldwide the incidence of which is also rising in the United States. Much of this increase can be attributed to the current epidemic of hepatitis C. The epidemiology of hepatocellular carcinoma has not been extensively studied in this country, and few studies have recruited population-based cases and controls. Well-recognized environmental risk factors for hepatocellular carcinoma include chronic viral hepatitis, other chronic liver diseases, and exposure to aflatoxins. However, risk factors that predispose patients with chronic liver disease to hepatocellular carcinoma are not well defined. It is likely that genetic risk factors for hepatocellular carcinoma exist, since familial and ethnic clustering of the tumor are well documented, iron is a recognized co-factor for the development of malignancy in other sites. Hemochromatosis is an inherited disorder in which excess iron accumulates in the liver, heart, pancreas, and other organs. A gene for hemochromatosis, HFE, has recently been identified. Patients with hemochromatosis are at up to 200-fold increased risk of developing hepatocellular carcinoma. We hypothesize that HFE mutations are risk factors for HCC in patients either with or without underlying liver disease. Thus, the specific aims of tills proposal are: 1) to determine whether mutations in the HFE gene are a risk factor for hepatocellular carcinoma; and 2) to recruit a cohort of patients with chronic hepatitis C for prospective studies of the epidemiology of hepatocellular carcinoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
32
Liver Disease
•
Project Title: GENE THERAPY FOR ALCOHOLIC LIVER DISEASE Principal Investigator & Institution: Lemasters, John J.; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2003; Project Start 27-DEC-2002; Project End 30-NOV-2007 Summary: (provided by applicant): Alcoholic liver disease is associated with an increase in oxidative stress and inflammatory mediators such as TNFalpha. Recently, work by this group has clearly demonstrated an essential role of oxidant production and TNFalpha signaling in the liver pathogenesis due to chronic ethanol consumption in a intragastric ethanol-feeding model in mice. Two primary approaches have been employed thus far to elucidate the mechanisms of alcohol-induced liver injury: viral vector-mediated gene transfer and mutant (i.e., knockout and transgenic) mouse technology. The work proposed here will continue to rely on the strengths of these approaches and build on our recent finding to test the unifying hypothesis that Kupffer cell-derived oxidants initiate a cascade of inflammatory responses including NFkappaB activation and TNFalpha production which subsequently induces mitochondrial dysfunction and oxidative stress in hepatocytes leading to tissue damage. First, isolated liver perfusion and superoxide production by cytochrome c reduction from transgenic and knock out mice following 4 weeks of intragastric ethanol feeding will be used to identify sources or oxidants (i.e., NADPH oxidase, CYP2E1, myeloperoxidase, iNOS, etc) and critical pathways responsible of hepatic oxidative stress due to alcohol (Aim 1). Next, in order to specifically target cellular and subcellular sources of oxidants, cellspecific gene delivery vectors will be used. Using recombinant adeno-associated viral (rAAV) serotypes and cell-specific promoter elements for Kupffercells or hepatocytes, optimized gene transfer to both Kupffer cells and hepatocytes in vivo will be achieved (Aim 2). Finally, using rAAV serotypes and cell-specific promoter elements, the over expression of cytosolic Cu/Zn-SOD, mitochondrial Mn-SOD and dominant-negative IkappaBalpha in each cell type will be evaluated in the mouse enteral ethanol feeding model to test the hypothesis that Kupffer cell-derived oxidants are initially responsible for activating an inflammatory cascade leading to mitochondrial oxidative stress and dysfunction and ultimately tissue damage (Aim 3). The experiments outlined in this proposal will not only provide important mechanistic data related to oxidant production and transcription factor activation involved in acute ethanol-induced liver injury, provide novel experimental tools that can be used to address numerous questions related to basic biology and disease of liver and potentially provide an effective therapeutic approach to treatment of alcoholic liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENE THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA Principal Investigator & Institution: Mathews-Roth, Micheline M.; Associate Professor of Medicine; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2003 Summary: Erythropoietic protoporphyria (EPP) is a genetic disease in which ferrochelatase, the enzyme that inserts iron into protoporphyrin, is defective. In EPP, protoporphyrin accumulate in erythrocytes, leaks into about 5% of patients. Since it has been demonstrated that the vast majority of the protoporphyrin found in plasma, skin and liver derives from the erythrocytes, we propose that gene therapy directed at the bone marrow could cure EPP. This would be especially beneficial for patients with severe photosensitivity or incipient liver disease resistant to pharmacological treatment. Using a mouse model of EPP (homozygous recessive mutation), we have recently
Studies
33
demonstrated that transplantation of bone marrow from normal syngeneic Balb/C donors into irradiated EPP recipients completely cures the disease phenotype. We have also shown that retrovirus-mediated transfer of human ferrochelatase cDNA into peripheral blood BFU-E from human EPP patients corrects the specific protoporphyrinmediated fluorescence. In addition, we are developing improved gene transfer methods for hematopoietic stem cells by means of Lentiviral vectors and in vivo selection protocols, which will be validated and optimized in the EPP gene therapy model. Based on these preliminary results, our Specific Aims are as follows: Specific Aim 1: To demonstrate that retroviral transfer of human ferrochelatase cDNA into hematopoietic stem cells of EPP donor mice followed by their transplantation into EPP recipient mice will cure or significantly ameliorate the disease phenotype. Specific Aim 2: To compare the efficiencies of Murine Leukemia Virus-verus HIV-1 Lentivirus-based vectors to transduce murine hematopoietic stem cells and correct the EPP phenotype by bone marrow transplantation. Specific Aim 3: To evaluate the efficacy of gene therapy protocols for EPP that combine minimal myeloablation prior to bone marrow transplantation, Multi-drug Resistance (MDR) or Dihydrofolate Reductase (DHFR) retroviral vectors and corresponding in vivo selection regimens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENERAL CLINICAL RESEARCH CENTER Principal Investigator & Institution: Boat, Thomas F.; Director; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2001; Project Start 30-DEC-1993; Project End 30-NOV-2001 Summary: This is a proposal for the renewal of a multi-categorical General Clinical Research Center at the Children's and University Hospitals. Major areas of research include: 1. Pediatric Liver Disease. Studies are defining the pathophysiology and treatment of new inborn errors of bile acid metabolism and peroxisomal disorders and the pathogenesis of bone disease and growth failure in cholestatic liver disease. 2. Bone Health. Studies will examine the effect of maternal age during lactation on bone demineralization and the value of progestins in ameliorating the loss. Studies will evaluate the role of calcium supplementation on bone accretion in prepubertal children, the role of exercise in bone accretion in preschoolers and the pathogenesis and management of bone disease in juvenile rheumatoid arthritis. 3. Cancer. Using resources available through a proposed Tissue Procurement Facility supported by the GCRC, basic science and clinical investigators will obtain tumors for investigations of the cell biology and molecular mechanisms of malignancies. Studies will investigate thyroid cancer, neural tumors, breast cancer, and the APC and Bloom's Syndrome genes. 4. Gaucher Disease. Despite the availability of enzyme research for Gaucher Disease, disability from bone disease persists. Studies will evaluate the potential value of bisphosphonates as an adjunct to enzyme replacement for the treatment of bone disease in Gaucher Disease. 5. Cystic Fibrosis. Studies are defining the safety of a replicationdeficient recombinant adenovirus construct to deliver the CF transmembrane conductance gene to the nasal epithelium. 6. Cholesterol Synthesis. Studies are evaluating the potential effect of the cholesterol content in breast milk or infant formulae and cholesterol synthesis rates to determine if early exposure to cholesterol in the human infant may have an "imprinting" effect on cholesterol synthesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
34
Liver Disease
•
Project Title: GENETICS OF AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE Principal Investigator & Institution: Somlo, Stefan; Associate Professor; Internal Medicine; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2001; Project Start 30-SEP-1995; Project End 31-MAR-2003 Summary: Autosomal dominant polycystic liver disease without kidney cysts (ADPLD) is a genetically distinct, heritable disease characterized by the presence of multiple, scattered cysts in the liver parenchyma not associated with cyst formation in the kidney. We have performed a genome-wide scan for linkage using several ADPLD families and identified a major locus for the disease confined to a approximately 10 centiMorgan interval on human chromosome 19p13.2. The overall goals of our program for studying polycystic liver disease (PLD) are (1) phenotypic characterization of individuals with PLD and families with ADPLD, (2) identification of the gene (PLD1) mutated in human ADPLD, (3) elucidation of the mechanisms by which mutations result in the observed phenotype, (4) discovery of the factors that modify the expression of the ADPLD phenotype, (5) understanding the role of PLD1 in human cystic diseases in general and, (6) discovery of approaches for modulating the phenotypic effects of mutations in PLD1. The present proposal focuses on the characterization of the ADPLD phenotype and the identification of responsible human disease gene by positional cloning. We propose to undertake a comprehensive characterization of the clinical phenotype of ADPLD to determine whether patients with ADPLD have extrarenal manifestations that overlap with those of patients with autosomal dominant polycystic kidney disease (ADPKD) and establish whether the severity of the liver cystic disease in ADPLD correlates with the same factors known to influence the severity of the liver cystic disease in ADPKD. We plan to establish whether most patients with a presentation of polycystic liver disease (PLD) without renal involvement have familial ADPLD. We will use positional cloning to identify PLD1. Positional cloning will require refinement of the recombinatorial boundaries of the ADPLD genetic interval by definition of "critical recombinants" and construction of a detailed physical map of the interval. This physical map will be used to isolate all expressed sequences from the refined ADPLD candidate region. Candidate genes will be scanned to identify disease related mutations. Once identified, we will characterize the nature of the ADPLD mutations, study the genomic organization of the PLD1 gene, and determine if there is a relationship between genotype and phenotype in ADPLD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENOMIC DETERMINANTS OF NONALCOHOLIC FATTY LIVER DISEASE Principal Investigator & Institution: Merriman, Raphael B.; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2008 Summary: (provided by candidate): Nonalcoholic fatty liver disease (NAFLD) is a group of diseases characterized by hepatic steatosis without significant alcohol use, often associated with hyperlipidemia, obesity and insulin resistance. Nonalcoholic steatohepatitis (NASH) is part of the spectrum of NAFLD, with steatosis and added necroinflammation and fibrosis. NASH is common and may progress to cirrhosis. The pathogenesis of NAFLD is unknown but may incorporate a polygenic susceptibility with a phenotype strongly influenced by environmental factors. Disorders of lipid homeostasis underlie all forms of hepatic steatosis. Fat accumulation as triglyceride (TG)
Studies
35
in the hepatocyte is the critical first step in the development of NAFLD. The central hypothesis of this proposal is that the pathogenesis of NAFLD is based upon increased flux of TG precursors (fatty acids, FA) with increased synthesis or decreased mobilization of TG in the hepatocyte, leading to fat accumulation. We postulate that NAFLD evolves to NASH when genetic abnormalities of fatty acid flux and environmental factors converge. Triglyceride accumulation may relate to increased peripheral FA mobilization, regulated in part by peroxisome proliferator-activated receptor gamma (PPARgamma). Alternatively, FA within the hepatocyte may be misdirected from oxidative pathways to TG synthesis: genomic variants in PPARalpha are likely candidates. Impaired lipidation and hepatocyte VLDL secretion would also potentiate steatosis and variants in Microsomal Triglyceride Transfer Protein (MTP) and apo-B render these as further prime candidate genes. Clinical and tissue databases at UCSF will be utilized and further characterized. The specific aims are (1) To perform mutation analysis on key genes of lipid metabolism, PPARalpha, PPARgamma, MTP and apo-B, for known and novel mutations in patients with NASH. We aim to extend our preliminary data showing increased prevalence of genomic variants of PPARalpha in patients with NASH, supporting our postulate that these are important in disease progression (2) To genotype polymorphisms detected, permitting screening of case control sample populations (3) To assess the contribution to NASH of genomic variants uncovered, in kindred identified with NASH, using cosegregation analysis (4) To determine the biochemical effects of mutants using in-vitro transfection studies. These projects will increase our understanding of NASH and with mentoring and coursework will foster the candidate's development as an independent researcher. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLYPICAN-3: A NOVEL MARKER FOR HEPATOCELLULAR CARCINOMA Principal Investigator & Institution: Filmus, Jorge E.; Sunnybrook & Women's Coll Hlth Scis Ctr Health Sciences Centre Toronto, Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2005 Summary: (provided by applicant): Human hepatocellular carcinoma (HCC) is usually asymptomatic at early stages. As a result, HCC is generally at an advanced stage when discovered, and the therapeutic options very limited. HCC is associated with chronic liver injury, primarily chronic viral hepatitis and alcoholic liver disease. The risk of developing HCC is 50 - 100 fold greater in individuals with chronic hepatitis B virus infection than in non-infected individuals, and the incidence of HCC in cirrhotic carriers of hepatitis C virus (HCV) may be as high as 5% per year. In principle, therefore, screening protocols are justified for chronic HBV carriers and cirrhotic HCV patients. The only molecular marker that has been widely used for the diagnosis and detection of HCC is alfafetoprotein (AFP). However, AFP expression is significantly increased in a considerable number of patients with non-malignant chronic liver diseases. Thus, more specific markers for HCC are required. Results recently obtained in this laboratory have shown that a protein called glypican-3 (GPC3) can be detected in most HCC tissue sections but it is undetectable in normal liver or benign liver disease. In addition, examination of a limited number of patients has shown that whereas GPC3 is undetectable in the serum of healthy individuals, its levels are significantly elevated in a large proportion of HCC patients. These results suggest, therefore, that GPC3 could be a better marker than AFP for the diagnosis and detection of HCC. The main goal of this study is to test this hypothesis. To this end, serum GPC3 and AFP will be measured in a cohort of 100 patients with HCC, and in patients with benign liver disease. The
36
Liver Disease
specificity and sensitivity of both markers will then be compared. GPC3 levels will also be assessed in 50 additional tissue sections from HCC patients, and a similar number of sections from various benign liver diseases. Another objective of this project is to investigate whether GPC3 could be used as a marker of tumor burden in experimental cancer. If this is the case this study will provide a tool that will simplify the search of novel treatments for HCC, and may open the possibility of using GPC3 measurement for the follow-up of HCC patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HBV-ETHANOL INTERACTIONS IN LIVER DISEASE Principal Investigator & Institution: Feitelson, Mark A.; Associate Professor; Pathology, Anat/Cell Biology; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2008 Summary: (provided by applicant): Chronic alcoholism and hepatitis B virus (HBV) infection are associated with chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) in millions of people worldwide. Epidemiologic evidence shows a higher frequency of HBV markers among chronic alcoholics compared to the general population, and more severe liver disease among chronically infected alcoholics compared to patients suffering from chronic alcoholism or HBV infection alone. The applicant laboratory has recently developed an HBV transgenic mouse on a severe combined immunodeficient (SCID) host, which supports consistent levels of virus gene expression and replication. Since the SCID host is not tolerant to the virus, adoptive transfer of unprimed syngeneic splenocytes resulted in the development either acute or chronic hepatitis, with either complete or partial clearance of virus markers from serum and liver, respectively. Interestingly, the introduction of ethanol in a liquid LieberDiCarli diet strongly up-regulated HBV gene expression and replication in these mice, and that when ethanol fed mice were adoptively transferred with 5 x 107 splenocytes, which usually results in acute hepatitis, they develop chronic liver disease (CLD) instead. Since the pathogenesis of hepatitis B is immune mediated, and T cells play a central role in the clearance of virus infected hepatocytes, the objective of this work is to identify the changes in anti-viral T cell immunity that are responsible for the ethanol mediated changes in pathogenesis. This will be addressed by asking whether the shift from acute to chronic liver disease is associated with changes in the presence, frequency, and distribution of T cell responses to one or more virus antigens (aim 1). Experiments will also be conducted to ask whether chronic hepatitis could be converted back to acute, resolving hepatitis by (1) polarizing the immune response toward Thl, or (2) adoptively transferring primed splenocytes to one or more virus antigens (aim2). Together, these experiments will identify the T cell subsets and specificities associated with the ethanol mediated shift from acute to chronic hepatitis, and then therapeutically manipulate T cell immunity so as to prevent the development of CLD in ethanol fed, adoptively transferred mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HCV & ALCHOOL-- EPIDEMIOLOGY & HOST-VIRUS CORRELATES Principal Investigator & Institution: Peters, Marion G.; Professor; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-JUL-2005
Studies
37
Summary: Alcohol and hepatitis C virus (HCV) infection are recognized as independent causes of chronic liver disease and cirrhosis. Further, significant alcohol ingestion, defined variably as >30 gnvday (women) or >50-60 grnlday (men) has been associated with more severe histological disease, including cirrhosis and hepatocellular carcinoma and an accelerated rate of disease progression in patients with chronic HCV infection. The effect of more limited alcohol intake or non-daily drinking patterns on the progression of HCV disease are not known. In this study, we will establish a prospective cohort of at least 550 HCV-infected patients who drink varying amounts of alcohol at study entry. Total lifetime alcohol intake, patterns of alcohol ingestion, and periods of abstinence will be ascertained using validated questionnaires (Skinner, 1979; Russell, 1991) at study entry and annually for four years. Additional data collected at study entry include demographic, epidemiological and dietary history (including duration of HCV infection, mode of acquisition, use of iron supplements). A comprehensive evaluation of HCV RNA including viral titer in serum, liver and peripheral blood mononuclear cells (PBMCs), and baseline quasispecies complexity, will be obtained. Subjects with an alcohol intake of >30 gm/day (females) or >60 gm/day (males) will be counseled to completely abstain. A subset of 150 subjects drinking <15 gm/day (females) or <30 gm/day (males) of alcohol will be randomized to abstinence or no change in alcohol intake (control group). Annually we will readminister an alcohol questionnaire (12-month quantity/frequency questionnaire, National Alcohol Survey) and perform tests for ferritin, transfenin saturation, and serum aminotransferase activity. HCV viral quasispecies variability (assessed by heteroduplex mobility assay) HCV RNA quantitation and cytokine profiles will be compared in different tissue sources (serum, PBMCs and liver). Liver biopsies will be obtained at baseline and at the end of 4 years follow-up to assess severity and progression of liver disease. This study will determine 1) the quantity and pattern of alcohol intake associated with progression of HCV liver disease; 2) whether abstinence from alcohol among "moderate" or "light" drinkers reduces the rate of HCV disease progression; and 3) the host (including proinflammatory or profibrotic host genes which may be activated in the presence of alcohol) and viral factors (including quasispecies heterogeneity which may be altered by alcohol ingestion) which underlie the enhanced rate of disease progression in HCVinfected patients using alcohol. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HCV GENOMIC VARIABILITY IN HIV INFECTED HEMOPHILIACS Principal Investigator & Institution: Sherman, Kenneth E.; Associate Professor; Internal Medicine; University of Cincinnati 2624 Clifton Ave Cincinnati, Oh 45221 Timing: Fiscal Year 2001; Project Start 01-JUN-2001; Project End 31-MAY-2005 Summary: Hemophiliacs with symptomatic disease are multiply exposed to blood products including factor concentrates to correct the Internet clotting factor deficiencies. Prior to routine use of heat inactivation and screening of donor blood for specific viral pathogens, hemophilia patients were routinely exposed to, and infected with, viruses such as hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV). Cohort studies in hemophiliacs suggest several clinically and scientifically important findings that warrant further detailed investigation including; a) Liver disease progression may be altered in hemophiliacs infected with HCV with more rapid progression to liver failure and death; b) The source of infection from large pools of concentrate that were potentially infected by multiple discreet donors leads to a high risks of mixed infection represented by both genotype and quasi species heterogeneity; c) The HIV coinfected hemophiliacs may have different clinical outcomes and an altered
38
Liver Disease
immune response may facilitate our understanding of the underlying process of mutant virus selection, and the associated clinical outcomes. The overall goals of this proposal include the study and characterization of the genomic RNA of HCV in infected hemophilic patients with and without confection with HIV. In the retrospective Phase 1, we utilize the NCI Multi center Hemophiliac Cohort Study serum bank database to study the relationship between progression to decompensated liver disease and quasi species variability in the viral envelope hyper variable and core domain. Heteroduplex analysis will be used to rapidly screen samples from index patients and matched controls using samples longitudinally collected over a 10 year or longer period of time. Peptides will be produced from unique quasi species and these peptides will be evaluated for their function as CTL epitomes. Phase 2 involves the initiation and performance of a clinical intervention trial designed to determine variable kinetic response rates to PEG-interferon+ribavirin between hemophiliacs with HCV alone vs HCV/HIV coinfected subjects. Quasi species populations will be modified/cloned, sequencing will be performed to generate families of closely related core peptides that will be studied for their ability to bind and stimulate an immune response. Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HCV INFECTION--RISK FACTORS FOR PROGRESSION Principal Investigator & Institution: Stuver, Sherri O.; Assistant Professor; Epidemiology; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02460 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-JUL-2006 Summary: (provided by applicant): For individuals who are infected with hepatitis C virus (HCV), knowledge of co-factors affecting the occurrence of liver disease is crucial. However, the mechanisms of HCV-associated pathogenesis, particularly with regard to the role of the virus and the host immune response, remain unclear. The primary goal of the proposal is to elucidate the natural history of HCV infection with respect to progression to hepatocellular carcinoma (HCC) and other health outcomes in a Japanese community-based population in which infection with HCV is highly endemic. As part of an annual ultrasonographic tomography screening program in this population, nearly 1,000 adult residents with HCV have been under surveillance for liver cancer since 1994. The proposed study will extend the observation of this cohort, with the additional collection and analysis of virologic, epidemiologic, and clinical data. The specific aims of the research are: to determine the predictive value of markers of HCV infection in the development of liver damage and HCC; to estimate the effect of host-related factors, including heavy alcohol consumption, cigarette smoking, and diet, on HCV-induced liver disease progression and hepatocarcinogenesis; to examine the role of co-infection with hepatitis B virus and human T-lymphotropic virus type I in the natural history of HCV; to characterize the function of host immune status and response in the persistence of HCV infection as well as in the progression of liver disease and HCC among HCV carriers; to evaluate the utility of serologic markers of liver damage in predicting the development of HCC in individuals infected with HCV; to identify predictors of extrahepatic morbidity and mortality among HCV carriers. The uniqueness of the study population and the richness of the data parameters combined with the extensive experience of the assembled multi-disciplinary team provide an important opportunity to increase our understanding of the natural history of HCV and to contribute to our
39
Studies
ability to identify and potentially treat those carriers who are at increased risk of an adverse outcome related to their HCV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HCV-ALCOHOL EPIDEMIOLOGY
INTERACTIONS--
PATHOGENESIS
AND
Principal Investigator & Institution: Stapleton, Jack T.; Professor; Internal Medicine; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2001; Project Start 01-SEP-1999; Project End 31-AUG-2003 Summary: Hepatitis C is the commonest cause of chronic hepatitis in the US and can lead to progressive liver injury with the development of cirrhosis, liver failure and liver cancer. Liver injury may be caused by an interaction of the virus with the host immune response leading to inflammation and fibrosis in the liver. We plan to examine the mechanism of HCV induced liver injury in three distinct groups of patients: 1) those with chronic HCV infection and evidence of moderate to severe necroinflammatory disease, who are at average risk of progression to cirrhosis; 2) those with persisting viremia but normal or minimally elevated transaminases and normal or mildly inflamed liver biopsies, who are at low risk of progression to cirrhosis; and 3) patients with chronic HCV liver disease and active daily alcohol use (greater than 50 gm/day), who are at the highest risk of progression of liver disease. Specifically, we propose to evaluate the role of intrahepatic viral load on immune response and liver injury by measuring liver derived CTL response and cytokine production and correlating the immune response to the degree of liver injury. The response in the liver will be compared with that seen in the periphery to determine whether there is compartmentalization of immune responses and whether peripheral immune response can correlate with the injury and immune response seen in the liver. The role of antiviral therapy and alcohol on these responses will also be studied. These studies may lead to insights on the mechanism of liver injury and help define those patients who are most likely to have progressive liver injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HCV-HIV COINFECTION: IMPACT OF IMMUNE DYSFUNCTION Principal Investigator & Institution: Sterling, Richard K.; Internal Medicine; Virginia Commonwealth University Richmond, Va 232980568 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): This proposal for the Mentored Clinical Research Award (K-23) is to provide supervised experience in patient oriented clinical research. The candidate is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Virginia Commonwealth University Health System/Medical College of Virginia campus (VCUHS/MCV). His career goals are: (1) to be an outstanding clinician and (2) to be a leading scientist in patient-oriented research in liver disease. During the period of support, the applicant will be primarily mentored by Dr. Arun J. Sanyal with support from other faculty from Hepatology (Dr. Mitchell L. Shiffman), Infectious Disease (Dr. Evelyn Fisher), Biostatistics (Dr. Chris Gennings), and Quality Health Care (Dr. Wally Smith). Effective therapy for human immunodeficiency virus (HIV) infection has markedly prolonged survival in infected individuals. As a result, other comorbid conditions in these patients are becoming more clinically important. Approximately 30% of HIV infected patients are also infected with hepatitis C virus (HCV) which is now the leading co-morbid disease in HIV-infected individuals. The
40
Liver Disease
histologic severity and natural history of HCV has been reported to be accelerated in those co-infected with HIV. It is hypothesized that: 1) the severity and progression of hepatic fibrosis in patients with HIV-HCV co-infection is directly related to the immunologic competence of the individual, and 2) the virologic response to anti-HCV treatment is directly related to the degree of immunologic competence. These will be tested by the following specific aims: 1) to perform a longitudinal prospective cohort study of subjects with HIV-HCV co-infection and to define the change in the distribution of hepatic fibrosis scores and the relationship between these changes and the immunologic status, and 2) to prospectively define the relationship between the immunologic status and the sustained virologic response to anti-HCV therapy. The institution and departmental environment as well as the facilities and resources are excellent for career development in academic medicine. The K-23 award will protect this candidates time and help him mature into a senior investigator in Hepatology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEPATITIS C VIRUS PROTEINS AND ETHANOL Principal Investigator & Institution: Polyak, Stephen J.; Assistant Professor, Research; Laboratory Medicine; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2005 Summary: (provided by applicant): This revised R21 exploratory proposal focuses on the interaction of alcohol with hepatitis C virus (HCV) proteins in the pathogenesis of HCV liver disease. HCV infection is a significant clinical problem and is a major cause of liver disease worldwide. The prevalence of HCV infection is significantly higher in alcohol abusers, who are also at greatly increased risk for development of liver diseases that include fibrosis, cirrhosis and hepatocellular carcinoma. Moreover, the incubation period for development of liver disease is much shorter in HCV-infected alcohol abusers. HCV infected patients who abuse alcohol also have reduced responses to interferon (IFN) therapy. Alcohol and HCV proteins have separately been shown to induce a plethora of changes in signal transduction cascades in human cells, including inhibition of the IFN system and increased expression of pro-inflammatory cytokines and chemokines, such as TNF-alpha and IL-8. Our preliminary data indicate that the HCV NS5A protein induces IL-8 to inhibit the IFN system, while the HCV core protein activates the IFN system. However, very little is known about how alcohol affects cellular signal transduction pathways in the context of HCV protein expression, and the resultant effects on liver cell horneostasis. We hypothesize that alcohol and HCV proteins induce pro-inflammatory cytokine and chemokine expression, inhibit IFN signal transduction, and perturb the expression of other cellular proteins and signal transduction pathways in human hepatocytes. Using human hepatocyte cell lines stably expressing the HCV NS5A and core proteins under tetracycline regulation, this exploratory application will address two specific aims. Specific Aim 1 will determine the effects of physiological concentrations of ethanol with HCV core and NS5A protein expression on pro-inflammatory cytokine and chemokine expression, and IFN signal transduction. Specific Aim 2 will characterize the global transcriptional changes in human hepatocytes induced by HCV core and NS5A proteins, ethanol, and IFN by CDNA microarray analysis. These studies will provide mechanistic information on how alcohol interacts with the HCV-infected patient to promote liver disease, and may lead to strategies to counteract the deleterious effects of these agents on the liver. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
41
Project Title: HGF AND HEPATOCYTES IN NEOPLASIA AND LIVER FAILURE Principal Investigator & Institution: Michalopoulos, George K.; Professor and Chairman; Pathology; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2001; Project Start 15-AUG-1981; Project End 31-MAY-2002 Summary: In this renewal application we designed experiments aimed to capitalize on two major advances which occurred during the last funding period; 1. HGF biology: Hepatocyte Growth Factor (HGF) is now fully cloned and sequenced, in part from work funded by this grant in its earlier periods. Its receptor (encoded by the proto-oncogene c-met) is now well characterized. Activation of HGF by urokinase is now well documented. 2. In its new location in the university of Pittsburgh the lab has now access to hepatic tissue from the largest liver transplantation program in the world. Approximately 450 cases of liver at end stages of disease is available annually. The lab has now access to an existing collection of frozen tissue and paraffin blocks from hundreds of well defined stages of human hepatic disease. It also has access to all the new livers resected from transplantation cases. The project is now focusing on utilizing the new knowledge on HGF biology and the access of human liver tissues to focus on two lethal forms of human liver disease where growth disregulation leads to death: A. Hepatocellular Carcinoma (HCC). This is the most frequent cancer in the world. HGF is mitogenic and motogenic in normal human hepatocytes but is only motogenic and sometimes mitoinhibitory in human hepatocellular carcinomas. We will examine the role of HGF as a mitogen, motogen and mitoinhibitor in the evolution of human hepatocellular carcinoma from its earliest stages (atypical adenomatous hyperplasia, (AAH) seen as solitary nodules in cirrhosis), to its most advanced widely invasive forms. The role of HGF activation by urokinase in the evolution of this disease will be also examined. The potential mitoinhibitory effects of HGF on HCC, if properly documented understood, may have a therapeutic potential in this disease. B. Fulminant liver Failure (FHF): In this condition, hepatocyte regeneration ceases, stem cell compartment (ductular hepatocytes) becomes activated, solitary clonal growths of hepatocytes (pseudoadenomas) grow to a hugh size. HGF levels in the plasma are extremely high. We will investigate; a. the role of HGF as a mitogen, motogen and morphogen in the evolution of new cell populations in this disease; b. the role of high doses of HGF in the inhibition of hepatocyte regeneration (leading to death of the patient); c. the effect of high doses of HGF in the activation of the stem cell compartment in the human liver. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HIV HCV COINFECTION--ANTIVIRAL THERAPY AND FIBROSIS Principal Investigator & Institution: Thomas, David L.; Associate Professor; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 20-SEP-2000; Project End 31-JUL-2005 Summary: (Applicant's Abstract) Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections occur with alarming frequency in persons who misuse alcohol and illicit drugs. In East Baltimore, 80 percent of HIV-infected injection drug users also have HCV infection and one-half acknowledges regular, heavy alcohol use. This disease cluster may cause cirrhosis since HIV infection and heavy alcohol use are the two conditions that accelerate progression of hepatitis C. Recently the significance of these cofactors has been magnified by improved anti-retroviral treatments that dramatically reduce other opportunistic infections but may themselves
42
Liver Disease
cause liver toxicity. Accordingly, the 1999 US Public Health Service guidelines for management of HIV opportunistic infections considered hepatitis C but withheld recommendations for medical management because of the paucity of supporting data. In this investigation, we hypothesize that treatment of HIV and HCV infections will reduce progression of liver disease, after controlling for alcohol use. To test the hypothesis, we will first examine the success of prior anti-retroviral use with respect to liver fibrosis and then the change in fibrosis over three years of anti-retroviral experience. In addition, we will examine the effect of alfa-interferon based treatment for HCV infection with respect to fibrosis changes and eradication of HCV. Innovative tools will be tested to assess liver fibrosis (morphometrics), predict liver fibrosis (markers), and measure use of alcohol and medical adherence (A-CASI). Given the experience of the investigative team and the extensive preliminary data, we anticipate providing data that will directly affect forthcoming guidelines for the medical management of HIVHCV coinfected persons. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUMAN POLYCYSTIC KIDNEY DISEASE Principal Investigator & Institution: Schrier, Robert W.; Professor; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2001; Project Start 01-APR-1985; Project End 30-JUN-2006 Summary: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common potentially lethal genetic diseases. It occurs worldwide and affects about 1 in 500 to 1000 Americans. The costs for treatment of end- stage renal disease (ESRD) are estimated to exceed 1.5 billion US dollars per year, not including the cost for treatment of other renal and extrarenal manifestations. Over the last 15 years this Program Project Grant (PPG), which is the largest study of ADPKD manifestations in children and adults in the world, has contributed significantly to our understanding of the natural history of this disease. The long-term objective for the competitive renewal is to develop strategies to prevent disease progression. This application focuses on ADPKD kidney and liver disease. Combining a clinical trial with investigations into genetic mechanisms of disease severity and with basic research in an animal model and cell culture systems will be the overall strategy to achieve the goal. The competitive renewal of the PPG continues to take advantage of the unique adult and child population, which has been assembled as a result of the 15-year PPG. This patient population will e used in the first Project-A randomized trial of anti-hypertensive therapy in children, adolescents and young adults with ADPKD- and in the second Project- Identification of modifying gene sin ADPKD. The premise is that identifying genes that promote disease severity will not only help to understand the pathophysiology, but will also allow development of new treatments and section of high-risk patients for treatment trials. The third and fourth will complement the two clinical investigations by performing basic science studies, which have clinical implications for patients with ADPKD. The third Project investigates the role of apoptosis and caspase (apoptosis) inhibitors in the progression to ESRD in the Han:SPRD rat model of ADPKD and in the Pkd2/WS25 mouse model provided by Dr. Somlo, and the fourth Project examines the pathogenesis of hepatic cystic disease. Very little is known about the pathogenesis of liver cysts and thus focused interventions are not possible. Study of the liver will also contribute to our understanding of the factors that cause ESRD in ADPKD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
43
Project Title: IMMUNITY TO HEPATITIS C IN LIVER TRANSPLANT RECIPIENTS Principal Investigator & Institution: Koziel, Margaret J.; Assistant Professor; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2001; Project Start 01-JUN-1997; Project End 31-MAY-2002 Summary: (Adapted from the applicant's abstract) Hepatitis C virus (HCV) is a significant cause of end stage liver disease in the United States, and in most transplant centers is a major indication for transplantation. Following liver transplantation, HCV viremia occurs in nearly 100% of HCV-infected individuals. Approximately half of infected liver transplant recipients will develop clinically significant hepatitis, which has a more rapid progression than HCV hepatitis in the immunocompetent host. A subset of HCV infected transplant recipients may have rapid graft loss and impaired survival. The only currently licensed therapy for HCV infection, interferon-alpha (IFN-a), has a low sustained response rate and increases the risk of chronic rejection in allograft recipients. Given the impact of HCV on transplant recipients, there is a need for a greater understanding of pathogenesis of this infection. Neither the viral nor the host factors which determine outcome are defined. At present, there is no small animal model for HCV infection; so examination of host responses in infected individuals is critical to understanding the possible role of host factors in determining clinical outcome. Cellular immune responses are a crucial component of host defenses in most viral infections and are attenuated in transplant recipients. In particular, cytotoxic T lymphocytes (CTL) are an important element of protective host immunity, but under certain circumstances may induce host tissue damage without clearing viral infection. By comparing the immune response against HCV in immunocompetent hosts and transplant recipients, it may be possible to determine which host factors are important in controlling viremia and which host factors may be responsible for accelerated disease. The goal of this proposal is understanding the role of cytotoxic T lymphocytes in limiting viral replication. The specific aims of this proposal are to: 1) define HCVspecific cellular immune responses in transplant recipients; 2) correlate the spectrum of HCV-specific CTL responses with disease activity in transplant recipients; and 3) characterize the role of cytokines in HCV-specific CTL responses in transplant recipients. These studies will provide the necessary scientific background for the development of vaccines or immunotherapies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMPACT OF HIV ON HEPATITIS C INFECTION IN HEMOPHILIA Principal Investigator & Institution: Ragni, Margaret V.; Professor; Medicine; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2001; Project Start 11-APR-2001; Project End 31-MAR-2005 Summary: (provided by applicant) The purpose of this study is to determine the impact of HIV infection on hepatitis C virus (HCV) liver disease outcome, and the prevalence, risk factors, and viral and immunologic characteristics of liver disease in HCV-infected hemophiliacs, both HIV(+) and HIV(-). Approximately 826 HCV-infected hemophiliacs from 10 U.S. hemophilia treatment centers will be available for study. This group is unique in that patients are well characterized, closely followed, the time of HCV infection is known, HCV infection duration is greater than 20 years, and the incidence of liver disease progression is increasing. The specific objectives of this study include: (1) a cross-sectional cohort study in which hemophiliacs with HCV infection, both HIV(+) and HIV(-), are enrolled and undergo transjugular liver biopsy to determine the prevalence of cirrhosis and fibrosis progression rate. (2) a cross-sectional study
44
Liver Disease
comparing HCV-infected patients, both HIV- and HIV+, to determine clinical, life-style, and laboratory, e.g. biochemical, serologic, molecular biologic, and immunologic characteristics associated with development of cirrhosis and stage of fibrosis progression. (3) a cytokine study, comparing cytokine mRNA levels, interleukin-6 (IL-6), interleukin-10 (IL-10), and transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) in liver tissue, cytokine immunoassay levels in plasma, and cytokine expression genotypes with liver histopathologic score and with fibrosis progression rate in prospectively-biopsied hemophiliacs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INCIDENCE OF DRUG-INDUCED LIVER INJURY Principal Investigator & Institution: Chan, Kin-Wei A.; Epidemiology; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02460 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): This is a new application of an epidemiology study among five health maintenance organizations (HMOs) to evaluate the incidence of druginduced liver injury that results in hospitalizations and to assess the association between exposure to specific drugs and liver outcomes not attributable to non-drug cause. The proposed study will be based on collaborative research infrastructure that has already been established at the HMO Research Network, which is funded as a Center for Education and Research on Therapeutics by the Agency for Healthcare Research and Quality. Five HMOs in different regions of the U.S. will participate. They are Fallon Community Health Plan in central Massachusetts, Harvard Pilgrim Health Care in Eastern Massachusetts, Kaiser Permanente Colorado in Denver area, Kaiser Permanente Northwest in Oregon, and Lovelace Clinic in New Mexico, with a combined health plan population of more than two million. Automated hospital discharge data from the HMOs will be used to identify all patients hospitalized with acute liver disease in 2001. Medical records of potential cases will be reviewed and the liver disease attributed to pre-defined causes. Cases not clearly attributed to a non-drug cause will be independently reviewed by two hepatologists to determine their severity and etiology. Cases of probably drug-induced acute liver injury, possibly drug-induced acute injury, idiopathic acute liver disease, and those whose liver events did not have enough information to evaluate causality will be described. Population-based incidence of these acute liver events will be calculated, and they will form the case series in a case-control analysis designed to evaluate the strength of association between drug exposure and these liver events. Two control series (hospital controls and health plan controls) will be identified. This proposed study will serve as a long term valuable data source for the study of drug-induced liver injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INDUCTION OF AP1 AND NFKB BY ETHANOL Principal Investigator & Institution: Brenner, David A.; Professor; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2003; Project Start 27-DEC-2002; Project End 30-NOV-2007 Summary: (provided by applicant): Alcoholic liver disease in patients appears to progress from steatosis to alcoholic hepatitis, fibrosis, and finally cirrhosis. Recent studies in rodents have elucidated many of the pathways by which chronic alcoholic intake leads to steatosis and steatohepatitis. However, the progression to hepatic fibrosis and cirrhosis is largely unknown. The overall goal of this project is to define the
Studies
45
mechanism by which steatohepatitis leads to fibrosis in alcoholic liver disease. We will perform studies using the intragastric lavage model in mice to take advantage of mouse genetics and using primary cultures of hepatic stellate cells. This proposal is based on several underlying hypotheses: 1. Activation of the hepatic stellate cell (HSC) is the key mediator of the progression of alcoholic liver disease from steatohepatitis to fibrosis. 2. Activation of HSCs in culture recapitulates critical components of activation and hepatic fibrosis in vivo. 3. Lipopolysaccharide (LPS) is a critical factor in alcohol-induced fibrosis. 4. Female mice are more susceptible to alcoholic fibrosis than male mice. The specific aims to be addressed in this project are: 1. To determine if NF-rJ3 transcriptional activity is an early marker of HSC activation. 2. To determine if HSC activation and proliferation proceeds type 1 collagen expression in alcoholic liver disease. 3. To determine if fibrogenesis exceeds matrix degradation in activated HSCs in alcoholic liver disease. The experimental design will use three novel transgenic mice that were created in our laboratory. The trangenic lines express reporter genes driven by the collagen alpha1(I) promoter and enhancer, the smooth muscle a actin promoter, or an NF-kappaB responsive element. These mice will be treated chronically with ethanol by the intragastric ethanol feeding model. By combining in vivo and in culture studies using these transgenic mice, our goal is to discover new insights into the molecular pathogenesis of alcoholic liver fibrosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INSULIN RESISTANCE IN HCV INFECTION Principal Investigator & Institution: Khalili, Mandana; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 30-JUN-2007 Summary: (provided by applicant): The overall objective of this proposal is to support the principal investigator's development in a career focused on patient-oriented research. This application has both training and scientific components. The training component includes course work towards a Master's in Clinical Research as well as a solid sponsorship structure for career development. The scientific component integrates a multidisciplinary approach in order to assess the impact of hepatitis C (HCV) infection on insulin action in patients with chronic HCV infection. Epidemiological studies have shown that there is an association between HCV and type 2 diabetes mellitus (DM). Type 2 DM in turn, is characterized by insulin resistance. Thus, it is possible that HCV infection promotes tissue resistance to insulin-mediated glucose uptake. Insulin resistance is of importance to liver disease because it can lead to hepatic steatosis (fatty liver). HCV also causes hepatic steatosis, and is associated with accelerated hepatic fibrosis. Therefore, it is of great importance to determine whether insulin resistance represents a cause of steatosis in patients with chronic HCV infection that could worsen the outcome of liver disease. The specific aims of this study are: 1. To characterize the variability in insulin sensitivity and insulin secretion in non-diabetic patients with HCV infection. 2. To determine the correlation between severity of steatosis and the degree of insulin resistance in HCV-infected individuals. 3. To determine the effect of HCV eradication on insulin resistance and insulin secretion. 4. To correlate changes in insulin sensitivity with changes in hepatic steatosis after successful HCV eradication. A prospective cohort design will be used to assess an outpatient HCV population. Insulin resistance, insulin secretory function, lipid and lipoprotein profiles will be evaluated using specific methodologies. Parameters of insulin sensitivity/insulin resistance will be compared to host and viral factors associated with HCV, in an effort to identify specific factors that may be causal. Finally, because we believe that the connection between HCV
46
Liver Disease
and insulin resistance is causal, we anticipate that successful treatment of HCV will result in improved insulin sensitivity together with a reduction in hepatic steatosis. One of the important advantages of this study is that patients will be evaluated before and after HCV treatment. This will permit a direct evaluation of the causative role of HCV in promoting insulin resistance and hepatic steatosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERFERON-GAMMA TO TREAT CHRONIC HCV INFECTION Principal Investigator & Institution: Muir, Andrew J.; Medicine; Duke University Durham, Nc 27706 Timing: Fiscal Year 2001; Project Start 21-SEP-2001; Project End 31-AUG-2003 Summary: (adapted from the application) Current treatment options for chronic hepatitis C infection remain limited and unsatisfactory. Treatment with interferon-alpha and ribavirin leads to a sustained response in the minority of patients, and many patients may not be eligible for treatment due to side effects associated with these medications. Other treatment options are clearly necessary for chronic hepatitis C infection. A major complication of chronic hepatitis C infection is fibrogenesis, ultimately leading to development of cirrhosis. Animal models have demonstrated that interferon-gamma reduces fibrogenesis through its effect on stellate cells. A recent report in patients with idiopathic pulmonary fibrosis found that interferon-gamma was well-tolerated and led to improved pulmonary function, ostensibly due to a reduction in fibrogenesis. Given these data, we postulate not only that interferon-gamma will be effective for treatment of hepatitis C mediated fibrogenesis, but also that it will be safe. We have therefore proposed a phase I study to assess the effectiveness of interferongamma in twenty patients with chronic hepatitis C infection. The patients will include those who have failed previous therapy with interferon-alpha or are not candidates for interferon-alpha therapy. Men or women 18 years of age or older are eligible. Other inclusion criteria are serum positive for hepatitis C virus by PCR; liver biopsy consistent with chronic hepatitis and with a fibrosis score of at least one on the Knodell scale; compensated liver disease; and informed, written consent obtained prior to entry. All patients will receive 200 micrograms of interferon-gamma three times a week for twelve months. Patients will undergo liver biopsy prior to treatment and at the end of treatment. Safety and tolerance will be evaluated at weeks 1, 2, 4, 8 and then every 4 weeks during treatment and at weeks 4 and 12 following the completion of therapy. Serum HCV-RNA will be evaluated prior to initiating therapy and at the end of therapy. The primary endpoint of this study will be the histological response of patients with chronic hepatitis C infection to treatment with interferon-gamma. Secondary endpoints include the biochemical response, inflammatory and regulatory cytokine levels, and quality of life during treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: LIVER PATHOBIOLOGY AND GENE THERAPY RESEARCH CORE CENTER Principal Investigator & Institution: Shafritz, David A.; Professor; Medicine; Yeshiva University 500 W 185Th St New York, Ny 10033 Timing: Fiscal Year 2001; Project Start 01-JUN-1989; Project End 31-MAY-2004 Summary: An interdisciplinary Liver Research Center was established at the Albert Einstein College of Medicine in 1974 with support from NIDDK. At present, 38 faculty investigators, 1 emeritus investigator, and 2 provisional investigators in 12 departments
Studies
47
at the medical school, together with 17 Consultants/Collaborators and 4 Supporting Staff Faculty at AECOM, constitute the Liver Research Center. The major objective is to understand fundamental mechanisms of normal liver function, as well as alterations in these functions resulting from diseases caused by metabolic, drug, metal, inheritable and viral agents. Specific areas under study include transport processes, membrane receptor biology, and structural-functional relationships; molecular biology, somatic gene transfer and gene therapy, hepatic fibrosis and mechanisms of hepatic carcinogenesis; hepatic cell transplantation, liver cell metabolism, heavy metal metabolism, mechanisms of liver injury and organelle pathology. By bringing excellent basic scientists into disease-related research, together with hepatologists interested in fundamental mechanisms of hepatic dysfunction, we believe that imaginative approaches to basic cell biology, pathophysiology, diagnosis, treatment and prevention of liver disease will emerge. The Center is the focus of an active research-oriented education program (research seminars, visiting scientists, pathobiology sessions and work-in-progress discussion groups), and has extensive collaborative studies with investigators in other institutions. Core facilities, including Molecular Biology and Genetics, Cell Culture and Genetic Engineering, Imaging and Cell Structure, Special Animals and Administrative, efficiently facilitate interdisciplinary research projects. Facilities include 38 well-equipped laboratories for major investigators, 5 core facilities. Animal Institute, and all institutional support services (library, machine shop, engineering, computer center, etc.) The available clinical facilities include a 1100 bed general hospital (Bronx Municipal Hospital Center), Montefiore Hospital (729 beds) and the Jack D. Weiler Hospital of Albert Einstein College of Medicine (375 beds). A large and diverse patient population provides many individuals with viral, alcoholic and parasite liver disease, as well as varius inheritable disorders of the liver. The Center is directed by the Principal Investigator (Dr. David A. Sharfritz) and Associate Director (Dr. Allan W. Wolkoff), governed by an Executive Committee, advised and reviewed by a Scientific Advisory Committee and functions through several school-wide committees. The Center was officially chartered by the medical school in 1977 as a free standing, extra- and supra-departmental entity. The importance of the Liver Research Center to the College of Medicine has been reconfirmed by extensive renovation of existing facilities, updating of equipment, an endowment fund and recruitment of new faculty with resources provided by the Dean, Dominick P. Purpura, M.D. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LIVER REGENERATION IN PEDIATRIC LIVER DISEASE Principal Investigator & Institution: Rudnick, David; Pediatrics; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2005 Summary: Liver regenration occurs after many types of injury, including metabolic, toxic, infectious, and traumatic injuries. It is thought to influence recovery from acute insults, but also to contribute to the development of cirrhosis and neoplasia when deranged during chronic disease. From studies of the response of experimental animals to partial hepatectomy (PH) it is known to be a highly regulated response that proceeds until the original hepatic mass is restored. Recent studies in knockout mice have provided new information about the specific molecules involved in initiation of regeneration. Still, relatively little information is known about downstream signals involved in initiation, or the signals that very precisely terminate regeneration. Furthermore, there is little known about how liver disease influences the signaling pathways that activate and terminate the regenerative response, how they may be
48
Liver Disease
deranged, or whether novel pathways are involved. The long term goal of this grant application is to determine whether the molecular signaling pathways involved in initiation and termination of liver regeneration after PH are also involved in the regenerative response in pediatric liver disease using genetically altered mouse models. Preliminary results using specific antagonists and knockout mice suggest that prostaglandin metabolism, specifically that involving COX-2, is critical for initiating regeneration after PH and may precede the action of the cytokine IL-6 in the regenerative response. Other preliminary results using a knockout mouse suggest that the prapoptotic protein Bid plays a role in terminating regeneration. Finally, the preliminary results provide evidence for the feasibility of generating a novel transgenic mouse model of alpha1-AT deficiency using liver specific, inducible expression of human alpha1-ATZ to study liver regeneration in pediatric liver disease. Further studies using genetically altered mice proposed in this application are designed to provide a basis for novel pharmacologic and cell transplantation strategies for treatment/prevention of pediatric liver diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MANAGEMENT/HEPATITIS C/HIV-INFECTED AND UNINFECTED IDU'S Principal Investigator & Institution: Sulkowski, Mark S.; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 30-JUN-2008 Summary: (provided by applicant): Injection drug use is the predominant mode of HCV transmission in the United States and most injection drug users have HCV infection. In East Baltimore, 80-90% of IDUs are infected with hepatitis C, which can cause progressive hepatic fibrosis (cirrhosis) over 20 or more years, leading, in some patients, to end-stage liver disease, hepatocellular carcinoma and death. Furthermore, coinfection with human immunodeficiency virus (HIV) is present in 30% of HCVinfected IDUs, and is associated with the more rapid progression of HCV-related liver disease. Treatment of hepatitis C with pegylated interferon/ribavirin (PEG/RBV) eradicates HCV infection in approximately one-half of patients. However, persons who use or have used injection drugs are typically excluded from these treatment protocols, as are persons with other comorbidities such as HIV infection and psychiatric disease. This research aims to address the reality that the persons most affected by HCV infection are the least studied and the least treated, a disparity that becomes even more compelling as the success of HCV therapy increases. However, the implementation of HCV care is hindered by the paucity of data regarding which HIV-infected and uninfected IDUs are eligible and need HCV treatment. To address these issue we propose to accomplish the following aims: 1) to determine proportion of HIV-infected and uninfected IDUs who are eligible for HCV therapy with PEG/RBV according to absolute and relative criteria; 2) To determine the medical necessity of HCV treatment among HIV-infected and uninfected persons who are eligible for the PEG/RBV (determined by liver histology and non-invasive markers); and 3) Given the experience of the investigative team and the extensive preliminary research, we anticipate providing data that will have important impact on the medical care HCV-infected IDUs with and without HIV coinfection as well as the development of policies for the management and delivery of hepatitis C care among IDUs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
49
Project Title: MATERNAL LIVER DISEASE AND FATTY ACID OXIDATION DEFECTS Principal Investigator & Institution: Ibdah, Jamal A.; Internal Medicine; Wake Forest University Health Sciences Winston-Salem, Nc 27157 Timing: Fiscal Year 2001; Project Start 21-SEP-2001; Project End 31-AUG-2006 Summary: Mitochondrial trifunctional protein (TFP) catalyzes the last 3 steps in the beta-oxidation spiral of long chain fatty acids and consists of 4 alpha and 4 beta subunits. Long chain 3- hydroxyacyl Co-A dehydrogenase (LCHAD) resides in the alpha- subunit. Mutations in the alpha-subunit such as the prevalent G1528C mutation cause "isolated" LCHAD deficiency. Other mutations cause complete TFP deficiency (all the 3 enzymes are deficient). Recently, we have documented a fetal-maternal interaction that causes maternal liver disease in heterozygote women who carry fetuses with isolated LCHAD deficiency. This raises several questions. First, what is the mechanism of this fetal-maternal interaction? Second, what is the effect of environmental factors such as high fat diet and fasting on the development of maternal liver disease in the susceptible heterozygotes? Our hypothesis is that heterozygote women develop acute fatty liver of pregnancy (AFLP) or HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome due to accumulation of hepato-toxic fatty acid metabolites generated by either the affected fetus or the susceptible heterozygote under conditions of oxidative stress. To test this hypothesis we propose the following studies. 1) To use conventional and inducible Cre/lox P strategies to generate and characterize two knockout mice models for complete TFP deficiency (null mutation) and isolated LCHAD deficiency (G1528C mutation). Clinical, biochemical, histological, and molecular analyses will be performed. Tissue-specific and developmental stage-specific gene expression will also be characterized in these mice. Differences in the accumulated fatty acid metabolites will be correlated to the genotypes and phenotypes to elucidate the role of fatty acid metabolites in the genotype-phenotype correlations in these disorders. 2) To employ preimplantation genotyping and embryo transfer to independently study the effects of fetal and maternal genotypes on development of maternal liver disease in knockout mice. Pregnant dams will be monitored for evidence of liver disease. Fatty acid metabolites will be measured in fetal and maternal sera, fetal and maternal livers, and placentas, and will be correlated to the fetal/maternal genotypes and maternal phenotypes to identify the fatty acid metabolites that are potentially toxic to the maternal liver. 3) To conduct dietary studies in knockout mice to elucidate the effects of high fat diet and fasting on pregnant heterozygotes while carrying unaffected fetuses. Four different high fat diets will be studied to elucidate the effects of fat content, fatty acid configuration, and protein/carbohydrate contents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISM OF NOD.IDD3/10/17/18/9(LD) LIVER DISEASE Principal Investigator & Institution: Ridgway, William M.; Medicine; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 30-JUN-2006 Summary: (provided by applicant): The goal of this proposal is to determine mechanisms of a novel autoimmune and biliary tract disease discovered in the NOD.ldd3/10/17/18/9(LD) mouse. The Nonobese diabetic (NOD) mouse is an animal model of spontaneous, genetically complex autoimmune diabetes. NOD mice develop lymphocytic infiltrates into the pancreatic islets (insulitis) progressing to diabetes. The NOD.ldd3/1 0/17/1 8/9(LD) congenic mouse, which has a 95% NOD genetic
50
Liver Disease
background and 5% "protective" B6/B10 genetic background, was bred from the NOD.ldd3/10/17/18 and NOD.ldd9 congenic mice, and is completely protected from autoimmune diabetes. However, we have discovered that it develops an entirely separate disease characterized by lymphocytic infiltrates into the portal tract, antipyruvate dehydrogenase complex (PDC) and other autoantibodies, and progressive polycystic liver leading to fatal biliary obstruction. In this grant, we will dissect the immunological, cellular, and genetic mechanisms of this novel disease. The central hypothesis of this grant is that the biliary disease in NOD.ldd3/10/17/18/9(LD) mice is an autoimmune disease arising via an interaction between the NOD background genes and B6/B10 loci, which are "protective" for autoimmune diabetes. This model provides a unique opportunity to dissect genetic and immunologic mechanisms resulting in 2 different organ specific autoimmune diseases in a genetically related pedigree. In specific aim one, we will define cellular and immunogenetic mechanisms of the liver disease in NOD.ldd3/10/17/18/9(LD) congenic mice by using transfer studies and related NOD congenic strains. In specific aim two, we will dissect cellular and immunogenetic mechanisms of immune subphenotypes in NOD.ldd3/10/17/18/9(LD) and related NOD congenic mice, including autoantibody production, T and B cell responses to PDC (Pyruvate dehydrogenase, specifically the E2 component), and mechanisms of lymphocytic liver infiltration in NOD.ldd3/10/17/18/9(LD) and related congenic mice. These studies are important for understanding the pathogenesis of autoimmune biliary diseases, autoimmune diabetes, and the genetics of autoimmunity in families. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF CHRONIC HEPATITIS B INFECTION Principal Investigator & Institution: Milich, David R.; President; Vaccine Research Institute of San Diego San Diego, Ca 92109 Timing: Fiscal Year 2001; Project Start 01-MAY-1984; Project End 31-MAR-2006 Summary: (Adapted from applicant's abstract): The hepatitis B virus (HBV) is a major cause of infectious liver disease throughout the world. There are 1.2 million carriers of HBV in the U.S. and approximately 300 million worldwide. Neonatal HBV infection is rarely cleared and as many as 90 percent of perinatally infected children become chronically infected. Therefore, in addition to worldwide vaccine programs to prevent new infections, methods for treating HBV chronic carriers will be necessary to eradicate this disease. This application is focused on understanding the mechanisms responsible for inducing and maintaining chronic HBV infection, and specifically the role of HBV nucleoprotein antigens, the nucleocapsid (HBcAg) and the secreted non-particulate HBeAg. The specific aims are addressed through the use of HBc/HBeAg-expressing and HBV replicating transgenic (Tg) mice, the eight recently developed HBc/HBeAg-specific T cell receptor (TCR)-Tg lineages and various combinations of "double and triple-Tg" hybrids. The specific aims are: (1) production and characterization of TCR-Tg lineages; (2) development of models to explore the relationship between chronicity and perinatal infection; (3) examine the potential of the secreted HBeAg to elicit and maintain immune tolerance and promote chronicity; (4) explore mechanisms that allow HBc/HBeAgspecific CD4+ T cells to escape tolerance induction and co-exist with viral antigens; (5) examine mechanisms by which residual (i.e., non-tolerized) HBc/HBeAg-specific CD4+ T cells cause liver injury; and (6) use the models of liver injury to screen HBc/HbeAgspecific immunotherapies potentially useful in the treatment of chronic infection. It is anticipated that the results of these studies will have diagnostic, therapeutic, and
Studies
51
vaccine applications and will provide a better understanding of basic immune mechanisms responsible for viral persistence and clearance in chronic HBV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF LIVER DISEASE IN A MOUSE MODEL OF AIH Principal Investigator & Institution: Gorham, James D.; Pathology; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, Nh 03755 Timing: Fiscal Year 2003; Project Start 01-DEC-2002; Project End 30-NOV-2006 Summary: (provided by applicant): Autoimmune hepatitis (AIH) results from a dysfunction in normal immune homeostasis in the liver. Little is understood, however, about either the normal mechanisms that regulate the hepatic immune system, or about the pathogenesis of AIH. A new mouse model recapitulates the important features of AIH, and is characterized by (1) extensive liver inflammation (2) significant hepatocyte damage (3) spontaneous disease development (4) the strong influence of genetic background and (5) the involvement of T helper type 1 (Th1) cells. Additional features render the model particularly amenable to experimental manipulation, such as predictability of kinetics, genetic homogeneity, and intensity of disease. Balb/c mice with a knockout in the gene encoding the immunoregulatory cytokine transforming growth factor-beta1(TGF-b1) predictably and uniformly develop a lethal Th1-mediated fulminant hepatitis, that is under strict genetic control. Experiments are proposed using this mouse model to understand the mechanisms that regulate the initiation, progression, and effector phases of autoimmune liver disease in BALB/c-TGF-b1 (-/)mice. The first aim of this project is to determine whether cell compartment-specific expression of TGF-b1 dictates the development of liver disease. The second aim is to determine whether the development of immune mediated hepatocellular damage in BALB/c-TGF-b1 (-/-) mice is antigen-specific or antigen nonspecific. The final aim is to analyze the genetics, mechanisms, and specificity of hepatic BALB/c-TGF-b1(-/-) effector cytotoxic T lymphocytes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF LIVER INJURY BY HEPATITIS C AND ALCOHOL Principal Investigator & Institution: Weinman, Steven A.; Professor of Internal Medicine and Physi; Physiology and Biophysics; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2001; Project Start 27-SEP-2000; Project End 31-AUG-2005 Summary: Hepatitis C is the most common form of chronic liver disease in the U.S. with an estimated 4-5 million people infected. The disease is characterized by hepatic inflammation and progressive fibrosis leading to eventual development of cirrhosis and/or hepatocellular carcinoma in as many as 20-30% of individuals. Alcohol consumption greatly increases the severity and rapidity of disease progression but the mechanism of alcohol/HCV synergy is unknown. Development of new therapeutic approaches has been hampered by the limited experimental models systems available and a lack of understanding of the pathogenic mechanisms involved. The long-term objective of this study is to characterize a transgenic mouse model which expresses HCV proteins in the liver and to use this model to determine the role of oxidative stress and mitochondrial dysfunction in producing the increased liver toxicity of alcohol in chronic hepatitis C. The specific aims are 1. To examine the mechanisms and consequences of HCV protein-induced stimulation of ROS production. These experiments will use cell culture expression systems to determine the effects of HCV core protein on basal and
52
Liver Disease
TNF-induced ROS production and examine the source of abnormal ROS. The consequences of core-induced ROS changes to cell survival and its modification by antioxidants and NF-XB activation will be determined. Changes in gene expression induced by HCV protein expression in cell lines will be measured using RNase protection assays. 2. To determine the effects of HCV protein expression on ethanolinduced liver injury. Chronic alcohol feeding of normal and a-ansgenic mice will be performed and liver histology and oxidant injury compared. Alcohol induced changes in liver gene expression will be measured using DNA microarrays. 3. To evaluate antioxidant based approaches to modify HCV/alcohol-induced cell and liver injury. Ethanol-fed transgenic animals and cell culture systems will be used to determine the potential to modify HCV/alcohol -induced liver injury with antioxidants and anti-TNF antibodies. Successful completion of these studies will result in the development of a new model for the study of HCV-induced liver injury, new insight into the role of oxidative stress in HCV/alcohol induced liver injury, and a preliminary evaluation of potential therapeutic modalities for this disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MEDIATORS OF PULMONARY VASODILATATION IN LIVER DISEASE Principal Investigator & Institution: Fallon, Michael B.; Associate Professor; Medicine; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2004 Summary: Endothelial dysfunction underlies the vascular abnormalities of chronic liver disease and is characterized by changes in the levels and activity of endothelial nitric oxide synthase. How these changes occur and why there is variability in the vascular beds involved is incompletely characterized. The hepatopulmonary syndrome is one important vascular complication of liver disease where 15-20 percent of patients with cirrhosis develop pulmonary microvascular dilatation leading to hypoxemia. No effective medical therapies are available. Experimental biliary cirrhosis reproduces the pulmonary vascular and gas exchange abnormalities of human hepatopulmonary syndrome in association with an increase in pulmonary microvascular endothelial nitric oxide levels and activity. Pre-hepatic portal hypertension alone does not cause pulmonary vascular or endothelial nitric oxide synthase alterations, implying that mediators released during hepatic injury may trigger endothelial alterations in the lung. Hepatic and plasma endothelin-1 levels rise and correlate directly with the degree of intrapulmonary vasodilatation in experimental biliary cirrhosis and preliminary studies reveal that chronic low level endothelin-1 infusion in pre-hepatic portal hypertensive animals results in selective pulmonary microvascular dilatation. Although classically recognized as a vasoconstrictor, circulating endothelin-1 stimulates endothelial cell endothelial nitric oxide synthase activity and can cause vasodilatation. Our hypothesis is that endothelin-1, released into the circulation during liver injury, preferentially activates pulmonary vascular endothelial nitric oxide synthase and triggers pulmonary microvascular dilatation. To test this hypothesis our specific aims will 1) define the effects of chronic endothelin-1 infusion on the development of intrapulmonary vasodilatation and endothelial nitric oxide synthase expression and activity in normal, pre- hepatic portal hypertensive and biliary cirrhotic animals in vivo 2) assess the effects of exogenous emdothelin-1 on endothelial nitric oxide synthase expression and activity in isolated pulmonary vascular segments and endothelial cells from normal, pre-hepatic portal hypertensive and biliary cirrhotic animals and 3) directly measure the effects of exogenous endothelin-1 on pulmonary microvascular reactivity in normal, pre-hepatic
Studies
53
portal hypertensive and biliary cirrhotic animals. Our long-term goal is to use an understanding of endothelial dysfunction in hepatopulmonary syndrome to develop specific medical therapies and as a paradigm for understanding the pathogenesis of other vascular complications of liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MESENCHYMAL STEM CELL THERAPY: A1 ANTITRYPSIN DEFICIENCY Principal Investigator & Institution: Verfaillie, Catherine M.; Professor; Medicine; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): Alpha-l-antitrypsin (alpha1AT) is a plasma protein, produced in the liver that inhibits elastase, alpha1AT-deficiency is an autosomal recessive disorder that affects approximately 105 individuals in the US. Liver injury in alpha1AT-deficiency is caused by the hepatotoxic effects of mutant alpha1AT retained within the endoplasmic reticulum (ER) of hepatocytes, and emphysema by uninhibited proteolytic damage to elastic tissue in the lung parenchyma. Orthoptic liver transplantation is the only curative therapy for alpha1AT-mediated liver disease. If a reliable source of hepatocytes were available, they could conceivably be used to replace 20-25% of the host liver, elevating plasma levels of alpha1AT to greater than 10 muM, and preventing pulmonary toxicity due to alpha1AT-deficiency. We have identified multipotent adult progenitor cells, or MAPC, that can be cultured from human, mouse and rat bone marrow (BM). Single MAPC differentiate into mesodermal, neuroectoderm-like cells and functioning hepatocyte-like cells in vitro. MAPC do not form tumors when infused IV, IM or SQ, but differentiate in response to local cues into hematopoietic cells and epithelium of lung, intestine and liver. For MAPC derived hepatocytes to be suitable for therapy of alpha1AT, or other liver disorders, better characterization of the in vitro differentiation process will be needed. In addition, we will need to demonstrate that MAPC-derived cells function like hepatocytes in vivo. We propose three aims to determine whether MAPC-derived hepatocytes may be a source of cells to treat alpha1AT-deficiency mediated pulmonary and/or liver disease. Studies in SA1 will further demonstrate that hepatocyte like cells can be generated from bone marrow derived MAPC, and develop methods to select progenitors/precursors for hepatocytes generated during culture. Selection of such progenitors will serve two purposes: characterization of differentiation from pluripotent adult stem cells to hepatocytes, and generation of a potential source of cells for effective transplantation in liver disease. Studies described in SA2 that will assess all functions of mature hepatocytes in spheroid cultures should help confirm that hepatocytes generated from BM MAPC are similar to hepatocytes derived from primary liver. Studies in SA3 will establish whether MAPC themselves, MAPC-derived hepatocyte progenitors or mature hepatocytes can restore liver function in vivo, in the setting of hepatocyte cell death and in the setting of abnormal liver function but without liver cell death. This should lay the groundwork for future studies testing whether MAPC or MAPC-derived hepatocyte progenitors/hepatocytes can serve as a suitable source of cells for therapy of alpha1AT, a single gene defect associated with lung damage and/or liver failure. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MODELS FOR OPTIMAL LIVER TRANSPLANT OUTCOMES Principal Investigator & Institution: Dickson, E R.; Mary Lowell Leary Professor of Medicine; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905
54
Liver Disease
Timing: Fiscal Year 2002; Project Start 15-JAN-1986; Project End 30-NOV-2006 Summary: Orthotopic liver transplantation (OLT) is now a well- established means of restoring health in patients with end stage liver disease. Our long-term objective is to provide evidence- based information to help optimize the outcome of OLT, which is relevant not only at the individual physician and patient level, but also at the health policy level. Building on our achievements from the previous program period and data collaboration from a network of academic transplant centers, we propose to study the three most important issues that face liver transplantation in the United States today. In specific aim 1, we will prospectively validate the Model for End-stage Liver Disease (MELD) in current OLT candidates. The MELD scale, a liver disease severity index developed by this program, has recently been adopted by the United Network for Organ Sharing (UNOS) as the national liver allocation system for OLT. Our central hypothesis is that the addition of further variables to the model will not materially improve the model, except in patients with hepatocellular carcinoma, in whom the risk of tumor progression needs to be considered in addition to the severity of underlying liver disease. In specific aim 2, we will identify determinants of the outcome of recurrent hepatitis C following OLT. OLT recipients with hepatitis C, the most common indication for the procedure today, have shorter survival and poorer quality of life. Our hypothesis is that pretransplant alcohol consumption and post-transplant obesity affect the rate of progression of recurrent hepatitis C and thus, the outcome. In specific aim 3, we will study the cardiovascular morbidity in long-term survivors following OLT. Based on the number of patients and length of follow-up available in our database, we will identify traditional (e.g., diabetes, hypertension, and hyperlipidemia) and transplant-specific (e.g., cytomegalovirus infection and liver disease diagnosis) risk factors that are associated with cardiovascular complications. The results of these studies will provide relevant information not only to clinicians in practice, but also transplantation policy makers. The feasibility of the proposed projects is supported by the extensive experience and track record of this program in creating and maintaining a large, multicenter, liver transplant database and strong statistical expertise. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTERED RANDOMIZED TRIAL OF HIGH-DOSE URSO IN PSC Principal Investigator & Institution: Lindor, Keith D.; Professor and Director; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): Primary sclerosing cholangitis (PSC) is a progressive chronic cholestatic liver disease of unknown etiology that is commonly associated with chronic colitis. PSC, a common liver disease among adults, usually leads to advanced liver disease and liver failure, and as such, is an important indication for liver transplantation. Unfortunately, no effective medical therapy currently exists for PSC. The group of investigators has a longstanding track record of clinical trials in chronic cholestatic liver disease, particularly in primary sclerosing cholangitis. Recently we have generated promising results from a pilot study using high doses of ursodeoxycholic acid in the treatment of PSC. Lower doses of ursodeoxycholic acid in patients with PSC led to biochemical improvement but did not affect other clinically important endpoints in a previous study. Our pilot data is supported by data from another group showing in a small, randomized trial that high dose ursodeoxycholic acid led to biochemical, histologic, and cholangiographic improvement compared to placebo at two years. In this submission, we propose a large-scale multi-center placebo-
Studies
55
controlled randomized trial with a minimum follow-up of four years for 150 patients with primary sclerosing cholangitis. Primary endpoints of the study will include histologic progression to cirrhosis, development of esophageal or gastric varices, need for liver transplantation, and survival. Secondary endpoints will include measurements of the effects of urosodeoxycholic acid (28-30 mg/kd/d) on liver biochemistries, histologic stage, cholangiographic features, Mayo risk score, and quality of life, using validated questionnaires. This study will be the largest ever conducted in PSC and the follow-up will be the most extensive. This will provide an invaluable resource for studying the natural history of this disease and as part of this study we will also collect serum, cells for extraction of DNA, bile, and tissue from the liver and colon as a resource for future studies. The multi-centered nature of this trial will allow recruitment of patients into this study from a diverse patient population, representative of the gender and racial distribution of this disease. Chances of successful completion of this study are enhanced by the large PSC patient population that the participating centers currently manage, recognition of these sites as referral centers for new patients with PSC, as well as a longstanding track record in clinical trials in cholestatic liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NATURAL HISTORY OF HCV INFECTION IN DRUG USERS Principal Investigator & Institution: Klein, Robert S.; Professor; Montefiore Medical Center (Bronx, Ny) Bronx, Ny 104672490 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: Hepatitis C virus (HCV) infection is a major cause of morbidity and mortality. Injection drug users have the highest prevalence of HCV infection among all populations in the U.S. at risk. We will study prospectively the natural history of HCV infection among all populations in the U.S. at risk. We will study prospectively the natural history of HCV infection in a cohort of drug users with or at risk for HIV infection. Subjects will be recruited from among participants already enrolled in a large longitudinal study of the natural history of HIV infection in drug users. We will, therefore, be able to take advantage of the large and complex sets of data being collected in that study, and we will be able to link new data that will be collecting on the natural history of HCV infection with those data. Participants will have detailed standardized interviews on demographics, medical history, sexual and drug use behaviors, HIV and immunological testing, and testing for HCV infection, including quantitative HCV RNA levels, including quantitative HCV RNA levels, HCV genotyping, anti-HCV antibodies and, in a subset of participants, HCV sequencing. Persons found to have HCV infection will be referred to the study hepatologist to be evaluated for liver disease and they will be offered standard medical therapy for their HCV infection. Our aims are to determine 1) the effects of HIV infection and its associated immunodeficiency, HCV genotype, and drug use behaviors on HCV viral load and progression of liver disease, 2) the effects of HIV infection and immunodeficiency on response to therapy for HCV infection, 3) the effects of highly active anti-retroviral therapy and control of HIV viral load on the natural history of HCV infection, and 4) whether genetic diversity of HCV is facilitated by immunodeficiency. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NATURAL HISTORY OF HEPATITIS C INFECTION IN HIV DISEASE Principal Investigator & Institution: Craven, Donald E.; Professor; Boston Medical Center Gambro Bldg, 2Nd Fl, 660 Harrison Ave, Ste a Boston, Ma 02118
56
Liver Disease
Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: Each year more than 20 percent of the 3.5 million Americans infected with hepatitis C progress to cirrhosis and ten to fifteen thousand develop end-stage liver disease. Because hepatitis C and HIV disease share common modes of transmission, coinfection occurs in 8-10 percent of all HIV-infected individuals overall and is present in over 70 percent of those with parenteral risk factors. There are few data available on the natural history of HIV and HCV co-infection in specific risk groups, as most previous studies have not assessed the impact of confounding variables such as alcohol use, continuing substance abuse, malnutrition, duration of HCV infection, and degree of HIV-related immune suppression. Moreover, current data regarding the impact of HIV on HCV infection are changing rapidly due to the widespread use of highly active antiretroviral therapy (HAART). New cases of HIV and HCV are expected to continue to occur in substance abusers, since HIV infection is increasing rapidly in inner-city populations. The purpose of this study is to examine the natural history of HIV and HCV co-infection in a large inner city cohort who are predominately minority and have a history of polysubstance abuse. We will compare three groups: 1) HIV and HCV infected, 2) HCV infected alone, and 3) HIV infected alone. Epidemiologic studies will be conducted to explore the risk factors associated with HCV progression, morbidity, and mortality, using both standard clinical parameters and novel surrogate markers of liver fibrosis. Additional targeted substudies will examine the important clinical question of whether therapy of either the HCV or HIV disease alters progression of liver disease. Finally, immunologic studies aimed at increasing our understanding of the pathogenesis of liver injury and why it may be accelerated in HIV disease will be performed. The central hypothesis of this proposal is that alterations in immune function associated with HIV infection are the main determinant of poorer hepatitis C outcomes. The specific aims of this grant are: 1) to identify the variable(s) that impact the progression of HCV infection in HIV-infected individuals; 2) to determine the effect of HAART on HCV in dually infected persons; and 3) to define the immunologic variables that predict more rapidly progressive liver disease. These studies are expected to improve our understanding of the natural history and pathogenesis of HCV in immunosuppressed hosts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL APPLICATION
ALT
ISOENZYMES
AND
THEIR
DIAGNOSITC
Principal Investigator & Institution: Gong, Da-Wei; Assistant Professor; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2004 Summary: (provided by applicant): For nearly fifty years, alanine transaminase (ALT) has been a widely used clinical diagnostic marker of acute and chronic hepatic injury. Although elevated serum ALT is a common feature of liver damage, it is also observed in other diseases such as obesity, muscle disease, and in apparently healthy people. The cellular mechanisms leading to ALT changes in the above situations are poorly understood, which often renders the interpretation of ALT data problematic. The work proposed in this application is based upon our recent discovery of a novel homologue of human ALT, which we have designated ALT2. ALT2 has significant homology to ALT1 (the only previously known ALT) with 69% identity and 78% similarity at the peptide level. Importantly, the two isoenzymes are encoded by distinct genes and differ significantly in tissue distribution; ALT2 is highly expressed in muscle, kidney and adipose tissue, whereas ALT1 is mainly expressed in liver, kidney and heart. Since
Studies
57
current assays to measure serum ALT levels are enzymatic, they do not differentiate between ALT1 and ALT2. Measurement of an isoenzyme in serum may have more diagnostic value than total enzyme activity, as exemplified by creatine kinase-MB for cardiac infarction and bone-specific alkaline phosphatase for bone disease. We hypothesize that ALT2 circulates in serum and contributes variably (depending on disease etiology) to total ALT activity measured in currently available clinical assays. Furthermore, we hypothesize that ALT2 will be particularly elevated in patients with fatty liver and/or obesity, since ALT2, but not ALT1, is abundantly expressed in adipose tissue. To examine these hypotheses, we propose to develop an ALT isoenzyme-specific immunoassay. This assay will be used to measure serum levels of ALT isoenzymes in a host of disease states including liver disease and obesity (stable and during weight loss). We predict that serum ALT2 will be higher in patients with fatty liver or obesity and may be a clinically useful marker for this and other disease states. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ONTOGENY OF HEPATIC ION TRANSPORT Principal Investigator & Institution: Suchy, Frederick J.; Professor of Pediatrics; Pediatrics; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029 Timing: Fiscal Year 2001; Project Start 01-SEP-1985; Project End 31-MAR-2003 Summary: This is a renewal application to further define the ontogeny of hepatic ion transport as well as define the mechanisms by which transporters are modified under conditions of cholestasis. The overall objective of this competing renewal application is further defined by the mechanisms underlying the expression of basolateral and canalicular transporters for bile acids and other organic anions during development and cholestatic liver disease. Since transcriptional activation of the liver Na+ /bile acid cotransporter gene (Ntcp) is largely responsible for the abrupt expression of transport activity in the perinatal period, the investigators propose that a change in chromating structure, reflected in an increase in DNASE I hypersensitivity and a decrease in gene methylation precedes the onset of transcription during development. Transgenic mice expressing various portions of the 5' untranslated region linked to the luciferase reporter gene will be used to define sequences that direct tissue- and developmental stagespecific expression of Ntcp. Transgenic animals will be used to show that the rapid postnatal increase in Ntcp transcription could in part be mediated by prolactin. To demonstrate the importance of the Na+/bile acid cotransporter to hepatobiliary function, the Ntcp gene will be rendered nonfunctional in mice by targeted disruption. The phenotypes of the mice with null mutations will be defined including whether liver disease (cholestasis) is induced and how the mutation alters hepatobiliary function and enterohepatic cycling of bile acids. The signaling mediating the targeting of the liver and ileal Na+/bile acid cotransporters to the plasma membrane will be determined through transfection and analysis of native transporters, truncated mutants lacking cytoplasmic tails, and chimeric transporters comprised of portions of the liver and ileal transporters. Finally, the development of the canalicular multi specific organic anion transporter (cMOAT/Mrp1) will be defined including a correlation of transport activity in canalicular membrane vesicles with levels of Mrp2 mRNA and protein. The investigators will determine the mechanisms underlying the effects of bile acids and the inflammatory cytokines TNF-alpha and IL-beta on expression of Ntcp and Mrp2 through transfection of chimeric promoter/reporter gene constructs into primary hepatocytes. DNA foot printing and gel mobility shift assays will determine the importance of known or novel cis-acting elements and trans-activating factors in
58
Liver Disease
regulating gene expression. These studies should provide insights into the biology and pathobiology of hepatic anion transporters and help explain the susceptibility of the infant to develop cholestatic liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OXIDANT HEPATIC INJURY IN CHOLESTASIS Principal Investigator & Institution: Sokol, Ronald J.; Professor; Pediatrics; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2001; Project Start 10-MAY-1987; Project End 31-MAR-2006 Summary: (Adapted from the Applicant's Abstract): The pathogenesis of liver injury in human cholestatic diseases is poorly understood. Current therapies for these disorders are inadequate, thus progression to end-stage liver disease is common. Developing novel treatment approaches will require an expanded understanding of the fundamental mechanisms causing hepatocyte necrosis and apoptosis in this condition. The overall objective of this proposal is to test the hypothesis that oxidative stress and hepatic mitochondrial dysfunction are key elements involved in the pathogenesis of liver injury in cholestasis. In this grant renewal, we will expand our previous investigations to now examine mechanisms involved in hepatocellular apoptosis and necrosis induced by toxic bile acids that accumulate in the liver during cholestasis. We will test the following interrelated hypotheses, using freshly isolated rat and human hepatocytes, hepatic mitochondria, an intravenous bile acid toxicity model developed in our laboratory, the bile duct-ligated model of cholestasis and transgenic mice. To determine if generation of reactive oxygen species (ROS) are a proximate event in bile acid-induced hepatocyte necrosis and apoptosis, the time-sequence of related intracellular events will be carefully assessed during these two forms of cell death in isolated hepatocytes and, by using various inhibitors of critical processes involved, the role of ROS generation will be evaluated. Digitized confocal fluorescent microscopy will also be used to better define the role of mitochondria in these processes. To determine the role played by the hepatic mitochondrion in bile acid-induced liver injury, we will investigate the role of the mitochondrial permeability transition, cytochrome c release, ROS generation, activation of caspases, translocation of Bcl-2 family proteins, ATP concentrations and mitochondrial iron in bile acid-induced necrosis and apoptosis. To determine the role played by nitric oxide (NO) in this injury, generation of NO and its metabolites and their effect on cellular steps of apoptosis and necrosis will be studied in isolated hepatocytes and mitochondria undergoing bile acid-induced injury. To explore oxidative mechanisms to explain the increased susceptibility of the neonatal liver to cholestatic injury, we will investigate developmental differences of mitochondrial processes involved in necrosis and apoptosis in hepatic mitochondria isolated from the developing rat. The results from these investigations will improve our fundamental understanding of the mechanisms of hepatocellular necrosis and apoptosis in cholestasis, and may form the basis for the development and application of new therapies for these disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PATHOGENESIS OF LIVER DISEASE IN HEPATITIS Principal Investigator & Institution: Chisari, Francis V.; Professor & Head; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2003; Project Start 01-JUL-1983; Project End 31-DEC-2007 Summary: (provided by applicant): The hepatitis B virus (HBV) is a non-cytopathic, hepatotropic DNA virus that causes acute and chronic hepatitis and kills a million
Studies
59
people each year from cirrhosis of the liver and hepatocellular carcinoma. Understanding the mechanisms responsible for viral clearance, persistence and disease pathogenesis during HBV infection is, thus, scientifically and medically important. We have previously shown that the immune response plays a key role in the outcome of HBV infection in humans; and we have used transgenic mice to identify immunological mechanisms that are probably responsible for viral clearance and liver disease. In the current funding interval, we used acutely infected chimpanzees in order to study the early host-virus interactions that occur at the site of infection and likely determine its outcome but, for practical and ethical reasons, aren't accessible in man. Those results indicate that the course and duration of HBV infection are clearly related to the kinetics and extent of viral spread, and to the kinetics, magnitude, quality and cytokine profile of the intrahepatic T cell response. In the next funding interval we will determine which of these factors actually decide the outcome of HBV infection by selectively regulating viral spread, the cellular immune response, inflammatory cytokines, and expression of a putatively immunosuppressive HBV protein in acutely infected chimpanzees. The results of these experiments should establish the basis for viral clearance, persistence and disease pathogenesis in acute and chronic HBV infection, and thereby identify new therapeutic strategies to, hopefully, cure this deadly disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PILOT--ALCOHOL AND HEPATITIS C HOST RESPONSE AND DISEASE ACTIVITY Principal Investigator & Institution: Fried, Michael W.; Associate Professor of Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2003; Project Start 27-DEC-2002; Project End 30-NOV-2007 Summary: The clinical spectrum of chronic hepatitis C is variable and the factors responsible for these divergent outcomes remain unknown. Alcohol consumption has been identified as a co-factor in accelerating the progression of liver disease in patients with chronic hepatitis C. Studies of this issue are difficult because there is no animal model of hepatitis C-induced fibrosis. We propose to prospectively study a cohort of patients infected with hepatitis C who also consume alcohol to define the effects of alcohol consumption on hepatic fibrogenesis, oxidant stress, and expression of mediators of inflammation and fibrogenesis in liver tissue and peripheral blood mononuclear cells. The hypothesis to be tested is that alcohol consumption will increase markers of hepatic inflammation, fibrogenesis and oxidant stress, and ultimately reflect an increase in the progression of liver disease. Subjects with concurrent hepatitis C infection on ongoing alcohol use/abuse will undergo a detailed clinical evaluation, including liver biopsy and blood sampling. A control group of non-drinking subjects with chronic hepatitis C will be matched for gender, estimated duration of HCV infection, and mode of HCV acquisition. We will study the effects of alcohol use on hepatic fibrogenesis using standard histologic techniques and novel immunohistochemical markers of stellate cell activation (alpha-smooth muscle actin, collagen II propeptide) in liver biopsy specimens from alcohol consuming and nondrinking patients with chronic hepatitis C. We will also evaluate lipid peroxidation production products using immunohistochemical techniques with antibodies to 4nonalal and malondealdehyde. In addition, using specimens obtained from these two cohorts, we will identify mRNAs in liver tissue and peripheral blood mononuclear cells encoding host mediators of inflammation and fibrogenesis that are up-regulated in
60
Liver Disease
patients with hepatitis C who consume alcohol. This information will provide key information for developing additional hypotheses to be tested in a larger clinical trial. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PORPHYRIN BIOSYNTHESIS IN NORMAL AND DISEASE STATES Principal Investigator & Institution: Kushner, James P.; Professor of Medicine; Internal Medicine; University of Utah 200 S University St Salt Lake City, Ut 84112 Timing: Fiscal Year 2002; Project Start 01-SEP-1977; Project End 30-JUN-2007 Summary: (provided by applicant): Porphyria cutanea tarda (PCT), the most common form of porphyria in humans, is due to sub-normal activity of uroporphyrinogen decarboxylase (URO-D), a cytosolic enzyme in the heme biosynthetic pathway. Our preliminary data indicate that diminished activity of URO-D in the livers of rodents with experimentally induced porphyria and in humans with PCT is due to the generation of a low-molecular-weight inhibitor. Generation of the inhibitor can be initiated by both environmental and genetic factors, and involves an iron-catalyzed reaction. We hypothesize that the inhibitor is generated from oxidized hydroxymethyl bilane, an early intermediate in the heme biosynthetic pathway. We propose to chemically synthesize this inhibitor and to establish that an identical compound is generated in vivo in rats and mice with experimental porphyria. We have identified the presence of a URO-D inhibitor in liver biopsy samples from subjects with PCT. We plan to confirm this finding in additional subjects and to establish that the inhibitor occurs only in patients with PCT by attempting to detect inhibitor in liver biopsy samples from patients with hepatitis C, alcoholic liver disease, and hemochromatosis. Murine models of PCT will be developed in carefully characterized genetic backgrounds by intercrossing a strain we have generated by disrupting one allele of the URO-D gene (URO-D+/- mice). These animals have been intercrossed with homozygous hemochromatosis knockout animals (HFE-/-) and the resultant animals develop PCT without the need for any exogenous agents. We plan introduce null alleles of cytochrome P4501A2 (CYP1A2) and null alleles of peroxisome proliferator activated receptor (PPARa) onto the URO-D+/-:HFE-/- background to define the genetic components required for the development of experimental PCT. Our findings in PCT could serve as a paradigm for other dominantly transmitted porphyrias where clinical expression cannot be simply explained by half-normal activity of non-rate-limiting heme biosynthetic enzymes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PREDICTING LIVER DISEASE IN HIV-HCV-INFECTED WOMEN Principal Investigator & Institution: Taylor, Jill; Wadsworth Center Empire State Plaza Albany, Ny 12237 Timing: Fiscal Year 2002; Project Start 27-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): The purpose of this retrospective pilot study is to identify adaptive mutations that are selected in nonstructural coding regions of the hepatitis C virus (HCV) genome. The dominant virus population that was present in women co-infected with Human Immunodeficiency virus (HIV) and HCV, when clinical signs of progressive liver disease were apparent, will be analyzed. The long-term goal is to understand the viral genomic characteristics of HCV that result in enhanced viral replication, and lead, in conjunction with host immunity and environmental factors, to liver damage. The central hypothesis is that efficient replication of specific HCV variants with enhanced growth properties contributes to liver damage. It is postulated that the
Studies
61
enhancement of viral replication is due to the selection of adaptive mutations in the nonstructural coding regions of the genome. This viral population can then become dominant over time in a hepatic environment in which control of viral replication has been weakened by HIV-induced immunosuppression, alcohol and substance abuse. To test this hypothesis we will sequence the NS3/NS4A and NS5B nonstructural coding regions of the HCV genome in virus from HIV-HCV co-infected women with and without clinical signs of progressive liver disease. The rationale for the proposed research is that once specific mutations are identified as markers of advanced disease, a prognostic assay can be developed to identify patients at higher risk of progression. The study population is 100 HlV-HCV co-infected women, with the additional risk factors of alcohol and substance abuse, enrolled in the Women's Interagency HIV Study (WIHS) at SUNY Downstate in Brooklyn, NY. The experienced investigators collaborating on this proposal represent the cross-disciplinary fields of molecular virology, HIV-HCV primary care and clinical research, and biostatistics. The WIHS cohort at SUNY Downstate has been selected, not only because of the availability of robust demographic and clinical information and stored plasma samples collected since 1994, but also because of the potential for expansion to include the entire WIHS cohort of >2,000 women. HIV-HCV co-infected individuals have been specifically chosen because of the mounting evidence that HIV infection exacerbates HCV disease. Liver failure has become a leading cause of death in the HIV-HCV co-infected population, emphasizing the urgent public health need for earlier treatment intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RACE & VIRAL RESISTANCE IN CHRONIC HEPATITIS C (VIRAHEP* Principal Investigator & Institution: Brown, Robert S.; Associate Professor; Medicine; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 30-JUN-2006 Summary: (provided by applicant): The pathogenesis of hepatitis C (HCV) associated liver injury is poorly understood. Studies of HCV pathogenesis have been impeded by the lack of an animal model, the inability to maintain HCV in cell culture systems, and the slow progression of disease, which hinders natural history studies. However, though host and viral factors likely play a role in liver injury, neither has been rigorously analyzed. Early studies suggest that viral clearance with acute infection as well as with treatment is markedly decreased iin patients of African American heritage. The reasons for this poor response are not understood, but possibly relate to differences in demographics (e.g socioeconomic status), comorbid conditions (e.g., obesity), genotype distribution or virulence, viral kinetics, immune response, and compliance with therapy. Previous studies have been limited by small sample size and referral bias. Over the last 2 years, The Columbia-Cornell Liver Clinical Trials Network has established an extended network of care that has performed clinical trials including a large number of African Americans. This Network includes the Columbia Presbyterian and Harlem Hospital Centers both within the Harlem section of Manhattan and The New York-Cornell Center in central Manhattan. Within this ethnically diverse population, we will answer several questions. The primary hypothesis is that treatment response to PEGylated interferon and ribavirin is decreased in African Americans. However, we postulate that most of this decrease can be explained by differences in baseline characteristics and non-biologic parameters, including body mass index, comorbid medical conditions, socioeconomic status and the ability to complete therapy. Additionally we will search for clinical predictors of response to therapy including
62
Liver Disease
differences in immunogenetics and early viral kinetics. The secondary hypothesis is that the progression of liver disease in African Americans is comparable to that in a Caucasian American population after controlling for potential confounders including the variables mentioned above and alcohol consumption. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF HBV REPLICATION BY THE IMMUNE SYSTEM Principal Investigator & Institution: Guidotti, Luca G.; Associate Professor; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2002; Project Start 01-JAN-1997; Project End 31-DEC-2006 Summary: (provided by applicant): The hepatitis B virus (HBV) causes acute and chronic necroinflammatory liver disease and hepatocellular carcinoma. Over 350 million people worldwide are persistently infected by HBV, representing an enormous reservoir for horizontal and vertical spread of this virus to others. The long term objective of this application is to elucidate the molecular basis for liver disease, viral clearance and viral persistence in the pathogenesis of HBV infection with the ultimate hope that this knowledge will lead to the development of new therapeutic strategies to terminate persistent infection and its attendant costs and complications. Using transgenic mice that replicate HBV at high levels in the liver as recipients of HBVspecific CTLs, we have shown that the antiviral potential of the CTLs is primarily mediated by noricytolytic mechanisms that involve the intrahepatic production of type I inflammatory cytokines by these cells. This occurs after the CTLs specifically recognize viral antigens on the surface of the hepatocyte. Following antigen recognition, the CTLs also trigger the death of a small number of hepatocytes and this process leads to the recruitment of many host-derived lymphomononuclear and polymorphonuclear cells into the liver that contribute to the formation of necroinflaminatory foci histologically identical to classical viral hepatitis in man. The recruited inflammatory cells are likely to be responsible for antigen-nonspecific amplification mechanisms that greatly enhance the liver damage initiated by the CTLs. The recruitment of these cells is probably mediated by secretion of chemokines by either the antigen-activated CTLs or other cellular components of the liver. In support of this, we have performed preliminary experiments showing that a large variety of chemokines are rapidly and strongly induced in the liver of HBV transgenic mice after CTL transfer and their expression is regulated by type 1 inflammatory cytokines. Chemokines are likely to play a role in viral pathogenesis by regulating the trafficking of inflammatory cells to tissue sites of infection and, perhaps, by directly inhibiting viral replication. Whether this is the case during HBV infection is not known. To explore these hypotheses, we will use in vivo (HBV-replicating transgenic mice) and in vitro (HBV-replicating hepatocytes) systems to determine the function of chemokines and chemokine receptors on the recruitment, antiviral and pathogenic effector functions of CTLs and other inflammatory cells. We will also define the role that type 1 inflammatory cytokines may play in these processes. The results of these experiments will provide insight into the basic immunological processes that may determine liver disease, viral clearance and viral persistence in the pathogenesis of HBV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RESEARCH NETWORK FOR DRUG-INDUCED LIVER DISEASE Principal Investigator & Institution: Bonkovsky, Herbert L.; Professor of Medicine; Clinical Research Center; University of Connecticut Sch of Med/Dnt Bb20, Mc 2806 Farmington, Ct 060302806
Studies
63
Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): Drugs and other chemicals have numerous salutary effects on humans, but they may also cause toxicity. Because of the central role played by the liver in metabolism, the liver is the most frequent and important site of drug- or chemical-induced tissue injury. As more drugs have been developed and used and more so-called complementary medicines (CAM) and herbal remedies are used, drug-induced liver disease (DILD) has become a problem of major and growing importance, and there is a growing need for better systems for early detection, characterization, and reporting of instances of DILD. Such systems should be applied both to drugs still under development and to drugs, CAM, and herbal remedies already on the market. The longterm aim of this research program is to develop a regional consortium and network in the Northeastern U.S.A. for the detection and clinico-pathological and molecular (genomic, proteomic) characterization of DILD. A key aspect of this work will be to develop a clinical, laboratory, and histopathological data base of "phenotypic" information on subjects with known or suspected DILD, and also to establish DNA, RNA, serum, and tissue banks on these same subjects. This will facilitate the development of "genotypic" (DNA), gene expression (RNA), and protein expression (proteomic) profiling of the same subjects, eventually permitting the detailed phenotypic-genotypic-proteomic correlations that will be possible as candidate genes and gene products involved in DILD are identified and characterized. Indeed, the regional and national data bases that will be established as a result of this program will aid us in discovering and identifying such genes and gene products, thereby bringing to fruition the enormous potential implicit in the successful sequencing of the human genome. The specific aims of this proposal are to: (1.) establish one of the national interactive Clinical Centers of the Hepatotoxicity Clinical Research Network, based at the University of Connecticut Health Center (UCHC). Our Center will serve as the coordinating center for a consortium of academic and practicing hepatologists and groups in the Northeastern U.S.A. We will take advantage of the strong research infrastructure of the UCHC Office of Clinical Research and the NIH-supported GCRC at UCHC; (2.) work with other members of the Network nationwide to develop consistent, standardized approaches and instruments to identify and fully characterize bona fide cases of drug-, CAM-, and toxin-induced liver injury, identified retrospectively. We will also obtain data from suitable control subjects thereby allowing for case-control studies, which will facilitate studies of the epidemiology and clinical spectrum of such hepatotoxicity; (3.) do prospective studies of selected, commonly used hepatotoxic drugs (HAART for HIV, INH for tuberculosis, methotrexate (MTX) for psoriasis); and (4.) obtain biological samples (blood, liver, plasma, serum) for study of the pathogenesis of DILD, using biochemical, serological, genetic, and proteomic techniques. The clinicopathological database and the tissue and DNA repositories will permit us to create and test numerous hypotheses relating to the pathogenesis and pharmacogenomics of DILD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RETROVIRUS ISOLATION FROM PRIMARY BILIARY CIRRHOSIS Principal Investigator & Institution: Mason, Andrew; University of Alberta Edmonton T6g 2E1, Canada Edmonton, Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Approximately 1 in 2,000 women above the age of 50 develop primary biliary cirrhosis (PBC). There is no cure for this progressive hepatobiliary disease, which is one of the major indications for liver transplantation in the US. About 95% of patients develop anti-mitochondrial antibodies (AMA) reactive to
64
Liver Disease
pyruvate dehydrogenase complex E2 component (PDC-E2), which is aberrantly expressed on cell surface of biliary epithelial cells of patients with PBC. This abnormal distribution of PDC-E2 is only observed in patients with PBC and considered a phenotypic manifestation of the disease. We have cloned an exogenous retrovirus from a PBC biliary epithelium cDNA library with homology to betaretroviruses. Most PBC patients have specific antibody reactivity to the virus by Western blot and evidence for infection in lymph nodes using RT-PCR and immunohistochemistry. Also, we have found that affinity purified AMA from PBC patient's serum react with the virus. To study the viral infection in vitro, we have developed a model for PBC by co-culturing normal biliary epithelium cells with perihilar lymph nodes from patients with chronic liver disease. The biliary epithelium cells incubated with PBC lymph node extracts express increased levels of PDC-E2 autoantigen after 5 days, which is a finding specific for the PBC co-cultures. The supernatants from the PBC co-cultures also induce PDC-E2 expression in fresh biliary epithelial cells, which can be abrogated by gamma irradiation. We have also demonstrated that the development of the PBC phenotype corresponds with betaretrovirus infection in the biliary epithelium cells and supernatants. In a pilot study of anti-retroviral therapy with Combivir, 40% of patients completely normalized their liver function tests and there was a significant reversal of ductopenia on liver biopsy. In order to test the hypothesis that a retrovirus is associated with PBC, we plan to isolate the retrovirus and use our in vitro model of PBC to demonstrate that the specific isolate induces the phenotypic manifestation of disease in normal biliary epithelial cells. We will then assess whether patients with PBC have serologic evidence for infection. We anticipate that our studies will help to further our knowledge of how viral infections can promote autoimmune disorders and provide alternative strategies to help manage PBC patients with anti-viral therapy or vaccination for susceptible individuals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SCRATCH-INDUCING CAPACITY OF CHOLESTATIC EXTRACTS Principal Investigator & Institution: Bergasa, Nora V.; Medicine; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2001; Project Start 21-SEP-2001; Project End 31-JUL-2003 Summary: (provided by applicant) The etiology of the pruritus of cholestasis is unknown and its treatment unsatisfactory. The pruritus of cholestasis has a negative impact on the quality of life of patients and it can be so severe that it alone can be an indication for liver transplantation in children and adults, even in the face of good hepatic function. Accordingly, the provision of satisfactory treatment for this symptom is needed. The spontaneous disappearance of pruritus in patients with cholestasis heralds liver failure. In addition, replacement of the diseased liver in a patient who has cholestasis and pruritus is followed by the cessation of this symptom. These two clinical observations suggest that a certain degree of hepatic function is necessary for the pruritus of cholestasis to be perceived and that the cholestatic liver participates in the production of the pruritogenic substance. The measurement of substances that are found in plasma as a method of research in the field of pruritus has not led to progress in the elucidation of the pathogenesis of the pruritus of cholestasis. Because pruritus is a perception, it cannot be objectively quantitated. Recently however, clinical studies that have incorporated quantitative methodology to measure scratching behavior, have suggested that the pruritus of cholestasis is in part, mediated by endogenous opioids. In these studies, the administration of opiate antagonist drugs ameliorated the perception of pruritus and the scratching activity index, which is the behavioral manifestation of
Studies
65
the pruritus of cholestasis. An animal model of scratching behavior in animals has been developed recently. The use of animal models in the study of the pruritus of cholestasis offers the opportunity to discover the substance, or group of substances, which mediate this form of pruritus. The aim of this proposal is to adapt an assay of centrally mediated scratching behavior in rats. This assay will be used to study the scratch-inducing capacity of cholestatic extracts from patients with liver disease and itch and from rats after their central administration. The long term objective of these studies is to identify that substances that mediate the pruritus of cholestasis and to develop effective specific therapies for this complication of liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SOLID ORGAN TRANSPLANTATION IN HIV: MULTI-SITE STUDY Principal Investigator & Institution: Stock, Peter G.; Surgery; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JAN-2008 Summary: (provided by applicant): The primary aim of this study is to evaluate the safety and efficacy of solid organ transplantation in people with HIV disease by conducting a prospective, multi-center cohort of HIV-positive (+) patients who undergo kidney o liver transplantation. Our long-range goals are: (1) to provide patients and clinicians with information regarding the HIV-specific risks of transplantation, (2) to provide clinicians with information necessary to manage immunosuppressive and antiretroviral (ARV) medications together, and (3) to understand underlying basic science mechanisms that explain patient outcomes so that clinical management can be adjusted to maximize the outcomes. Patients with HIV infection are at significant risk for end stage organ disease. Prior to the advent of highly active antiretroviral therapy (HAART), such patients were often not considered as transplant candidates based on poor prognosis. However, with the use of HAART, HIV positive patients have experienced significant improvements in morbidity and mortality. Thus, increasing numbers of HIV+ patients with end stage kidney and liver disease are potential candidates for transplantation. Despite increasing referrals, patients and clinicians lack the necessary data to determine the safety and efficacy of transplantation and immunosuppression in this group. This lack of conclusive data has led to continued denial of care by many transplant centers and third party payers, resulting in frustration and confusion for both patients and their health care providers. Therefore, the primary clinical focus of this proposal is the design of a multi-center study that is powered to test the hypothesis that HIV+ liver and kidney transplant recipients will have patient and graft survival rates equivalent to other patient groups without HIV infection currently considered acceptable transplant candidates. In addition to providing the numbers required for a sufficiently powered study, the multicenter study provides access to 16 transplant centers for HIV+ patients facing end stage organ disease, facilitating regional access to avoid the logistic difficulties associated with limited access to distant sites. Of equal importance, the research plan establishes a prospective cohort that provides an ideal opportunity to explore mechanisms underlying disease progression in HIV+ transplant recipients and key issues in their medical management. The multi-center approach will capitalize on access to experts in the fields of virology and immunology. These investigators will explore the effects of immunosuppression (IS) on progression of HIV and viral co-pathogens known to be important in both transplant recipients and people with HIV infection. Progression of HIV and viral co-pathogens will be correlated with changes in the host immune response to HIV, viral co-pathogens, and allografts. These data will provide an essential contribution to an understanding of the factors that
66
Liver Disease
may be responsible for variations in graft and patient survival rates. This cohort will also provide the basis for describing the pharmacokinetic interactions between IS and the hepatically-metabolized ARVs, data that will greatly benefit health care workers managing HIV+ patients following transplantation, as maintaining appropriate levels of both of these classes of drugs will be essential for success. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STUDIES OF MECHANISMS AND TREATMENT OF LIVER DISEASE Principal Investigator & Institution: Sanyal, Arun J.; Associate Professor; Internal Medicine; Virginia Commonwealth University Richmond, Va 232980568 Timing: Fiscal Year 2001; Project Start 01-SEP-1999; Project End 31-AUG-2004 Summary: This candidate is an Associate Professor of Gastroenterology and Hepatology at the Medical College of Virginia (MCV). He has played a key role in the growth of the Hepatology program at MCV and has won national recognition for his research on the role of transjugular intrahepatic portasystemic shunts (TIPS) in the treatment of portal hypertension. His career goals are: (1) to be an outstanding clinician, (2) to be a leading scientist in patient- oriented research in liver disease, and (3) to train junior clinicians as bio-medical scientists. This application has been written to mainly consolidate his status as a clinical scientist and teacher. During the period of the proposed studies, the candidate will perform research and serve as a mentor to junior colleagues. Two specific research projects will be performed: (1) a randomized prospective multi-center trial of total paracenteses (TP) vs TP + TIPS for refractory ascites of which he is the principal investigator. (2): studies on the pathogenesis of nonalcoholic steatohepatitis (NASH), a common yet poorly understood disease. It is hypothesized that susceptibility to NASH results from spontaneous mutations of mitochondrial DNA (mtDNA) which cause defective expression of electron-transport chain enzymes in a fraction of hepatocyte mitochondria. Functionally, this results in abnormal oxidation/phosphorylation. when such individuals develop insulin-resistance e.g. from obesity or diabetes, increased lipolysis provides more fatty acid for hepatic uptake and beta oxidation. The resultant oxidative stress in hepatocytes with abnormal mitochondria generates free radicals which cause lipid peroxidation and cell injury. This will be tested by (1) comparison of insulin sensitivity and lipolysis in patients with NASH to three control groups( nonalcoholic fatty liver, matched normal controls, and non-fatty liver disease) using an euglycemic clamp, (2) comparison of hepatocyte mitochondrial structure and function across these four groups by electron microscopy and histochemical assessment of cytochrome oxidase and succinate dehydrogenase, (3) comparison of lipid peroxides in liver biopsy homogenates across these four groups, and (4) comparison of the prevalence and types of mtDNA mutations across these four groups. The latter studies will be done by Dr. Vantuyle (Dept. Biochem, MCV). The institutional and departmental environment as well as the facilities and resources are excellent for career development in academic medicine. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STUDIES OF THE NATURAL HISTORY OF HEPATITIS C IN LIVER Principal Investigator & Institution: Carithers, Robert L.; Director of Hepatology Section; Medicine; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2003 Summary: Chronic hepatitis C virus infection has emerged as the most important form of viral hepatitis in the United States. Although the disease often remains indolent for
Studies
67
many years, approximately 20 percent of patients with chronic hepatitis C progress to cirrhosis within 20 years. As a consequence, liver failure from chronic hepatitis C has become the leading indication for liver transplantation both in the United States and Europe. Despite remarkable progress in our understanding of many aspects of this disease, the mechanism of hepatocellular injury in patients with chronic hepatitis C is not well understood. Unfortunately, neither efficient cell culture systems nor animal models are available to study the pathogenesis of the liver disease. Given these limitations, we have systematically examined the evolution of liver injury in patients with recurrent hepatitis C after liver transplantation. By correlating the degree of injury to the transplanted organ with detailed analyses of viral replication we hope to provide insights into the pathogenesis of liver cell injury in these chronically infected patients. This proposal is designed to examine the hypothesis that differing patterns of mutation in the genomic sequence of HCV RNA have a profound influence on the severity of liver injury in patients with recurrent hepatitis C after liver transplantation. Our Specific Aim 1 is to prospectively determine the relationship between evolution of HCV quasispecies and hepatocellular injury in patients with recurrent hepatitis C. In Specific Aim 2 we plan to intensively investigate the clonal evolution of quasispecies and to determine the tissue origin of these viral strains both in patients with severe recurrent hepatitis C and in those with mild hepatocellular injury after liver transplantation. We plan to test the hypothesis that the primary site of quasispecies replication is critical to the development of hepatocellular injury. We propose that emergence of nonpathogenic strains of virus after liver transplantation result from continuous extrahepatic replication of HCV, whereas pathogenic strains of HCV originate from intrahepatic replication of the virus. In Specific Aim 3 we plan to assess in impact of HCV genotype, circulating levels of virus, and evolution of HCV quasispecies on the long term evolution of histologic injury in the transplanted liver. By carefully correlating the evolution of the virus with the degree of hepatocellular injury experienced by patients who develop recurrent hepatitis C after liver transplantation, we hope to provide insights into to the pathogenesis of this important liver disease. From these detailed analyses we also hope to isolate pathogenic strains of virus which can later be tested in cell culture systems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE EFFECT OF A PROBIOTIC ON HEPATIC STEATOSIS Principal Investigator & Institution: Diehl, Anna M.; Professor; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 15-JUL-2003; Project End 31-MAR-2005 Summary: (provided by applicant): Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States. NAFLD includes a spectrum of hepatic pathology that ranges from fatty liver (steatosis) at the most clinically indolent extreme, to cirrhosis at the opposite extreme where most liver specific morbidity and mortality occurs. Indeed, NAFLD is now thought to be responsible for most of what was once classified as 'cryptogenic cirrhosis'. Cryptogenic cirrhosis accounts for half of the annual liver-related deaths. The study of NAFLD has been hindered by the lack of an easily measurable, clinically relevant outcome measure. Safe, inexpensive, well-tolerated treatments for NAFLD are greatly needed. Recent breakthroughs using animal models have advanced understanding of the pathogenesis of NAFLD and provide hope for the development of effective treatments. Based on extensive work in our own laboratory, our OVERALL HYPOTHESIS is that alcohol and lipopolysacchride (LPS) production by intestinal bacterial overgrowth (IBO) cause inflammatory signaling in the liver that leads to hepatic insulin resistance and NAFLD.
68
Liver Disease
To evaluate this possibility, we treated a murine model of NAFLD with probiotics or anti-tumor necrosis factor a (TNF) antibodies. Indeed, both treatments decreased activation of well-defined molecular inflammatory pathways and improved steatosis by biopsy. This exciting preliminary data provides rationale for studying probiotics in humans. Therefore, this project has a single SPECIFIC AIM: to determine if probiotic therapy can decrease hepatic steatosis in humans with NAFLD. We propose a doubleblinded, randomized, placebo-controlled four month pilot study of 30 patients with NAFLD. The main outcome measure will be grade of hepatic steatosis evaluated by biopsy. We will also measure steatosis by magnetic resonance spectroscopy (MRS). The possibility that probiotics, which are safe, well-tolerated and natural therapies, might improve NAFLD is exciting because liver-related morbidity and mortality are late complications of most chronic liver diseases, including NAFLD. Thus, the safety profile of probiotics makes them an attractive treatment option for a disease that will likely require chronic therapy. If the efficacy of probiotics is established one type of chronic liver disease, the possibility that similar biological therapies might benefit other chronic inflammatory states would merit further evaluation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE EPIDEMIOLOGY OF HEPATITIS C INFECTION IN THAILAND Principal Investigator & Institution: Nelson, Kenrad E.; Professor; Epidemiology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 20-SEP-1999; Project End 31-AUG-2004 Summary: The proposed research program will involve integrated collaborative studies of the epidemiology, biology and natural history of hepatitis C virus (HCV) infections in Northern Thailand. Infections with HCV are a worldwide health problem and are a major cause of chronic liver disease, liver cancer and cirrhosis. It is estimated that 4 million persons in the United States and 180 million persons worldwide are infected with HCV. After infection 80 percent of individuals will become chronic carriers and 20 percent of them will progress to chronic liver disease or cancer in the next 15-20 years. Epidemiologic studies in some populations have found high rates of HCV in injection drug users and lower but elevated rates from sexual and perinatal transmission. However, infections in many individuals are cryptogenic. The reasons for the persistence of HCV infection in such a high proportion of infected individuals is not clear. However, the virus is genetically quite diverse and viral variation with the emergence of new quasispecies usually occurs in chronically infected people. Furthermore the epidemiology and transmission of HCV is intertwined with HIV, so many persons who are infected with both viruses may be immunosuppressed. The studies we have planned will involve comprehensive investigations of the epidemiology, virology and natural history of HCV infections in various populations in Northern Thailand, most of whom are being evaluated for HIV infection. Liver cancer is one of the leading causes of cancer in Thailand and HCV prevalence in blood donors is 8-10 fold greater than in the U.S. The study populations will include injection drug users, sex workers, STD patients, military recruits, blood donors and their spouses and general community populations. Through the transfer of technology for HCV research to our collaborators, we hope to focus on understanding the biology and epidemiology of HCV and the development of more effective prevention of HCV. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
69
Project Title: THE GENETIC BASIS OF HEREDITARY LIVER DISEASE Principal Investigator & Institution: Bull, Laura N.; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: (Investigator's abstract): The goals of this project are to identify and characterize the molecular bases for two forms of inherited liver disease, cholestasislymphedema syndrome (CLS) and familial hyperbileacidemia (FHB). We will work toward this goal through the following three specific aims: 1) identify the gene mutated in CLS, and further genetically characterize this disorder; 2) characterize the expression pattern of the CLS gene and protein; and 3) identify the gene mutated in FHB, and further genetically characterize this disorder. These genes will be genetically localized through use of recently developed, highly efficient genetic mapping techniques, and then candidate genes identified through analysis of available sequence databases, and use of laboratory-based gene identification techniques. Mutations causing CLS and FHB will be identified, and clinical data examined to identify any correlations between the type of mutation present in a patient, and the characteristics of that patient's disease. The types of cells in which the CLS gene is expressed will be identified using in situ hybridization approaches, and the cellular and subcellular localization of the CLS protein will be characterized, using immunohistochemical techniques. The identification of genes mutated in hereditary disorders, and the subsequent characterization of their protein products, has become a valuable tool for increasing our understanding of the pathophysiology of diseases, including disorders of the hepatobiliary system, which affect millions of people in the U.S. Identification of the genetic cause of a disease assists in diagnosis, and also aids further study that may lead to better treatment and prevention. Most importantly, the identification of a disease gene provides specific insight into the biological pathways that are deranged in the illness, and tools for further study of these pathways. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THE ROLE OF GDF-15 IN ORGAN INJURY Principal Investigator & Institution: Koniaris, Leonidas G.; Surgery; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): This proposal seeks funding for the scientific development of Leonidas Koniaris, M.D., an Assistant Professor of Surgery at the University of Rochester School of Medicine. The candidate, a gastrointestinal and trauma surgeon with over four years of basic science research training in the function and signaling of cytokines and growth factors, seeks funding for a mentored research program to examine the role of a novel secreted factor, GDF-15, in shock and organ injury. Shock and organ injury are common cytokine-dependent pathophysiologic processes that lead to the morbidity and mortality seen in virtually all serious disease states. We and others have cloned the new Transforming Growth Factor-B (TGF-B) superfamily members GDF-15, and its human homologue GDF-l 4. GDF- 15 expression is potently induced in mouse models of liver, bile duct, kidney and lung injury and shock. Likewise, GDF-14 is highly expressed in acute and chronic human liver disease. Macrophages from GDF-15 null mice hyper-express inflammatory cytokines and chemokines both in the unstimuiated state and after treatment with phorbol ester. Others report that GDF-14 can signal through the TGF-B receptor and exert TGF-B-like anti-proliferative effects. Taken together these data suggest that GDF- 14/15 is an early
70
Liver Disease
signal or mediator of shock and organ injury, that GDF- 14/15 may limit the inflammatory response by regulating cytokine production by macrophages, and that GDF 14/15 may regulate parenchymal cell proliferation after tissue injury. This proposal seeks to determine the function of GDF- 15 by describing its expression pattern, by evaluating the response of GDF-15 null mice to organ injury and shock, and by examining the effect of recombinant GDF-15 in vitro on macrophages and parenchymal cells and in vivo in over-expressing mice. The candidate will be sponsored by the Chairman of Surgery, James V. Silzmann, M.D., and Professor of Immunology I. Nickolas Crispe, Ph.D., who will provide expertise and training in the areas of murine surgery and shock and macrophage methodology respectively. The completion of this mentored research training will further the candidate?s goal of applying bench-derived scientific discovery to the treatment of surgical disease as an independent investigator. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INFECTION
TREATMENT
DISPARITIES/OUTCOMES
OF
HCV-HIV
CO-
Principal Investigator & Institution: Butt, Adeel A.; Medicine; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 30-JUN-2008 Summary: (provided by applicant): About 4 million Americans, and 170 million persons worldwide are infected with the Hepatitis C virus (HCV). Each year, 8,000-10,000 Americans die of HCV. End stage liver disease due to HCV is one of the leading cause for liver transplantation in the United States. Co-infection with HCV and human immunodeficiency virus (HIV) is common with over one-third of the HIV infected patients in the US being co-infected with HCV. Despite high prevalence and mortality, very few patients with HCV and even fewer with HCV-HIV co-infection receive treatment for HCV. Additionally, the long term outcomes after HCV treatment in HCVHIV co-infected patients are unknown. The goal of this application is to study the treatment patterns of HCV in patients with and without HIV co-infection, and the clinical outcomes after treatment and to prepare the applicant for an independent research career in the field of HCV-HIV co-infection. The specific research aims are to determine i) whether HCV-HIV co-infected patients are less likely to receive treatment for HCV than those infected with HCV alone, and whether this disparity could be explained by HIV co-infection itself, age, race, gender, history of psychiatric illness, and drug and alcohol use ii) whether HCV-HIV infected patients who do receive treatment for HCV are less likely to complete the course of treatment when compared with HCV alone infected patients, and to understand the factors associated with failure to complete treatment, and iii) whether patients who complete the treatment have improved outcomes as measured by survival, emergency department visits, liver disease related hospitalization and incidence of hepatocellular carcinoma. The study population will be all HCV infected Veterans who have been entered in the national VA administrative database between 1999 and 2002. The total number of patients newly diagnosed to be HCV antibody positive in the VA Healthcare System during 1999-2001 was 109,700. Demographic and social variables, prescription and completion of HCV treatment, clinical outcomes including survival, liver disease related hospitalizations, utilization of emergency care for liver disease related conditions and development of hepatocellular carcinoma will be studied. This information will be retrieved from the national VA administrative database using ICD 9 codes, and from the Pharmacy Benefits Management database. To attain the educational goals of this application, the applicant will enroll in University of Pittsburgh Clinical Research Training Program, to complete
Studies
71
course work for a Masters of Science degree in Clinical Effectiveness and Outcomes Research, and participate actively in the School of Medicine's continuing educational activities. The long term objective of the applicant is to make a clinically relevant impact on the HCV treatment patterns and outcomes, especially in the HCV-HIV co-infected patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TUMOR NECROSIS FACTOR AND ALCOHOLIC LIVER DISEASE Principal Investigator & Institution: Mcclain, Craig J.; Professor of Internal Medicine; Medicine; University of Louisville University of Louisville Louisville, Ky 40292 Timing: Fiscal Year 2001; Project Start 01-MAR-1996; Project End 31-JUL-2006 Summary: (Applicant's Abstract): Alcoholic liver disease (ALD) is a major cause of liver disease and liver related morbidity/mortality in the United States. One major difficulty in devising specific therapies for ALD has been our limited understanding of the mechanism(s) for the development and progression of this liver injury. Cytokines are low molecular weight mediators of cellular communication that are produced and released by numerous cell types such as monocytes, macrophages, and of particular relevance to liver disease, Kupffer cells. Pro-inflammatory cytokines, such as tumor necrosis factor a (TNF), and chemokines, such as interleukin-8, have been postulated to play a role in modulating many of the systemic manifestations of ALD and certain aspects of the liver injury in ALD. Many factors stimulate cytokine production, including endotoxin (lipopolysaccharide or LPS) and reactive oxygen intermediates (ROIs), both of which are of direct relevance to this proposal. Endotoxin stimulates cytokine production via interaction with LPS binding protein (LBP); membrane bound CD 14, and ultimately the recently described LPS receptor, Toll-like receptor TLR4. TLR4 then causes activation of the redox sensitive transcription factor, NFkB, with subsequent production of cytokines such as TNF. NFKB also has been identified as a survival factor against TNF induced apoptosis in multiple cell types. Thus, NFKB not only serves as a transcription factor for several inflammatory cytokines such as TNF and IL-8, but also for several potentially protective factors such as inhibitors of apoptosis (lAPs). Inhibition of NFkB can initiate fulminant liver injury and hepatocyte apoptosis, at least in part, by allowing unregulated signaling via the TNF "death domain." We postulate that in ALD there is: 1) increased NFkB activation and TNF production in the major cytokine producing cell in the liver (Kupffer cell); and 2) decreased NFkB activation and decreased "protective signaling" in conjunction with increased TNF death signaling in the target cell (hepatocyte). In this proposal, we will use in vitro systems, in vivo animal models of ALD and ultimately will perform translational human studies to further define mechanisms of liver injury in ALD and potential pathways for intervention. The specific aims of this proposal are to: 1) Evaluate mechanisms for increased NFkB activation and TNF production by monocyte/Kupffer cells in ALD (priming), 2) Evaluate mechanisms of increased susceptibility to TNF/cytokine hepatotoxicity in ALD (sensitization). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: URSODIOL-METHOTREXATE FOR PRIMARY BILIARY CIRRHOSIS Principal Investigator & Institution: Combes, Burton; Professor of Internal Medicine; Internal Medicine; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2001; Project Start 01-APR-1993; Project End 31-MAR-2004
72
Liver Disease
Summary: The major thrust of this randomized, double-blinded clinical trial is to determine whether treatment of patients with Primary Biliary Cirrhosis (PBC) with Ursodiol (Ursodeoxycholic Acid-UDCA) plus methotrexate (MTX) is more effective than treatment with UDCA alone. PBC is a chronic cholestatic liver disease, predominantly of women, in which interlobular and septal bile ducts undergo inflammation and destruction. Once initiated, the disease persists and progresses at varying rates. Neither the initiating nor perpetuating mechanisms are well understood. Current concepts of pathogenesis include (1) destruction of bile ducts is maintained and perhaps initiated by autoimmune mechanisms; (2) hydrophobic bile acids which accumulate in serum and liver cause functional and cytotoxic liver injury; (3) cytokines and lymphokines released at sites of inflammation may contribute to cell damage and fibrosis. A considerable body of evidence indicates that UDCA when fed orally leads to improvement in liver tests, in pruritus and in liver histology. There exist differences in opinion as to whether development of complications of liver disease, liver transplantation or transplant-free survival is affected. UDCA a relatively non-toxic bile acid, when administered orally, alters the composition of the bile acid pool in factor of its enrichment with UDCA and appears to protect against the cytotoxic effects of endogenous bile acids that accumulate as a result of bile duct destruction. MTX is being shown to improve liver tests, symptoms and liver histology in a small number of precirrhotic patients with PBC. The mechanism of action is unknown but felt to be related to antiinflammatoryimmunosuppressive effects of MTX. The current trial explores whether MTX improves the therapeutic effects of UDCA in PBC. Patients with PBC whose serum bilirubin is less than 3 mg percent, who have been on UDCA for at least 6 months, and who satisfy a series of inclusion and exclusion criteria are stratified into 2 groups on the basis of liver histologic stage (Ludwig classification), i.e. early (Stages I or II) versus late (Stages III or IV). They are then randomized to receive either methotrexate or its placebo as a second drug while continuing to receive UDCA. The relative value of the two treatment arms is assessed by comparing their effects on symptoms, results of laboratory tests, development of complications of liver disease, histologic changes in liver, liver transplantation, and on transplant-free survival. The safety of each therapeutic regimen is also being determined. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VARIATION IN THE EFFECTS OF ALCOHOL ON LIVER FUNCTION Principal Investigator & Institution: Whitfield, John B.; Queensland Institute of Medical Research Bramston Terr, Herston Brisbane, Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): This resubmission is one of a group of Interactive Research Project Grant applications, which have the broad objective of clarifying the role of genes in alcohol dependence and related disorders. Alcohol dependence is a common condition with a substantial genetic component. This application focuses on pre-clinical alcoholic liver disease in a community-based sample and will complement published studies on patients with more advanced disease. The objective is to identify risk factors able to predict which hazardous drinkers are at risk of eventual progression to liver disease. Successful identification of risk factors for alcoholic liver disease may lead to improvements in early identification of people at risk from their drinking, and early intervention to prevent progression to clinical disease. Known risk factors include lifetime quantity of alcohol consumed, and gender (women are more susceptible to alcoholic liver disease than men). The postulated risk factors to be studied are based on a small number of published studies on patients, and on our preliminary work with
Studies
73
community samples. They include obesity and related metabolic disorders; iron overload; and allelic variation in a range of candidate genes concerned with alcohol metabolism, inflammatory response within the liver, fatty liver and fibrosis. The specific aims are to test whether the postulated risk factors affect the probability of liver dysfunction in hazardous drinkers, using biochemical liver function tests to detect preclinical liver damage. The enzyme liver function tests are abnormal in a substantial proportion (approximately 30-40%) of hazardous drinkers and offer an opportunity for noninvasive testing in large numbers of subjects. Subjects will be drawn from twins and their families who have participated in previous studies of alcohol use and dependence. They will have met DSM-IV criteria for alcohol dependence and/or have reported hazardous levels of alcohol intake in the previous studies. They will provide information on recent alcohol intake, and blood samples will be taken for biochemical testing and as a source of DNA for genotyping. Data will be analyzed using standard methods for twin studies and tests will be included for the effects of postulated phenotypic risk factors, for heritability of liver abnormality conditional on hazardous drinking, and for allelic association at candidate genes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VASCULAR HYPRTENSION
RESPONSE
TO
HEMMORHAGE
IN
PORTAL
Principal Investigator & Institution: Sitzmann, James V.; Chairman & Robert J. Coffey Professor; Surgery; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2002; Project Start 01-SEP-1993; Project End 30-NOV-2006 Summary: (Provided by Applicant): The protean manifestations of portal hypertension (PHT) lead to the deaths of over 100,000 Americans each year, and disproportionately target minorities and women due to their greater susceptibility to liver disease. Hemorrhagic shock is the most common lethal complication of portal hypertension where patients tolerate massive hemorrhage poorly. Current treatment modalities may actually aggravate the underlying cause of bleeding, due to the poor understanding of the pathogenesis of the abnormal physiology. Our lab has been instrumental in elucidating the factors critical to the development of PHT, including the identification of the putative mediators of increased splanchnic blood flow (NO, PGI2, angiotensin [ANGII], endothelin [ET), and an altered transmembrane signaling in PHT that underlies the altered vascular response to hemorrhage. This proposal seeks to determine the relationship between the mechanical forces (increased flow, pressure and strain), and the putative mediators of increased splanchnic blood flow (NO, PGI2, ANGII, ET), and the abnormal vascular response to hemorrhage in PHT. Our central hypothesis is that changes in intraluminal mechanical forces (pressure and shear stress) increase endothelial expression of vasodilatory substances that chronically regulate pressor hormone receptor transmembrane signaling and vessel structural changes in PHT that determines the abnormal responsiveness of the hyperemic vasculature to hemorrhage and resuscitation. We will use in vivo models of PHT with and without cirrhosis (bile duct ligated [BDL] and partial portal vein ligated [PVL]) in wild type and iNOS, eNOS, COX 1, COX 2 knockout mice, in conjunction with in vitro models of perfused transcapillary endothelial cell (EC) and vascular smooth muscle cell (VSMC) co-culture system, and the Flexercell Strain System (mimicking the in vivo vascular architecture and mechanical forces of flow, pressure and strain). We will evaluate the effect of mechanical force upon EC nitric oxide synthase (NOS) and cyclooxygenase (COX) expression/activity and VSMC pressor hormone receptor (ANGII, ET) expression and transmembrane signaling and VSMC proliferation and migration. We will determine: 1)
74
Liver Disease
changes in endothelial expression of NOS and COX in response to changes in flow, pressure, or strain; 2) changes in VSMC receptor and transmembrane signal transduction as well as alterations in proliferation and migration; 3) if shear, pressure, or strain induced alterations are modulated by the presence or absence of liver disease (cirrhosis); and 4) if mechanical force induced changes in EC vasoactive substance expression or VSMC changes result in abnormal vascular response to hemorrhage and shock. In summary, we will determine the role of obstruction to portal flow and the influence of mechanical forces and cirrhosis upon the abnormal vascular response to hemorrhage and resuscitation. These experiments will provide significant new information central to our understanding of PHT, and lead directly to effective treatment programs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VIRAHEP-C CLINICAL CENTER Principal Investigator & Institution: Conjeevaram, Hari S.; Assistant Professor of Medicine; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 30-JUN-2006 Summary: (provided by applicant): Chronic hepatitis C is the leading cause of chronic liver disease and cirrhosis in the United States and is now the leading cause for liver transplantation due to end-stage liver disease. Approximately 1.8% of population (4 million) in the United States have antibody to hepatitis C virus (anti-HCV) and approximately 2.7 million Americans have evidence of chronic infection. The prevalence of antibody to HCV is higher among African Americans (3.2%) than among the nonHispanic whites (1.8%). Treatment of chronic hepatitis C remains problematical and unsatisfactory. Interferon (IFN) monotherapy given as three times weekly injections has been shown to have biochemical, virological and histological beneficial effects. However, sustained virological response (SVR) is seen in only a minority of patients (616%). Treatment with combination of IFN + and ribavirin for 24 or 48 weeks results in SVR rates of up to 35 to 43% respectively. Very limited published data is currently available on the impact of race on response to antiviral therapy in patients with chronic hepatitis C. Most available reports show that African Americans have a significantly lower SVR when compared to non-Hispanic whites with all treatment regimens. We are proposing a multicenter, controlled clinical trial of combination therapy of pegylated interferon + ribavirin for African Americans and non-Hispanic whites chronically infected with HCV genotype 1 virus. Treatment will be administered for a total duration of 48 weeks with a 48-week follow-up post completion of therapy. A total of 400 patients with equal numbers of Caucasians and African Americans (200 in each group) will be enrolled into this study. The primary end-point of this trial is to determine rate of SVR among African Americans and non-Hispanic whites. In addition, factors predictive for a favorable response and patterns of virological response will also be assessed in the two racial groups. The objectives of this trial are to evaluate: (a) the rates of SVR among African Americans and non-Hispanic Whites with chronic hepatitis C after treatment with combination therapy using pegylated interferon and ribavirin for 48 weeks; (b) the factors that are predictive of a SVR to combination therapy in each of the two racial groups and factors associated with poorer response in African Americans and (c) the patterns of virological response (including viral kinetics) early during treatment and determine if different responses predict the ultimate outcome (sustained response, relapse or a lack of response) in each of the two racial groups. The findings of this study will allow us to develop specific algorithms to predict rates of SVR to therapy among
Studies
75
African Americans based on their pre-treatment characteristics and patterns of virological response during therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “liver disease” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for liver disease in the PubMed Central database: •
Diagnosis of Hepatitis C Virus (HCV) Infection Using an Immunodominant Chimeric Polyprotein to Capture Circulating Antibodies: Reevaluation of the Role of HCV in Liver Disease. by Chien DY, Choo Q, Tabrizi A, Kuo C, McFarland J, Berger K, Lee C, Shuster JR, Nguyen T, Moyer DL, Tong M, Furuta S, Omata M, Tegtmeier G, Alter H, Schiff E, Jeffers L, Houghton M, Kuo G.; 1992 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50267
•
Granulocyte Colony-Stimulating Factor Improves Deficient In Vitro Neutrophil Transendothelial Migration in Patients with Advanced Liver Disease. by Fiuza C, Salcedo M, Clemente G, Tellado JM.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=119958
•
High Prevalence of TT Virus Infection in Healthy Children and Adults and in Patients with Liver Disease in Taiwan. by Hsieh SY, Wu YH, Ho YP, Tsao KC, Yeh CT, Liaw YF.; 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84962
•
In Situ Distribution of Hepatitis C Virus Replicative-Intermediate RNA in Hepatic Tissue and Its Correlation with Liver Disease. by Chang M, Marquardt AP, Wood BL, Williams O, Cotler SJ, Taylor SL, Carithers RL Jr, Gretch DR.; 2000 Jan 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111615
•
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. by Ku NO, Darling JM, Krams SM, Esquivel CO, Keeffe EB, Sibley RK, Lee YM, Wright TL, Omary MB.; 2003 May 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=156326
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
76
Liver Disease
•
Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. by Orange JS, Salazar-Mather TP, Opal SM, Biron CA.; 1997 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230227
•
Mortality from liver disease in the West Midlands, 1993-2000: observational study. by Fisher NC, Hanson J, Phillips A, Rao JN, Swarbrick ET.; 2002 Aug 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=117772
•
Prevalence of hepatitis G viremia among healthy subjects, individuals with liver disease, and persons at risk for parenteral transmission. by Feucht HH, Zollner B, Polywka S, Knodler B, Schroter M, Nolte H, Laufs R.; 1997 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229669
•
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. by Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ.; 2003 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=162288
•
Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. by Gunther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H.; 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190919
•
Uneven Distribution of Hepatitis C Virus Quasispecies in Tissues from Subjects with End-Stage Liver Disease: Confounding Effect of Viral Adsorption and Mounting Evidence for the Presence of Low-Level Extrahepatic Replication. by Laskus T, Radkowski M, Wang LF, Nowicki M, Rakela J.; 2000 Jan 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111624
•
Unusual skin findings in a patient with liver disease. by Fisman D.; 2002 Jun 11; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113805
•
Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. by Sheth M, Riggs M, Patel T.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=65516
•
Weak Association between SEN Virus Viremia and Liver Disease. by Yoshida H, Kato N, Shiratori Y, Shao R, Wang Y, Shiina S, Omata M.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130791
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site,